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Abstract  
REST is a transcriptional repressor protein and has been suggested to maintain the self-
renewal potential of several brain tumours including medulloblastoma.  REST represses 
transcription by recruiting several chromatin modifiers, including histone deacetylase 
(HDAC) enzymes to gene promoters which have been associated with several cancers.  
Nevertheless, HDAC inhibitors (HDACis) have shown promising results in targeting 
specifically tumour cells.  Interestingly, REST expressing cells showed higher sensitivity 
to HDACis yet, it is not known if they induce their action through the HDACs recruited in 
REST repression complexes.  Also, it is not fully understood how HDACis specifically 
inhibit the growth of tumour cells, and in what way normal cells protect themselves from 
the hyperacetylation effect of these drugs.  
In this study, I examined the contribution of REST in the medulloblastoma Daoy cell line 
by modulating its expression using CRISPR/Cas9.  To explore the HDACis anti-cancer 
molecular mechanism, I profiled the gene expression of HDACis-treated tumour and 
normal cells at a single cell level using the next generation sequencing analysis.   
The results showed that disrupting REST expression induced upregulation of neuronal 
genes, slightly (~6 %) reduced the cell growth, prolonged the cell cycle, and reduced the 
migration ability of the tumour cells.  However, it did not stimulate apoptosis or reduce the 
sensitivity of the cell to the HDACis.  Treating the tumour cells with HDACis resulted in 
activating the TNFα signalling via NFκB pathway and modulating the expression of the 
cell cycle and Myc pathways.  Whereas, exposing the normal cells to HDACis caused 
considerable changes on the transcriptome level. 
Collectively, the data of this study showed that blocking REST expression did not lead to 
tumour cell death.  It also showed the ability of HDACis to induce their action independent 
of HDACs recruited in REST complexes.  Treating with HDACis caused global gene 
expression changes in tumour and normal cells which activate a defined signalling 
pathways however, this raises concerns regarding the toxic side effects of HDACis in 
normal cells.  Hence, the use of HDACis should be revised carefully even with their 
minimal side-effect in clinical trials. 
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Chapter 1 
1 Introduction 
The Road Map 
This thesis aimed to study the contribution of Repressor Element 1-Silencing Transcription 
Factor (REST), HDAC and HDAC inhibitors in the Daoy medulloblastoma cells growth 
and treatment response.  Also, it aimed to uncover the molecular regulation of HDACis 
anticancer effect and how normal cells protect themselves from the hyperacetylation 
induced by these drugs.  This chapter begins with a literature review of four main elements 
(REST, HDAC, HDACis, and medulloblastoma) and then will move to talk in more details 
about the research hypothesis, goals, and the used methodology.  Chapter 3 Results I: 
presents the findings of REST modulation on the Daoy medulloblastoma cells.  Whereas, 
Chapter 4 (Results II) presents the findings of the gene profiling of the HDACis treated 
and untreated cells at single cell level. 
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1.1 REST 
REST [also known as Neuron-Restrictive Silencing Factor (NRSF)] is a DNA-binding 
protein that binds to a DNA sequence known as Repressor Element 1 (RE1) located in the 
promoter region of some genes where it is able to recruit several protein complexes.  In 
1995, REST was originally described as a transcriptional silencer of neuronal genes in non-
neuronal cells 1.  Though, this view was reformed after observing the repression activity 
of REST on actively transcribed genes rather than a silencer for all RE1-containing genes 
2.    
The main function of REST is to repress gene transcription through engaging several 
chromatin modifiers and histone alteration factors at gene promoter, which leads to 
chromatin condensation and blocks the binding of transcriptional machinery.  In humans 
there are more than 2000 REST-target genes, the majority of them are neuronal 
differentiation genes 3.  Hence, REST has a major role in regulating neurogenesis and 
prevents the neuronal phenotype in non-neuronal cells.  However, REST function is not 
limited to neuronal genes and it extends to regulate the tumour necrosis factor superfamily, 
complement genes, cadherins, synaptotagmins, immune responses, olfactory receptors, 
voltage-dependent calcium and potassium channels, and microRNA genes 3, 4.  Lately,  
REST has been reported to regulate the differentiation of stem cells by regulating 
pluripotent genes such as Oct4, Sox2, and Nanog 5.   
Deregulation of REST expression has considerable implications on the differentiation of 
neuronal stem cells (NSCs), proliferation of non-neuronal cells, and on tumour cells.  
REST plays a dual function in cancer; as a tumour suppressor in non-neuronal tumours, 
and as an oncogene in neuronal tumours.  In some non-neuronal tumours such as colon 
carcinoma and breast cancer the loss of REST expression, as a result of REST locus 
deletion, has been suggested to contribute to tumour formation 6, 7, 8.  In contrast, in 
neuronal cells, overexpression of REST induces oncogenic activity, which blocks cells 
differentiation and maintains the self-renewal potential of NSCs, and ultimately 
contributes to tumour formation 9, 10.  Hence, downregulating REST activity in 
medulloblastoma and glioblastoma has been suggested to block tumour cell proliferation 
and initiate apoptosis 9, 11, 12, 13.  
Chapter 1            Introduction 
3 
 
There is a considerable volume of published studies that associate– medulloblastoma with 
REST expression 11, 14, 15.  The most reasonable explanation for REST linkage with 
medulloblastoma is that the continuous REST expression in tumour stem cells prevents the 
expression of neuronal differentiation genes which maintains cell multiplication.  
Conversely, blocking REST expression has been suggested to release neuronal genes 
expression and produce the stimulation of tumour cell death 11, 14, 15.     
In order to provide a better understanding about the relation of REST with 
medulloblastoma, the following sections will present more information about REST gene 
structure, REST protein, its repression mechanism, and what it has been known about its 
contribution in medulloblastoma.  
 REST Gene Structure 
REST gene is located on chromosome 4q12, spans 24 kilo base-pairs of genomic DNA, 
and encodes REST protein and its isoforms.  As with most human multiexon genes, the 
REST mRNA transcript undergoes extensive alternative splicing sites (AS) which could 
be due to the nature of the neuronal cells that show the most complex repertories of splice 
variant.  The REST gene is composed of four constitutive coding exons; Exon1 with four 
AS (1a, 1b, N1 and 1c), Exon2 has 12 AS (2a to 2k), Exon3 contains 4 AS (AS3; a neuronal 
specific AS located between the third and the forth exons, N3a, N3b and N3c), and Exon4 
which includes 12 AS (Figure 1).  In additional to the previous four exons, a new exon 
(Exon5) has been found approximately 30kb downstream of exon4 16, 17, 18 (Figure 1).  At 
least, 45 variants of REST alternative splices have been reported most of them are 
expressed at low levels in a cell-type and in a tissue-specific manner, yet REST Isoform1 
was the most common among all tissues and cell lines that were tested 18.   
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 REST Protein 
There are at least four REST proteins have been reported; REST full length protein, also 
known as Isoform1,  is 122 kilodalton (kDa) zinc finger, structured from three domains: 
The DNA binding domain (DBD) which consist of eight Cysteine and Histamine zinc 
fingers flanked by amino or N-terminal domain (NTD) and carboxy or C-terminal domain 
(CTD) (Figure 2) 19.  Isoform2 which mainly localized in the cytoplasm and retains the 
NTD and four zinc fingers 19.  Isoform3, also known as REST4, localized in the nucleus 
and retains the NTD five zinc fingers (Figure 2).  The REST4 isoform has been suggested 
to be a posttranscriptional regulator of REST expression.  REST4 is generated from the 
inclusion of a neuronal-specific exon (known as exon N) located between the third and the 
fourth exons of REST.  The formed transcript has a frameshift sequence which contains a 
stop codon at the beginning of exon 4 which causes a premature termination of REST 
transcription and the formation of REST4 17.  REST4 protein has a stable structure that 
retains five of the eight zinc fingers present in REST but does not have the CTD.  Hence, 
it does not efficiently recruit the repression complexes which results in upregulating REST 
target genes expression in neuronal cells 7.    Interestingly, high expression of REST4 has 
been associated with several cancers such as neuroblastoma, breast cancer, and small cell 
lung cancers 7.   Isoform4 is similar to REST full-length though, it has a selective deletion 
of zinc finger 5 18 (Figure 2).  Not much are known about REST isoform 2 and 4 and their 
contribution in cancer may warrant further investigation.  
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Figure 2: Schematic illustration of human REST protein and its alterative isoforms 
Four isoforms of REST have been identified.  Isoform1 (REST full-length, 1097 amino acid 
(a.a), and 122 kDa protein) produced by skipping off the neuronal-specific alternative 
splice exon between exon 3 and 4, has two repressing domains (NTD and CTD), a DNA 
binding domain (159-412) which contains eight zinc fingers and the ninth zinc finger is 
located in the C-terminal (1006-1082), lysine-rich domain (400-603), proline-rich domain 
(595-815), two nuclear localization signals (shown in green), a phosphodegron 
(E1009/S1013 or S1027/S1030).  Isoform2 (313 a.a, 35 kDa protein) is a truncated 
protein, and retains from 1 to 4 zinc fingers only.  Isoform3 (also known as REST4) (329 
a.a, 37 kDa protein) is a truncated protein, and retains zinc fingers from 1 to 5.  Isoform4 
(1074 a.a, 119 kDa protein) is similar to isoform1 though, it has a deletion of zinc finger 
5.  The figure was adapted from (Faronato et al., 2010) 16. 
 REST DNA Binding Site  
REST transcriptional repression complexes are mainly recruited to a Repressor Element 1 
(RE1) DNA sequence (also known as NRSE) which works as a regulator for gene 
transcription 4.  RE1 is a group of highly conserved 21 to 23 bp DNA sequences that exist 
in the promoter region of a large number of neuronal genes and several of non-neuronal 
multigene families and microRNA genes 3.  These sequences represent the sole binding 
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site of REST, to which it recruits various chromatin remodelling and histone modifying 
factors 20.   
The number of functional RE1 sites in human has been estimated to reach to more than 
2000 sites most of them are located in neuronal genes 20.  The majority of RE1 sites are 
occupied by REST repression complexes, in particular, the sites in REST expressing cells 
such as embryonic and NSCs 3, 5, 21, 22.  In contrast, the expression of RE1-containing genes 
is higher in cells with low developmental potential as is the case with differentiated neurons 
5.  In addition, the RE1 sites have been found in more than 300 non-neuronal genes that 
are commonly downregulated by the pluripotency factors such as Oct4, Sox2 and Nanog.  
Interestingly, several pluripotency controlling genes, such as Nanog, Wingless signalling 
pathway, ZF206,  ZF281, Lin28, and some neurosecretory genes have been reported to 
have RE1 sites in their promoters which may demonstrate the broad function of  REST 5, 
22.  
 REST Expression  
Regulated REST expression is vital for cell development and neurogenesis and it has 
specific expression patterns based on the stage of the cell cycle and the tissue type.  During 
embryonic brain development REST expression is up-regulated in neuronal cells which 
induces a transient repression of most neuronal genes and drives cellular proliferation.  As 
neuronal progenitors differentiate into mature neurons REST and its corepressor disperse 
from the RE1 sites resulting in the expression of neuronal genes to the default level which 
stimulates neuronal cells differentiation 23.  In animal models, mice with blocked REST 
expression appear normal until embryonic day 9 and they die by day 11 due to the 
widespread of apoptosis 1, 24.   
In mature cells, REST mediates long term silencing and transient repression for specific 
genes based on the stage of cell differentiation and the developmental context.   During 
neural stem-cell differentiation, the CoREST complex remains bound and continues to 
repress the RE1-containing genes despite the cleavage of REST from the RE1 sites 25.  In 
normal developed neurons, REST expression is downregulated resulting in the expression 
of neuronal genes and increases the synaptic activity.  
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In non-neuronal cells, the expression of REST remains high which mediates a long-term 
silencing of most neuronal-specific genes.  However, during cellular multiplication, REST 
repression complexes transiently dissociate from most the RE1-containing genes and re-
established following mitosis 25.   
On the level of REST corepressors, REST has been found to selectively recruit part of its 
corepressor complexes at certain genes and not all complexes are recruited at all genes 25.  
This could explain the mechanism of short-term repression and long-term silencing and 
illustrate why certain chromatin markers are consistently associated with a particular 
cellular context.  However, the molecular mechanism that regulates the binding of a 
particular corepressor is not known.  It has been suggested that the sequence of the RE1 
site and certain sub-nuclear organization could play a significant part in defining which 
cofactors are recruited 5.   
 Regulation of REST Expression 
Despite the extensive studies aimed at understanding REST involvement in normal and 
disease states, little has been done to identify how the REST expression level is regulated.  
However, what is known about the regulation of REST expression suggests that it may 
occur at the REST gene transcriptional level, Rest mRNA, and posttranscriptional level.   
Analysis of REST gene structure has identified the presence of three alternative exons 
(1a,1b and 1c) located at exon1, each of which works as a transcription initiation point.  
The abundance of specific transcripts mainly depends on the initiating exon, for instance 
the transcripts that initiated from exon1a have the highest abundance compared to the 1b 
and 1c transcripts however, none of these transcripts is cell-specific as they were found in 
all tested cells 25.  Also, it has been reported that some of the main pluripotent transcription 
factors such as Oct4 and Nanog may play a significant role in regulating REST 
transcriptional expression 9.   
Also, miRNAs have been found to play a significant role in regulating the Rest mRNA 
level.  miRNA is an endogenous noncoding RNA sequence that regulates the expression 
of specific protein based on the complementarity of its sequence to the protein mRNA.  For 
example, miR-153 has been reported to target Rest mRNA expression and represses its 
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transcription 21.  Accordingly, ectopic induction of miR-153 to medulloblastoma cell lines 
showed a significant reduction in cell proliferation 26.   
With respect to posttranscriptional regulation, REST has been found to have conserved 
phosphodegron sites at serine 861 and 864 which are located in the proline-rich domain.  
Also another two phosphorylatable sites were found as part of a second phosphodegron 
motif at serines1027 and 1030 which are present in the CTD of REST 27, 28.  Serine 861/864 
have been identified to work as substrates for the Peptidylprolyl cis/trans isomerase (Pin1) 
enzyme, which induces protein conformational changes leading to REST protein cleavage.  
It has also been reported that both serine 861/864 work as targets for ERK1/2 (an 
extracellular signal-regulated kinase) kinases which catalyse their phosphorylation 27. The 
serine1027/1030 phosphodegrons are associated with REST downregulation in particular 
during neuronal cell differentiation.  Both of these phosphodegrons are recognised by Beta-
transducing repeat-containing proteins (β-TrCP) which work as a recognition site for 
Skp/Cullin/F box (SCF).  Interaction of the β-TrCP with the SCF protein forms the SCFβ-
TrCP complex which attracts E3 ubiquitin ligase and degrades REST 29, 30.  Likewise, 
overexpression of β-TrCP results in excessive REST degradation as reported in mammary 
epithelial cancer 28.   
 REST Transcriptional Repression Mechanism  
The mechanism of REST transcriptional repression is not entirely known however, it is 
initiated when the REST zinc finger domain recognises an RE1 site (Figure 3 A).  The 
interaction of REST with DNA is then increased by the bromodomain of Brahma-related 
gene 1 (BRG1, an ATP-dependent dependent helicase also known as SMARCA4) protein, 
which increases REST occupancy through increasing the acetylation of histone H4 lysine 
8 (H4K8) resulting in reducing the chromatin condensation around REST target site and 
allowing REST to form more stable binding with the RE1 site DNA 5, 31 (Figure 3 B).   
Then Both of REST terminal domains work as hubs to recruit several chromatin-modifying 
enzymes that cannot directly bind to DNA.  The NTD recruits mSin3 complex, which 
contains interaction domains for the histone deacetylases (HDAC1 and HDAC2).  The 
CTD recruits several transcriptional repression complexes including the CoREST (REST 
corepressor 1) complex, which incorporates HDAC1, HDAC2, LSD1 (a H3K8 
demethylase) and G9a ( a H3K9 methylase) 25, 32 (Figure 3 C).  Once REST is attached to 
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its connate site on DNA, the HDAC enzymes that are recruited by mSin3 and CoREST 
catalyse the removal of acetyl groups from lysine amino acids on H3 and H4 tails and 
promote the electrostatic binding between histone tails and surrounding DNA allowing 
histones to wrap the DNA more tightly 32.  Deacetylation of H3K9 stimulates LSD1 (a 
histone H3K4 demethylase) and G9a methyltransferase activity which removes the methyl 
group of H3K4 and di-methylate H3K9, respectively leading to chromatin condensation 
12.  Methylated H3K9 can recruit heterochromatin protein 1 (HP1) which interacts with 
adjacent nucleosomes resulting in long term silencing of an RE1-containing gene 25 (Figure 
3 D).   
These alterations cause DNA condensation and mobilize the nucleosomes with respect to 
the DNA allowing the nucleosomes to bind the DNA more tightly, which imposes a spatial 
control and constrains the access of the transcription machinery 25.  The ability of REST to 
recruit several chromatin alteration factors may also explain the ability of REST to induce 
long-term repression of RE1-containing genes, even when its expression is downregulated.  
Hence, removing REST from the promoter of an RE1-containing gene may not be adequate 
to restore gene expression due to the chromatin modifications that are induced by the REST 
complexes 33.   
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Figure 3: REST repression mechanism 
REST transcriptional repression starts when REST zinc fingers recognise an RE1 site (A).  
The bromodomain of BRG1 then acetylates H4K8, which reduces the chromatin 
condensation around the RE1 site (B) and facilities the recruitment of REST corepressors 
complexes (C).  REST corepressors contain several histone modifiers and chromatin 
modulators that induce spatiotemporal control of gene transcription (D).  
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1.2 REST Involvement in Medulloblastoma  
 Medulloblastoma  
Medulloblastoma is the most common and aggressive form of embryonal and childhood 
brain tumour.  It develops in both adults and children with a peak incidence between age 4 
and 7 years though it has a rare occurrence in adults.  The exact aetiology of 
medulloblastoma formation is not well known however, both genetic and epigenetic 
alterations have been reported to be involved in medulloblastoma development and 
treatment response 34.  As medulloblastoma is an embryonic tumour, the number of the 
tumour stem cells has been reported to be very low and they involved in cancer initiation, 
propagation, metastasis, and recurrence 35.  These cells characterized by expression of stem 
cell markers including CD133, regulate stemness pathways such as Wingless-Type 
signalling pathway (WNT) and Sonic hedgehog (SHH), and they have the ability to 
differentiate into multiple tumour cell types which contributes in the intratumoral 
heterogeneity 36.  The cells are also have high capability of DNA repair which contributes 
in tumour resistance to therapy 35.  The tumour stem cells have also been found to be tightly 
associated with medulloblastoma dissemination along the cerebrospinal fluid pathway in 
approximately 30% of cases especially in late stages yet, the dissemination outside the 
central nervous system is very rare 36, 37.  Hence, understanding the molecular regulation 
of stem cells in medulloblastoma will contribute to the discovery of more efficient 
anticancer agents and helps in improving the survival rate. 
Based on the genetic profiling analysis the medulloblastoma tumours were classified into 
four subgroups that vary in clinical outcome, age, gender, and molecular genetics and 
epigenetic signatures 38.  WNT subgroup, represents about 10% of medulloblastomas and 
shows wingless signalling pathway activation.  The majority of WNT medulloblastomas 
have been found to harbour Catenin Beta 1 (CTNNB1) mutations and are characterized by 
Tumour Protein P53 (TP53) mutation 39.  WNT subgroup has the best prognosis among 
the other subgroups even when metastasize and shows more than 5 years survival in more 
than 95% of cases under the current treatment regime 40.  Recently, two WNT subtypes 
have been identified WNT α and WNT β.  WNT α is enriched with monosomy of 
chromosome 6 and mostly observed in children.  WNT β has a high frequency of diploid 
chromosome 6 and mainly affects adults 41.   
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SHH subgroup, which represents 30% of medulloblastoma tumours, displays sonic 
hedgehog pathway activation and is dominated by mutations in MYCN Proto-Oncogene 
(MYCN, a transcription Factor), GLI Family Zinc Finger 2 (GLI2), Patched 1 (PTCH1) or 
Suppressor of fused homologue (SUFU) 42.  Four SHH subtypes have been reported.  In 
affected children  SHH α shows the worst prognosis.  SHH β is more dominant among 
infants, frequently results in metastatic outcome, and has worse overall survival rate. SHH 
γ  mainly affects infants and it is enriched for medulloblastoma with extensive nodularity.  
SHH δ  primarily affects adults and shows more favourable prognosis 41.  Generally, the 
SHH subgroup has an intermediate prognosis and around 64% of cases reach 5 years 
survival however, cases with TP53 mutations showed poor prognosis 43.  Both WNT and 
SHH medulloblastomas have been found to be driven from embryonic cell types.   
Group 3 and Group 4 medulloblastoma have the generic name as not much is known about 
their genetic origin however, they are significantly different.  Group 3represents 20% of 
medulloblastomas, occurs exclusively in children, frequently metastatic, and represents the 
worse prognosis of all subgroups.  Three subtypes of Group 3 have been identified; Group 
3α represents around 60% of cases with a favourable outcome.  Group 3β shows a 
favourable outcome with low frequency of dissemination and mainly affects the over 3 
years old.  Group 3γ has the worse prognosis and is enriched with isochromosome 17 q 
arm (iso17q) and MYC expression 41.   
Group 4 is the most common medulloblastoma subgroup and represents 40% of cases 
though it is the least understood of the subgroups and often exhibits iso17q.  Lately three 
subtypes of Group 4 have been identified; Group 4α which is enriched by MYCN 
amplification, chromosome 8p loss and 7q gain.  Group 4β enriched for Cyclin Dependent 
Kinase 6 (CDK6) amplification and shows a high level of neurodegeneration.  Group 4γ is 
enriched for chromosome 8p loss and 7q gain and CDK6 amplification 41.  Both of Group 
3 and 4 medulloblastomas do not have a specific therapy target, present unfavourable 
clinical prognosis and have been proposed to initiate from a foetal cell type 44.    
Approximately 87 % of medulloblastoma cases were diagnosed as Group 4, Group 3 or 
SHH, which show the unfavourable clinical outcome of most medulloblastoma cases 44.  
Based on the research findings it can be clearly seen that medulloblastomas display a 
considerable intertumoral and intratumoral heterogeneity which increases the difficulty of 
developing targeted treatments.  Also, the genetic signature of medulloblastoma metastases 
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is considerably different to their parent primary tumours which has important implications 
on medulloblastoma treatment as the vast majority of the research focuses on primary 
tumours. 
Molecular analysis of medulloblastoma has revealed the presence of somatic copy number 
aberrations and mutations in histone lysine methyltransferases, demethylases, 
acetyltransferases and deacetylates, and in some members of the polycomb transcriptional 
repressor complexes such as PRC1 and PRC2.  However, the frequency of the reported 
mutation is relatively low across the medulloblastoma subtypes 45.   
Current medulloblastoma treatment strategies mainly depend on patient stratification into 
Low-risk, High-risk, and Standard-risk groups, based on the clinical features and outcome.  
The Low risk is characterized by positive β-catenin (cell adhesion protein), presence of 
large-cell anaplastic (LCA), or it shows MYC amplification, though it does not 
metastasise.  The High-risk is defined as metastatic disease with LCA, or demonstrates 
MYC amplification.  Whereas, the Standard-risk are the cases that lacks the high and low 
risks discriminating features 46.  This classification, in general has improved the treatment 
response and the overall survival to more than 70% 46.  Unfortunately, nearly 30 % of 
patients demonstrate the High-risk form of the disease and they experience the recurrence 
of the tumour 14.  Apart from SHH pathway, targetable therapy such as Vismodegib (a 
smoothened inhibitor) and Sonidegib (a SHH inhibitor that blocks SHH through PTCH 
and Orthodenticle homeobox 2 (OTX2) genes) there are no targetable genes or pathways 
for the other medulloblastoma subgroups 7, 47.  Existing medulloblastoma treatment is 
mainly based on chemotherapy, radiotherapy and surgery however, they have serious and 
long-lasting side effects.  Clinical trial of children with medulloblastoma receiving 
radiotherapy plus chemotherapy showed more than 75% event-free survivals and 80% 
overall survival rate in five- and 10-years 48. Unfortunately, many of the recovered cases 
develop severe late toxicity which severely affects the growth, endocrine function, 
neurocognitive development.  It also could result in cardiac, pulmonary, and gynecological 
toxicity 49.  
Elevated REST expression has been reported in approximately 80% of the 
medulloblastoma tumours and it is associated with elevation in Myc pathway expression 
11, 14, 50, 51.  It has been proposed that elevated REST expression may sustain the 
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proliferation of the NSCs and prevent their differentiation which may propose REST as an 
attractive therapeutic target due to its reversible nature 11, 14, 51.  
 REST Contribution in Medulloblastoma  
The majority of REST expressing medulloblastoma cells do not express neuronal 
differentiation genes such as Synapsin I, Tubulin Beta 3 Class III (TUBB3), and Superior 
Cervical Ganglion-10 Protein (SCG10, also known as Stathmin 2 (STMN2)), which 
indicates the direct repression effect of REST 52.  Based on immunohistochemistry, western 
blot, and quantitative PCR analysis around 80 % of medulloblastoma cases show high 
REST expression and poor cellular differentiation 11, 14, 50.   It has also been reported that 
patients with high REST-expressing tumours exhibit worse overall survival, have higher 
occurrence of metastasis, and demonstrate the poorest prognostic indicator compared to 
REST-low and negative tumours 14, 37.  Knocking down REST in human medulloblastoma 
cell lines such as Daoy and D283 has been reported to repeal the tumorigenic potential of 
these cells, upregulate neuronal genes expression, and trigger apoptosis 9, 11, 14, 50.  
Exogenous induction of REST in normal neuronal progenitor cells has been claimed to 
stimulate tumour formation and maintain the self-renewal potential of NSCs 53.   Hence, 
REST has been suggested as a promising target for neuronal and non-neuronal cancer 
however, there is no accessible drug to target REST expression.  Nevertheless, targeting 
REST repression complexes, in particular recruited HDACs, has been an area of enormous 
research interest.  Some medulloblastoma subgroups such as SHH, Group 3 and Group 4 
have been found to overexpress HDACs.  Hence, targeting HDACs has been suggested to 
reduce  the viability of cells, especially in those expressing MYC 54.   
Several HDACis have been approved as anticancer drugs due to their ability to activate the 
transcription of silenced genes, arrest cell proliferation, induce differentiation, promote 
apoptosis, intensify host immune response to cancer cells and impair angiogenesis 55.  
Remarkably, HDACis have shown the most tolerable side effect profile compared to the 
traditional chemotherapy.   
As HDACs are one of the elements of this study, the following sections will introduce 
HDACs, their classes, deacetylation function and their role in cancer.  They also will give 
a summary about HDACis pharmaceutical properties and actions.  
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1.3 HDACs as a Potential Target for Cancer Therapy 
The genetic mutations have been considered as primary factors for cancer initiation and 
formation as they induce a dramatic effect on activating oncogenes and blocking the 
expression of tumour suppressor genes.  However, epigenetic changes such as methylation, 
acetylation, deacetylation and phosphorylation also play major roles in cancer cell growth, 
invasion, metastasis, and treatment response 44, 56.  A typical picture of human cancer shows 
a disruption in most of epigenetic regulators, including the balance between the acetylation 
and deacetylation (which has major implications in cancer cell growth), metastasis, 
heterogeneity and drug resistance.  Thus far there is no conclusive evidence about the 
mechanisms that cause the disruption in this balance.  However it has been widely observed 
that the irregular Histone acetyltransferases (HATs) expression in leukaemia, colorectal, 
gastric and, breast cancers is a result of overexpression, genetic mutations, or chromosome 
translocations of HAT genes 6.  Also, mutations in HATs binding complex such as p300 
and CBP, which function as tumour suppressor-like genes, have been found to stop HAT 
transcriptional coactivation 57.  However, mutations in HDACs genes were mainly reported 
in leukaemia cancers.   
 Acetylation and Deacetylation of Histone Lysine Residue    
Acetylation and deacetylation are the most common histone modifications that regulate 
chromatin structural remodelling through adding or removing the epsilon group of lysine 
(K) amino acid 58.  The histone is an octameric structure assembled from a histone H3 and 
H4 tetramer and two H2 and H2B dimers.  Histone tails contain a large number of 
positively and negatively charged amino acids which dictate the binding affinity between 
histones and DNA.      
Lysine is one of the amino acids in the histone tail that has a major role in regulating genes 
expression.  The lysine residue is an -amino acid that includes an -amino group (NH2) 
attached to the fifth carbon atom and has a positive charge at the physiological pH.  The -
amino group on histone tails works as a substrate for a variety of enzymatic activity and 
post-transcriptional modification; including acetylation and deacetylation, methylation, 
phosphorylation and ubiquitination.  The collective effect of these modifications generates 
an epigenetic coding system that regulates genes expression.   
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Acetylation of a lysine residue neutralizes the positive charge on the amino acid via HATs 
enzymes resulting in the transference of an acetyl moiety from acetyl-Coenzyme A to the 
-group of a lysine (Figure 4).  The acetylation process reduces the interaction between 
histones and the negatively charged DNA, resulting in more relaxed chromatin and the 
formation of euchromatin which holds the most active genes 59.  The acetylation 
mechanism can affect a single factor in several ways.  For instance, acetylation of 
transcription factors can change protein stability, protein-protein interactions, protein 
localization and DNA binding.  Also, the acetylation location of an acetyl group may 
enhance or repress DNA binding ability.  In addition, it may enhance the binding of non-
histone proteins such as p53, NF-κB, and several of other proteins, or reduce the binding 
of other factors such as FOXO1 (works as myogenic growth and differentiation), HMGA1 
(regulates gene transcription), and p65 (NF-κB Subunit) 60. 
Conversely, deacetylation is an antagonist process of acetylation, catalysed by HDACs, 
and results in the removal of acetyl group from acetylated lysine, adding a charge, and 
generating a free acetate (Figure 4).  Adding a positive charge to histone tails increases 
histone interaction with the negatively charged DNA backbone resulting in increasing the 
condensation of the surrounding chromatin (heterochromatin, inactive genes), and 
blocking the access of the transcriptional machinery 58.  Deacetylation of histone H3 and 
H4 is generally associated with gene transcriptional repression.  The machinery of lysine 
acetylation and deacetylation is a reversible post-transcriptional modification process that 
induces spatiotemporal control on gene expression.  Over the years it has become evident 
that histone deacetylase is a misnomer as HDAC enzymes targets many of non-histone 
proteins.   
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Figure 4: Acetylation and deacetylation of a lysine residue 
Acetylation of a lysine residue is the process that neutralize the positive change of lysine, 
using HATs enzymes and results in transferring an acetyl moiety from acetyl-Coenzyme A 
to the -group of a lysine.  Conversely, deacetylation is an antagonist process of 
acetylation, catalysed by HDACs, and results in the removal of acetyl group from 
acetylated lysine, adding a charge and generating a free acetate. 
 HDACs Classes  
Human HDACs are a family of 18 enzymes grouped into four classes (I, IIa, IIb and IV) 
based on the sequence homology of their catalytic domains to yeast (Saccharomyces 
cerevisiae) deacetylases.  The HDAC enzymes are different in their molecular structure, 
enzymatic function, expression level and subcellular localization 58.  These enzymes 
cannot solely bind to DNA and they are recruited to a target gene by association with a 
transcriptional activator or repressor protein, or through incorporation with multiprotein 
complexes such as Co-REST, mSin3, SMART/N-CoR, Polycomb Repressive Complex 2P 
(RC2), Nucleosome Remodeling Deacetylase (NuRD), and Zinc Finger MYM-Type 
Containing 3 (ZMYM3) complexes 45.   
HDAC classes I, IIa, IIb and IV are predominantly expressed in nucleus and they depend 
on zinc as a cofactor to deacetylate lysine residues 59.   HDAC Class III or (Sirtuins) is a 
specific group of nicotinamide adenine dinucleotide (NADs+) dependent HDACs that 
deacetylate histone and non-histone proteins.  There are more than 50 of non-histone 
proteins that are regulated by HDACs and they have different cellular function ranging 
from tumour suppressor, transcription factor, signalling mediator, oncoprotein, steroid 
hormone receptors, and DNA-repair protein 58 (Appendix 1). 
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 HDACs and their Involvement in Cancer  
In cancer the expression of HDAC enzymes is widely variable between various types of 
tumours and within the tumour cells of the same entity.  However, the elevated HDACs 
level is mostly accompanied with a severe disease condition and poor survival 61.  It has 
also been reported that the expression of class I HDAC is frequently upregulated in cancers 
whereas, the class II HDAC is often downregulated and its high expression is associated 
with a better prognosis 62.  The following 4 subsections will introduce the HDACs 
subclasses and their involvement in cancers.  
 Class I HDACs and its Involvement in Cancer  
Class I HDACs is a family of four members (HDAC1, 2, 3, 8) that show a high enzymatic 
activity to histone 3 and 4.  All the members are localized predominantly within the nucleus 
apart from HDAC8 which is found both in nucleus and cytoplasm.  HDAC1 and HDAC2 
are very similar and generally found together in most repression complexes such as mSin3, 
CoREST, PRC2 and NuRD complexes 58.  Cells with blocked HDAC1 and HDAC2 
expression have been reported to show high sensitivity to DNA damaging agents.  This 
could be due to the ability of HDAC1 and HDAC2 to repress the transcription at DNA 
damaging sites which allows DNA repair mechanism to take place 63.   In medulloblastoma 
elevated expression of HDAC2 has been reported in SHH, Group 3 and Group 4 
subgroups and it is connected with poor prognosis 54.  Modulating HDAC2 expression 
resulted in reducing the metabolic activity, cell growth and viability, and stimulated cell 
death 54.  HDAC3 shows a considerable role in DNA repair regulation, which may suggest 
the significant therapeutic benefits of targeting HDAC3 in cancer treatment 64.  HDAC8 
has the ability to deacetylate histone and non-histone proteins though its protein complex 
is not clearly known 58.  Recently HDAC8 has been reported to play an important part in 
regulating the transcription of wild-type and mutant p53 protein, suggesting that inhibiting 
HDAC8 could be a tool to block mutant p53 expression 65.      
 HDAC Class IIa and its Involvement in Cancer 
HDAC Class IIa consists of a family of four members (HDAC4, 5, 6 and 9) that have 
approximately 40% sequence homology.  They exhibit the lowest deacetylation activity 
among all HDACs and are primarily implicated in muscle cell differentiation and 
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development 59.  They are present either in the nucleus or the cytoplasm, bind to C-
terminal-binding protein (CtBP) and HP1 complexes, and display tissue-specific 
expression pattern 66.  They have also been reported to assist in recruiting Class I HDACs 
to a repression complex through their NTD, which probably accounts for a part of their 
repression function 58.    High expression of Class IIa HDACs members has been reported 
in cancer and they showed cancer-dependent expression.  For example, the expression of 
HDAC4 is higher in breast cancer compared to colorectal, bladder, and renal cancers 67.  
Overexpression of HDAC5 and HDAC9 has also been associated with a high-risk 
medulloblastoma group, and they were proposed as markers for poor survival 68.  HDAC7 
overexpression has mainly been reported in pancreatic cancer 59. 
 Class IIb HDACs and its Involvement in Cancer 
Class IIb is (HDAC6 and 10) a unique HDAC isoform as it has two homologues catalytic  
domains, is mainly expressed in cytoplasm, and has been reported to regulate cell cycle, 
cell migration, apoptosis, and metastasis of cancer cells 69.  Overexpression of HDAC6 has 
been reported to promote cancer cell proliferation through acetylating cancer-related 
pathways such as Heat Shock Protein 90 (Hsp90), cortactin (rearranges the actin 
cytoskeleton) and -tubulin.  It also reduces the sensitivity of HDACis through stabilizing 
Epidermal Growth Factor Receptor (EGFR).  Inhibiting HDAC6 expression in lung 
adenocarcinoma and glioblastoma has been found to reduce the EGFR level resulting in 
diminishing the associated signalling pathway and initiation of apoptosis  69.  Not much is 
known about HDAC10 though it has been found to be overexpressed in high-risk 
neuroblastomas and ovarian cancer.   
 Class IV HDAC and its Involvement in Cancer 
HDAC11 is the only isoform of Class IV and the depletion of its expression does not affect 
cell metabolic activity and viability 70.  Overexpression of HDAC11 has been suggested to 
suppress Bone Morphogenetic Protein 4 (BMP4) expression, which increases cancer 
malignancy in colon, prostate, breast, and ovarian cancers.  Inhibiting HDAC11 expression 
has been reported to induced apoptosis and inhibit the metabolic activity of some of non-
neuronal cancers 70.  See (Table 1) more information about the HDACs contribution in 
medulloblastoma. 
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Table 1: Summary of HDACs contribution in medulloblastoma 
HDACs The activity of HDACs in medulloblastomas 
HDAC1 Selective inhibition of HDAC1 in Med1-MB mouse cell line and reported 
to affect the SHH medulloblastoma cell growth 71.  In human, its expression 
is downregulated in the prognostically unfavourable medulloblastoma 
groups 68. 
HDAC2 Showed elevated expression in SHH, Group 3, and group 4 and has been 
associated with medulloblastoma unfavourable outcome.  Depletion of 
HDAC2 in Myc amplified cells such as MED8A, UW228-2, ONS76 and 
DAOY increased the acetylation of Histone 4 and induced cell death 54. 
HDAC3 Did not show high expression in medulloblastoma and its contribution in 
medulloblastoma tumorigenesis and treatment has not been investigated 68. 
HDAC4 Downregulated in the prognostically unfavourable medulloblastoma 
groups yet, not much are known about its role in medulloblastoma 68. 
HDAC5 
HDAC9 
Showed the high expression in primary medulloblastomas and 
prognostically poor subgroups and they are significantly associated with 
poor overall survival.  Knockdown their expression in medulloblastoma 
cells such as Daoy, UW228-2, UW228-3, ONS76, and Med8A resulted in 
decreased the cells growth and viability 68. 
HDAC6  Upregulated in SHH-MB mouse cell line and knocking down its expression 
lead to cell death 71. 
HDAC7 Its contribution in medulloblastoma tumorigenesis and treatment has not 
been investigated.  
HDAC8 Slightly elevated in medulloblastoma cell lines such as UW-288-2, 
DAOY, and ONS76 yet, its contribution in medulloblastoma 
tumorigenesis and treatment has not been investigated 72. 
HDAC10 Elevated HDAC10 expression is associated with poor outcome of treated 
medulloblastoma patients 73. 
HDAC11 Showed reduced expression in Smo/Smo medulloblastoma mouse model 
74. 
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1.4 HDACis As Anticancer Drugs 
HDACis are a group of epigenetic molecular drugs that interact with the catalytic domain 
of HDAC enzymes and block their activity.  The principle of the epigenetic cancer therapy 
mainly depends on reversing epigenetics abnormalities that support the disease formation 
which often results in loss or gain of function of many cellular regulators including 
proliferation, differentiation, cell cycle, angiogenesis and apoptosis mechanisms 75.  These 
simultaneous actions on multiple factors represent a major advantage of HDACis as 
anticancer therapeutics, and it explains their ability to treat different cancers.  Currently, a 
large number of HDACis are in clinical trials, and to date five were approved for clinical 
use (four drugs approved by the US Food and Drug Administration, namely  Vorinostat, 
Romidepsin, Panobinostat and Belinostat, while Chidamide is approved in China) 76.  
Clinically the inhibitors have shown potent anticancer activity with remarkable specificity 
to tumour cells and the side-effects were favourable in small set of patients with selected 
diseases 76.  Also, they showed several advantages over the classical anticancer drugs.  One 
of their major advantages is that they showed high selectivity to transformed cells and they 
have not shown damaging effects on normal cells 60.   
Most transformed cells showed high sensitivity to HDACis compared to normal cells 
however, this sensitivity mainly depends on cancer type, inhibitor structure, concentration 
and exposure length 6.   The exact mechanism of the effect of HDACis on tumour cells and 
not normal cells is unclear.   
1.5 The Therapeutic Action of HDAC Inhibitors  
In recent years the list of the HDACis has grown and the research work to uncover their 
biological and chemical mechanisms has become one major research theme in cancer 
treatment  77.  A large number of studies have tried to decipher the therapeutic mechanisms 
of HDACis though this regulation is too intricate and often embedded in a network of 
molecular interactions that occur simultaneously.  Generally, the findings of these studies 
have pointed out several of cellular mechanisms that collectively resulted in a lethal effect 
on the tumour cell.  These mechanisms result in cell differentiation and cell cycle effect, 
DNA damage, deregulation of non-coding RNA, autophagy, deregulation of cellular 
signalling pathways, and affect angiogenesis (blood vessels formation).  They also 
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modulate the immune response and stimulate apoptosis 78.  However, the onset and the 
regulation of these mechanisms are relatively different between cancers and they are 
mainly shaped by; the tumorigenesis regulation, the inhibitor selectivity, and the dosage 
and the duration of the treatment.  Interestingly, much of the crosstalk between these 
mechanisms is poorly understood and their initiation factors remain unclear. 
Current understanding of HDACis molecular action has outlined several important cellular 
and molecular mechanisms of HDACis anticancer effects including stimulation of 
apoptosis, DNA damage, anti-angiogenesis effect, and the effect on cell cycle. 
 HDACis Induce Apoptosis 
HDACis have been reported to stimulate both the extrinsic and the intrinsic 
(mitochondrial) apoptotic pathways (Figure 5).  The stimulation of the intrinsic pathway 
has been reported to be through decreasing the expression of the anti-apoptotic proteins 
such as B-Cell Lymphoma 1 Protein (Bcl-1) and B-Cell CLL/Lymphoma 2 (BCL2) and 
upregulating the proapoptotic proteins such as BCL2 Associated X Protein (Bax), BCL2 
Antagonist/Killer 1 (Bak) and BCL2 Like 11 (BCL2L11) which initiate the intrinsic 
pathway 60, 79, 80.  It has also been found that the hyperacetylation effect of HDACis in 
medulloblastoma initiates p53-dependent Bax activation, which delays the progression in 
cell-cycle and activates the proapoptotic genes 81.  HDACis stimulate the extrinsic pathway 
through activating death receptors such as Death Receptor 5 (DR5), Apoptosis Antigen 1 
(Fas), Fas Ligand (FasL, a TNF family member) and TNF-related Apoptosis-inducing 
Ligand (TRAIL) 34, 82.  It has been reported that Blockade of these factors resulted in 
decreasing the efficacy of HDACis in preclinical settings 83. 
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Figure 5: Role of HDAC Inhibitors in regulating apoptosis   
In cancer, HDACs function as apoptotic repressors factors therefore, treatment with 
HDACis has been suggested to release the repression effect and upregulate the expression 
of the pro-apoptotic proteins and downregulate the expression of the anti-apoptotic 
proteins.  HDACis activate apoptosis in cancer cells through both the extrinsic and 
intrinsic pathways.  Note: Black arrows mean activate, while red arrows mean 
downregulate.   This figure was adapted from Li et al., 2014 75. 
 HDACis Induce DNA damage  
HDACis have been suggested to promote DNA damage response though increasing the 
acetylation level leading to relaxation of the chromatin 78.  Consequently the DNA becomes 
more susceptible to damaging agents such as Reactive Oxygen Species (ROS), DNA 
damaging drugs, or radiation which eventually lead to caspase-independent cell death 78.  
HDACis have also been reported to downregulate the expression of homologous 
recombination DNA-repair genes through decreasing the expression of E2F Transcription 
Factor 1 (E2F1), RAD51 Recombinase (RAD51), HDAC1 and HDAC2 which are known 
through their role in regulating the expression of DNA-repair proteins 78, 84.   
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 HDACis Anti-Angiogenesis Effect 
In most transformed cells, HDACis have been found to block blood vessels formation by 
blocking the expression of angiogenesis-related genes such as Hypoxia-inducible factor -
1α (HIF-1) and its target Vascular Endothelial Growth Factor Receptor-2 (VEGF) gene.  
They also upregulate genes that are known by their angiogenesis suppressing  role such as 
p53, von Hippel–Lindau (VHL, a tumour suppressor), Neurofibromin 2 (NF2), and 
Thrombospondin-1 (TSP1) 85.   
 HDACis Interfere with Cell Cycle 
In cancer HDAC 1, 2, 3, 4 and 6, have been reported to have a considerable involvement 
in cell cycle progression and proliferation 78.   For example, the lack of HDAC1 and 
HDAC2 expression stops cell progression to G1 phase both in normal and cancer cells 
therefore, selective inhibition of these HDACs has been proposed to inhibit cancer 
proliferation 86.  Also, it has been found that diminishing HDAC4 expression is associated 
with an increase in Cyclin Dependent Kinase Inhibitor 1A (p21WAF1) expression in some 
cancer cells which contributes to inhibiting tumour cell growth and stimulates apoptosis 
87.  
1.6 The HDACis used in this study  
HDACis are a family of large and diverse naturally occurring and synthetic compounds 
that have different structures, function and specificity.  Generally, HDACis can be 
classified into four structural groups; hydroxamic acid, cyclic peptides, bibenzimides, and 
short-chain fatty acids.  Each HDAC inhibitor comprises three domains; a zinc-binding 
domain which chelates the zinc cofactor of a HDAC and inactivates its enzymatic activity, 
a surface binding domain that blocks the entrance of a HDAC channel to the active site, 
and a linker which connects the previous two domains and fills the hydrophobic channel 
leading to the HDAC catalytic site 60 (Figure 6).  In this study, five HDACis were used and 
the following sections will give a brief overview about each inhibitor.  See Appendix 2 for 
more information about the chemical properties of these inhibitors.  
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Figure 6: Representation of HDACis blocking the catalytic domain of a HDAC 
enzyme 
HDAC inhibitor comprises of three domains; a zinc-binding domain which chelates the 
zinc cofactor of a HDAC, a surface binding domain, and a linker.  Adapted from Kevin et 
al., 2005 88. 
 SAHA (Vorinostat) 
SAHA is a hydroxamic acid class HDACi and it is the first HDAC inhibitor approved by 
FDA-approved to treat Cutaneous T-cell lymphoma, non-Hodgkin’s lymphoma and 
mantle-cell lymphoma 60, 89.  In solid cancers, using SAHA as single treatment was 
ineffective in most clinical trials and it has been strongly recommended to use SAHA either 
in combination with other treatment or prior using conventional cancer treatments 90.  
SAHA shows a high effectiveness in inhibiting class I and class IIb in a sub-micromolar 
range 91.  In vitro analysis showed that SAHA exhibits rapid kinetic binding rate and it 
induces rapid acetylation, in particular with Acetyl-Histone H2B Lys5 (H2BK5) and 
Acetyl-Histone H4 Lys12 (H4K12).  Washout of SAHA induces a rapid dissociation of 
SAHA kinetic binding followed by decrease in acetylation to the basal level 91.  SAHA 
stimulates cellular apoptosis through activating TRAIL expression in breast cancer and 
ROS in leukaemia 78.   
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 MS-275 (Entinostat) 
MS-275 is a benzamide class HDAC inhibitor characterized by its slow binding and 
dissociation properties which has been attributed to the need to disrupt the hydrogen bonds 
that connect a protein structure in order to accommodate MS-275 lipophilic aromatic rings 
91.  MS-275 demonstrates a broad anticancer activity and well-tolerated side effects in the 
Phase I clinical trials of acute myeloid leukaemia and refractory solid tumour 92.  On the 
molecular level MS-275 exhibits a greater HDAC isoform selectivity to class I HDACs 
with sub-micromolar effectiveness to HDAC1 and 3 93.  
MS-275 has been found to display dose-dependent effect on cells.  For example, at low 
concentration (1 µM) MS-275 acts as an antiproliferative agent through increasing the 
expression of p21waf1 growth arresting protein, hypo-phosphorylate Retinoblastoma 
Tumour Suppressor Protein (pRB), and downregulates the expression of most cell cycle-
related proteins including cyclin D1 94.  However, at higher concentrations (5 µM) it 
induces early increase in ROS, followed by loss of mitochondrial membrane, cytosolic 
release of cytochrome c, and ultimately triggers apoptosis 94. 
 MI-192 
MI-192 is benzamide HDAC inhibitor, characterized by its inhibition selectivity to class I 
HDACs with high affinity to HDAC3 (> 60-fold effective that MS-275) and limited 
affinity to HDAC2 95. In Leukaemia, MI-192 has been reported to inhibit TNF and 
Interleukin 6 (IL-6) production and induced cellular differentiation and apoptosis with no 
observed effect on normal bone marrow cells 96. 
 Apicidin 
Apicidin is fungal metabolite that has cyclic tetrapeptide structure and exhibits HDAC 
inhibiting activity against class I HDAC with a higher affinity to HDAC2 and HDAC3 93.  
Apicidin has been reported to display anti-proliferative activity in many cancers through 
altering the expression of p21WAF1, cyclin A and E-cadherin 97.  Also, it showed apoptotic 
activity in leukaemia through Fas/Fas ligand, and activation of mitochondria-dependent 
caspase  98. 
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 Valproic Acid 
VPA is a short chain fatty acid HDACi with more affinity to class I (HDAC1, 2, 3 and 8) 
than class IIa (HDAC4, 5, 7 and 9).  Clinically VPA was exclusively tested as a 
monotherapy and it showed improvement in 24% of acute myeloid leukaemia and 
myelodysplastic syndrome patients 99.  It has also been approved to treat epilepsy and 
depression.  Combination treatment of VPA with other anticancer drugs appears to be more 
efficient and less toxic 99.  VPA has been found to act as a radioprotection for normal 
hippocampal neurones in radiation therapy through increasing the expression of the anti-
apoptotic proteins and downregulating the pro-apoptotic proteins.  It has also been found 
to act as a radio-sensitizer with glioblastoma cells through inducing cell cycle arrest 100.  
From more information about the HDACis targets and their effective inhibitory 
concentrations see table (Table 2). 
Table 2: Summary table of HDACis targets and their IC50  
HDACis HDACs Target IC50 
SAHA 
Classes I, II and IV marked 
decrease in HDAC1 75 
10 nM 101 
MS275 
Strongly inhibits HDAC1, 
HDAC2, and HDAC3 54 
HDAC1 (300 nM) 101 
HDAC2 (130 nM) 101 
HDAC3 (720 nM) 101 
MI192 HDAC2 and HDAC3 95 
HDAC2 (16 nM) 95 
HDAC3 (30 nM) 95 
Apicidin HDAC2 and HDAC3 93 
HDAC2 (1 nM)101  
HDAC3 (2 nM) 101 
VAP 
Class I and II HDAC inhibitor 
with a high potency for HDAC199 
0.4 - 20 mM 101 
1.7 HDACis Side-Effects 
Despite the HDACis favourable outcomes in clinical trials their chronic administration is 
possibly associated with risk of increasing the side effects and cytotoxicity which could 
bring fatigue, dehydration, diarrhoea, and moderate thrombocytopenia 61.  In addition, the 
effect of HDACis on normal neuronal and non-neuronal growing cells and stem cells has 
not been well addressed yet.  In several studies depletion of HDAC1 and HDAC2 in mice 
has been reported to cause sever structural abnormalities in brain cerebellum and 
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hippocampus which results in a lethal effect 102.  Depletion of HDAC3 also causes an 
imbalance between carbohydrate and lipid metabolism and leads to embryonic death 61.  
Therefore, using non-selective HDACis to treat cancer could unnecessarily block some 
HDACs that are required for normal cells function and may result in unfavourable side-
effects.  This may suggest the importance of understanding the pharmacodynamics of 
HDACis in tumour and normal cells. 
1.8 The Research Background and Questions 
 REST Contribution in Medulloblastoma   
The contribution of REST in medulloblastoma has been an area of disagreement in 
literature.  For example, some studies have suggested elevated REST expression as 
oncogene due to its ability to blockade the differentiation of cancer stem cells and retain 
their self-renewal potential, which ultimately contributes to tumour cell proliferation 9, 10.  
Knocking down REST expression in medulloblastoma cell lines such as Daoy and D283 
has been claimed to abrogate the tumorigenic potential of the cells and stimulates apoptosis 
11, 14, 50.  Whereas, the exogenous induction of REST into normal neuronal progenitors cells 
has been claimed to stimulate tumour formation and maintain the self-renewal potential of 
neuronal stem cells 53.  
In contrast, the gene expression studies of medulloblastoma have not proposed REST 
involvement, or at least its exclusive repression of the RE1-containing genes, in 
medulloblastoma tumorigenesis 39, 41, 44, 103.  Also none of the medulloblastoma genome 
sequencing studies have identified any direct or indirect genetic mutations that could 
contribute to increasing REST expression 42, 104.  These conclusions are further supported 
by a recent study which revealed that knocking down REST using an shRNA system 
resulted in inhibiting glioblastoma cells migration yet, it did not stimulate cell death or 
reduce tumour size 12.   Therefore, this research was set out to obtain more knowledge 
about the contribution of REST in the Daoy medulloblastoma cells growth and treatment.  
  HDACis Molecular Action in Tumour and Normal Cells 
Treating with HDACis results in increasing the acetylation level both in normal and 
transformed cells 105, 106, 107, 108.  However, it is not known how HDACis induce their 
anticancer effect in tumour cells and what are the consequences of the HDACis treatment 
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on the normal cell gene expression.  This study aimed to investigate the anticancer 
mechanism of HDACis in the Daoy medulloblastoma cells and explore their effect on 
normal neurons. 
 The Research Hypothesis and Questions  
In this study I hypothesized that: 
• Elevated REST expression in medulloblastoma cells sustains tumour cell growth.  
• HDACis induce their anticancer effect through the HDACs recruited in REST 
repression complexes  
• The study also explored the HDACis molecular regulation in Daoy 
medulloblastoma cells and examined their effect on normal neurons  
This study aimed to address the following research questions:  
➢ Is REST expression elevated in all medulloblastoma subgroups?  
➢ Does REST expression have a main contribution in sustaining the growth of the 
medulloblastoma?  
➢ What is the effect of HDACis on the cell cycle? 
➢ What is the effect of modulating REST on the expression of RE1-containing genes? 
➢ Does REST expression play a role in tumour cell migration ability? 
➢ Do HDACis induce their action through the HDACs recruited in REST repression 
complexes?  
➢ What molecular mechanisms and pathways are mainly targeted by the HDACis? 
➢ What is the effect of HDACis on normal neuronal cells? 
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Chapter 2 
2 Material and Methods 
2.1 Introduction 
 The Experimental Model    
Studying brain tumours in general, and medulloblastoma in specific, has been an area of 
hindrance due to; the intertumoral and intratumoral genetic variations, limited primary 
tumour samples, and the tissue samples are often contaminated with a mixture of 
genetically variant cancerous and non-cancerous cells.  Hence, the cancer cell lines could 
be the ideal model to understand the molecular regulations prior examining the therapeutic 
potential on animal model and eventually in clinical trials.   
Cancer cell lines have been the foundation of cancer treatment research as they are easy to 
expand, comparatively uniform, and their research outcomes can be reproduced.  Though, 
they have been an area of criticism as not always known from what type or subtype of 
cancer a particular cell line was generated from, or to what extent a specific cell line 
resembles the original cancer after years in culture 43.  The established cell lines are 
selected from specific tumour subsets that grow under in vitro culture conditions and this 
selection does not represent the diversity of human tumours 109.  Therefore, cell lines do 
not completely mimic the primary cells and they usually used in the absence of their local 
environment which often contains many interactions with other cell types 110.  The culture 
conditions and the infections with mycoplasma can also affect the morphology, the gene 
expression, the cellular pathways, and the response of a cell line toward tested drugs could 
be different form patient response. Hence, with many studies, what it has been 
therapeutically promising in cell lines and animal models comes back negative in clinical 
trials 111.  This may express the importance of identifying a cell line that best mirrors a 
particular medulloblastoma condition, which will considerably help in generating more 
accurate disease picture both in primary and preclinical research.   
Comparing to other tumours, medulloblastoma has relatively less cell lines which it could 
be due to the rarity of the tumour and the difficulty of establishing a continuous cell line 
from paediatric brain tumour.  Currently, there are around 44 medulloblastoma cell lines 
have been produced over a period of four decades 43.  Eighteen of these cell lines have only 
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been classified into the current medulloblastoma subgroups; eleven cell lines grouped 
under Group 3, four cell lines sub-grouped with SHH, two cell lines under Group 4, and 
one cell lines represents the WNT medulloblastoma 15.  Among these cell lines, Daoy has 
been the most frequently used cell in literature to study medulloblastoma 15 . 
The Daoy cell line was established in 1985 from a biopsy taken from a posterior fossa 
tumour of four-years-old boy 112.  The cell has a polygonal shape with irregular shaped-
nucleus, prominent nuclei, multiple nucleoli, and the cytoplasm contains a large number 
of rough endoplasmic reticulum, Golgi apparatus and many small mitochondrial 
aggregates 112.  On the chromosome level, the cell is hypertetraploid with 93 to 99 
chromosomes and two normal X chromosomes however, the Y chromosome is not 
detectable 112.  The Daoy cell expresses a mutated non-functional form of p53 protein as 
the TP53 gene has a single point mutation at base 725, which results in substituting the 
phenylalanine at amino acid 242 by a cysteine 113.  The original tumour of the cell reported 
to show both of neuronal and glial phenotypes though, the cell line dose not retain these 
phenotypes and it has been reported to contain a mixture of CD133- and CD133+ side 
population 43, 114.  Based on the current molecular profiling of medulloblastoma, Daoy was 
classified as SHH subgroup with mutant p53 43.  Elevated REST expression in Daoy has 
been reported in a large number of literatures which brands the cell as an ideal modal to 
study the effect of REST modulation on tumour cell growth and to study its functional 
effect on the RE1-containing genes 11, 14, 52, 115.  Hence, Daoy was used in this research as 
an experimental model for medulloblastoma. 
To study the effect of hyperacetylation on normal cells, the cerebellum cells are possibly 
the most appropriate counterpart of medulloblastoma however, due to the unavailability of 
such cells the analysis was performed using primary human neurons (ScienCell, 1520).  
The neurons were isolated from a male donor and they are categorized as neurons with 
highly communication networks.  As a result of limited amount of the neurons they were 
exclusively used for the analysis and their sensitivity to the used HDACis was not 
examined.  
 Modulating REST Expression using CRISPR/Cas9 and shRNA 
In most of the earlier studies, the shRNA and the REST-VP16 knockdown approaches 
were the tool of choice to uncover the contribution of REST in medulloblastoma, 14, 50, 53, 
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116, 117, 119.  However, these approaches showed some limitations as the efficiency of the 
knockdown is highly variable between studies and they do not completely block the 
expression of REST, which may affect the interpretation of REST contribution in cancer.  
Therefore, in this study the CRISPR/Cas9 system was used to completely knockout REST 
expression.  As the CRISPR/Cas9 system has not been used before to modulate REST 
expression, the shRNA knockdown approach was used to further confirmed the results of 
the knockout.   
 CRISPR/Cas9 to Knockout REST Expression  
CRISPR/Cas9 is one of the tools that has a high degree of accuracy to modify DNA 
sequence and interrupt gene translation.  CRISPR (or Clustered Regularly Interspaced 
Short Palindromic Repeats) is a pre-designed sequence of around 20 RNA bases known as 
guide RNA (gRNA) designed to target a unique complementary sequence in genome.  
Also, it contains a recognition component for CRISPR associated protein 9 (Cas9) 
endonuclease enzyme known as Protospacer Adjacent Motif (PAM) and located at the 3' 
end.  Both the gRNA and PAM sequences are integrated within a longer RNA scaffold 
which encompasses a sequence-code that activates Cas9.  Cas9 is a Streptococcus 
pyogenes immunity system used with CRISPR to cleave the DNA at the PAM site which 
could result in activating either the non-homologous end joining (NHEJ) or the 
homologous recombination (HR) DNA repair systems 118.  The NHEJ repair pathway is 
the most dynamic mechanism and it frequently causes small nucleotide insertions or 
deletions (indels) at the double-strand break site which leads to disrupting the open reading 
frame of a gene.  Whereas, the HR repair pathway can be utilized to insert specific 
homologous nucleotide sequence immediately upstream or downstream of the target 
sequence.  In this study, I used pCas-Guide system (Origene) which characterized by its 
ability to produce both of the gRNA and the Cas9 expression sequences (Figure 7).  
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Figure 7: The map of the pCas-Guide Vector 
The pCas-Guide is an 8-kb vector, designed for cloning a gRNA insert between a U6 
promoter and gRNA scaffold.  The vector contains a Cas9 cassette driven by a CMV-
optimized codon and an ampicillin resistance gene for E. coli transformation selection.  
The sequence above shows the gRNA1 (green) and its PMA site (blue), and the gRNA2 
(blue) and its PAM site (black). 
 shRNA to Knockdown REST Expression  
short hairpin RNA (shRNA) is an artificial double-stranded RNA molecule used to cleave 
mRNA and knockdown the expression of gene.  In this study, the shRNA was delivered 
into the Daoy cell through an expression vector (pSUPER-Puro) which has a 
Phosphoglycerate Kinase promoter (PKG) promoter sequence located before the cloning 
site and it helps in achieving a robust expression of the shRNA (Figure 8 A).  Also, the 
plasmid contains a puromycin resistance PUR gene which protects the cell from the lethal 
effect of the puromycin selective treatment.   
Once the vector is integrated into a cell genome, the transcription of the shRNA starts by 
producing a pre-miRNA (a hairpin RNA) which then processed by Nuclear RNase III 
enzyme (Drosha) into approximately 70 base pairs long known as small hairpin RNA 
(shRNA).  The resulted shRNA is exported by Exportin 5 into the cytoplasm where the 
connection loop is further processed by riboendonucleases (Dicer).  The antisense (guide) 
strand is then loaded into a ribonucleoprotein known as RNA-induced silencing complex 
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(RISC) and when the sequence of the guide-strand perfectly matches a complementary 
mRNA sequence, the enzymatic activity of the RISC is activated and results in degrading 
the mRNA and silencing the transcription 119 (Figure 8 B).   
In small proportion of the transfected cell, the pSUPER-Puro plasmid is integrated into the 
cell genome and passed into the cell progeny.  This causes a stable expression of the shRNA 
which sustains the knockdown of REST expression.  The selection for the stable expression 
can be achieve by exposing the cells to Puromycin (an amino-nucleoside antibiotic) which 
acts by covalently binding to the elongated polypeptide chains on ribosomes resulting in 
terminating protein synthesis and cell death.  Though, cells that express the puromycin 
resistance gene (puro) inactivates the cytotoxic effect of puromycin 120.  
 
Figure 8: pSUPER-Puro vector map and the shRNA knockdown concept  
(A) pSUPER-Puro is 4.3 kb mRNA expression vector contains an mRNA cloning site driven 
by polymerase-III H1-RNA gene promoter.  Also, it contains a puromycin resistance Pur 
gene cassette driving by the PGK promoter.  This vector produces a small RNA transcript 
missing the polyadenosine tail though, it contains five thymidine basses (T5) signal at the 
start of the transcription and at the termination site.  The termination site is after two 
uridine bases, which yields a transcript that has similar ends to the synthetic shRNA.  (B) 
An illustration for the shRNA knockdown mechanism. 
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 Profiling the Gene Expression at Single Cell Level using the 10x 
Genomics Chromium Single Cell 3’  
One of the aims of this study is to investigate the molecular regulations of the HDACs and 
the HDACis in tumour and normal cells at the transcriptome level.  Until recently, the 
method of choice to address such research question was profiling gene expression using 
microarray analysis yet, the sensitivity and the accuracy of this approach tend to be 
relatively low especially with gene that show low expression.  Also, the microarray results 
should be used for screening only and the findings should be conformed using qPCR 
analysis.  With the advance in Next Generation Sequencing (NGS), the bulk gene 
expression profiling by the RNA-seq has been the preferable alternative due to its high 
analytical sensitivity and accuracy.  This research work was originally designed to be 
performed using the bulk NGS analysis (see Appendix 3 and Appendix 4 for more 
information about the suggested NGS plan).  However, with the advance in the NGS 
analysis, the single cell NGS (scNGS) has become the method of choice to avoid the effect 
of cells heterogeneity especially, and it provides a higher statistical power data to dissect 
the molecular regulation of an individual cell in a diverse population of cells.  With the 
single cell analysis approach measuring the gene expression at a single time point could be 
sufficient to uncover the molecular regulation and understand the differences between the 
cells.  For example, at an early time point of treatment, there will be a mixture of cells at 
their early and late stages of apoptosis, cells that have not initiate the apoptosis mechanism 
and they will die during the late hours of the treatment.  These cells are also distributed 
among each phase of cell cycle.   
The scNGS is a gene expression profiling technique that measure the expression at an 
individual cell level.  The main concept of the scNGS is relying on barcoding the mRNA 
with specific DNA sequence during the reverse-transcription step and measuring the 
transcripts using the NGS.  The barcodes were then used to index the transcripts back to 
their original cell.  Currently, there are several platforms of scNGS all share the previous 
concept but, they are mainly different in; the way of partitioning the cells into a single cell 
reaction, and in their ability to target few hundreds to several thousands of single cells at a 
time.  In this study, the scNGS analysis was performed using the 10x Genomics Chromium 
platform.  
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This platform mainly depends on partitioning a single cell suspension into nanolitre-scale 
reaction vesicles known as Gel Bead in Emulsions (GEMs).  The GEMs are formed on a 
microfluidic chip by combining; gel beads containing barcoded oligonucleotides, in 
parallel with the single cell suspension within an oil vesicle (Figure 9).  This allows 
producing hundreds to tens of thousands of single cells reaction vesicles in less than 7 
minutes using the Chromium Instrument.  The gel beads contain an Illumina R1 sequencing 
primer, a 10x barcode of 16 nucleotides (used to associate the individual reads back to the 
individual cells), a unique molecular identifier (UMI) of 10 nucleotides (10X Barcode, 
used to; count the number of reads of specific sequence, identifies transcriptomes from 
individual cells also, helps in reducing the bias and the noise created during the cDNA 
amplification), and a poly-dT primer.  Whereas, the single cell suspension contains a 
mixture of RT primers and enzymes mix.  Within each GEM reaction vesicle, the poly-
adenylated mRNA was reverse-transcribed and used to generate a barcoded full-length 
cDNA containing the Illumina Read 1 (a primer site for sequencing read 1 and used to 
encode UMI), the 10x Barcode, and the UMI.   After lysing the GEMs, the contents of the 
gel beads are mixed with; the cell lysate, and the master mix.  Due to the small amount of 
the mammalian transcriptome (10 picograms (pg) of the RNA and 0.1 pg the mRNA in a 
typical cell) the full-length cDNA is amplified first.  Simultaneously, the Illumina P5 
primer, the Read 2, the sample index (i7), and the P7 primer (used for Illumina paired-end 
sequencing) are incorporated in the cDNA library.  The Read 1 is used to sequence the 10x 
barcode and the UMI whereas, the Read 2 is utilized to sequence the cDNA fragment.  
Next the library is sequenced on Illumina sequencers using paired-end sequencing with 
single indexing.   
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Figure 9: 10x Genomic Single Cell Generation and Library Construction  
The 10x Genomics platform uses emulsion-tagging to generate single cell reaction vesicles 
or GEMs.  The generation of GEMs is performed on a microfluidic chip by encapsulating 
gel beads and a single cell suspension within an oil vesicle (A).  When dissolution the 
mixture, the reaction generates full-length cDNA from poly-adenylated mRNA containing 
Read 1, 10x Barcode, and UMI.  The cDNA is then amplified and the Illumina P5 primer, 
the Read 2, the sample index (i7), and the P7 primer are incorporated into the cDNA 
library (B).  Next, the library is sequenced on Illumina sequencers using paired-end 
sequencing with single indexing.  Read 1 is used to sequence the 10x barcode and the UMI, 
where Read 2 is utilized to sequence the cDNA fragment. (The images above were adapted 
from the 10x Genomics website (https://www.10xgenomics.com/).  
 Selecting the HDACis 
In this study, five HDACis (SAHA, MS-275, MI-192, Apicidin, and VPA) were used in 
studying the contribution of REST in medulloblastoma.  Yet, due to the high cost of the 
scNGS analysis, the gene expression profiling was performed using SAHA and MS-275.  
The selection criteria for these two inhibitors were based on the inhibitor potency, 
selectivity, and if the inhibitor has been in clinical trials.  In the Daoy cell analysis, all the 
five inhibitors showed high anticancer activity apart from the VPA hence, it was excluded.  
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MI-192 and Apicidin showed high affinity to HDAC3 and HDAC2 and HDAC3, 
respectively.  MI-192 was not selected as it has not been thoroughly investigated, and both 
of MI-192 and Apicidin have not been in clinical trials.  SAHA is a pan-inhibitors and was 
approved for clinical used whereas, MS-275 showed higher selectivity to HDAC 3 and 2 
and it has been in phase II clinical trial 60.  Both of SAHA and MS-275 showed differences 
in the onset of their anticancer activity which attract research interest.  Hence, the scNGS 
analysis was performed using SAHA and MS-275.  
 The Cell Number and the Sequencing Depth of the scNGS  
The number of targeted cells and the transcript sequencing depth are important factor for 
the scNGS analysis.   There are no specific criteria for targeting a specific cell number yet, 
the required number increases with the increase in the heterogeneity of the cells.  
Undoubtedly, it is difficult to predict the degree of the heterogeneity however, the required 
number might be estimated based on the flowcytometry data.  As mentioned earlier, the 
Daoy cell-line has been reported to contain a mixture of CD133- and CD133+ side 
population whereas, the human neurons is a mixture of neurons and glia cells 43, 114.  It 
should be considered that with the Chromium technology there is an increasing chance of 
multiplets (two or more cells within a GEM) rate with the increase in the number of loaded 
cells.  Also, the presence of dead cells in the cell suspension could reduce the number of 
the observed cells.  Once the library prepared, the number of the successfully targeted cells 
can be estimated using the UMI.  Generally, the more cells the greater the statistical power, 
and in this study, we aimed to target 2000 cell for each sample.  
The sequencing depth (Coverage) with the scNGS analysis represents the number of the 
detected transcripts for each cell and can be estimated by normalizing the library as per the 
recommendations of the Illumina sequencing platforms.  The recommended sequencing 
depth for the 10x scNGS is ranged from 50.000 to 100.000 reads/cell whereas, the deeper 
sequencing often leads to saturation and does not improve the number of the detected genes 
121.  In this study, we aimed to reach to a read depth of 100.000 reads/cell. 
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2.2 The Methods  
  Standard Cell Culture 
The human medulloblastoma Daoy cell-line was purchased from ATCC (HTB-186).  The 
SH-SY5Y and HeLa cells were obtained from Dr I. C. Wood.  The cells were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies) supplemented with 10 
% (v/v) Fetal Bovine Serum (FBS, PAA Cell Culture Company) and 1% (v/v) Penicillin 
& Streptomycin (Sigma).  The cells were grown at 37°C humidified incubator in 5% CO2 
air.  Subculturing of the cells was performed every fourth day or when they reached a 
confluency of approximately 80-90%.  The subculturing was carried out by removing the 
old culture media and washing the cells with 10 mL of room temperature phosphate buffer 
saline (PBS, Oxoid [Dulbecco A, 10 mM phosphate buffer, 2.7 mM potassium chloride 
and 137 mM sodium chloride, pH 7.4, at 25 °C], 1 tablet in100 mL of ddH2O, solution was 
autoclaved) for one time.  The cells were treated with 1 mL of Trypsin-EDTA (Sigma) to 
dislodge the cells from the bottom of the culture plate and incubated at 37 °C incubator for 
5 minutes.  The cells were then examined under a microscope to check for their detachment 
and rounded appearance.   Around 9 mL of complete culture media was used to deactivate 
the trypsin, and the cells were released by pipetting the media up and down for 3 times.  
The cell suspension was transferred into 15 mL sterile conical tube.  The cells were pelleted 
by centrifuging the tube at 400 g for 5 minutes, and the supernatant was removed by 
aspiration without disrupting the cell pellet.  The pelleted cells were re-suspended in 5 mL 
complete culture media by gently pipetting the cells up and down to break up the clumps 
using a 10 mL serological pipette.  New subculture plates were prepared by using 1 mL of 
the resuspended cells with 9 mL of complete media and incubated  at 37°C in a humidified 
incubator at 5% CO2 air.  All experiments were conducted on cells with fewer than 15 
passages.   
The confluency of the cell was determined qualitatively using an inverted microscope and 
the confluence was defined as the proportion of the culture surface that was covered by the 
cells at the time of measurement (a confluency of 50 % means half of the culture surface 
was covered by cells). 
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 Culturing the Human Neurons  
Neurons from human brain (P0) were purchased from ScienCell (#1520) in a 
cryopreserved from.  Prior culturing, the surface of a 6-well culture plate was coated using 
2 µL of poly-L-lysine (10 mg/mL, ScienCell) in 2 mL of sterile water and the plate was 
left in a 37C incubator overnight.  The wells were washed twice with sterile water prior 
to use and the neurons were seeded using complete Neurons Medium (NM, contains 
neuronal growth supplement and penicillin/streptomycin solution, ScienCell) at a seeding 
density of ~2.5 x104 cells/well.  The plate was incubated at 37°C humidified incubator in 
5% CO2 air for 16 hours and the media was replaced with 2 mL fresh culture medium. The 
neurons were left in culture for 48 hours before treating them with the HDACis.  
Harvesting the neurons was carried out by removing the old culture media and washing the 
cells for 3 times with 2 mL of cold phosphate buffer saline (ScienCell).  The culture plate 
was then rocked back and forth for a few times and the PBS was drawn out by aspiration.  
The cells were overlaid with 300 µL of Tryple Express (Gibco) to dislodge the cells from 
the bottom of the culture plate and incubated at 37 °C incubator of 7 minutes.  The cells 
were then examined under a microscope to check for their detachment and rounded 
appearance and 1 mL of the NM was used to deactivate the Tryple Express, the cells were 
released by pipetting the media up and down for 3 times, and the cells suspension was 
transferred into 15 mL sterile conical tube.  The cells were pelleted by centrifugation at 
400 g for 2 minutes and the supernatant was removed by aspiration without disrupting the 
cell pellet.   
 Identifying a Suitable Daoy Seeding Density for HDACi Treatment 
The Daoy cells were seeded into 24-well culture plates (Nunc Cell-Culture Plate) using 
following concentrations:1 x 104, 2 x 104, 5 x 104, and 1 x 105 cell/mL.  The cells were 
harvested at 24, 48, and 72 hours post seeding using Trypsin-EDTA as described above. 
Post Trypan Blue staining (0.4%, Sigma), the cells were gently mixed and 25 µL of the 
stained cells were loaded underneath the coverslip of a cleaned haemocytometer allowing 
the cell suspension to be drawn out by capillary action.  The count was performed using 
Neubauer haemocytometer under an inverted microscope.  The cells with a dark blue 
staining were considered dead and excluded from the count.  The total number of viable 
cells was calculated by dividing the cell count by 4 (the average), multiplying by (104) and 
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then by 2 to correct for trypan blue addition.  To measure the sensitivity of the cells to 
HDACis, the cells were seeded at 3.5 x 104 cell/mL in 6-well culture plates and treated 
with HDACis (Table 3).  The cells were harvested (at 24, 48, and 72 hours) and counted 
as described in section 2.2.3). 
 HDACis Preparation  
The HDACis SAHA(10009929); MS-275(13284); MI-192(18288);  Apicidin(10575) were 
purchased from Cayman :and were dissolved in DMSO. Hence, a DMSO cell-treated 
control was included in all experiments.  VPA was purchased from Sigma (P4543) and 
was prepared in water.     
 Generating the Dose Response Curves, and Measuring the Cells 
Proliferation Rate and the Sensitivity to HDACis  
To generate the HDACis dose-response curves and to study the proliferation rate and the 
sensitivity of the cells to the inhibitors, the Daoy cells were harvested and counted as 
described previously (section 2.2.1) and a cell concentration of 3.5 x 104 cell/mL was used 
to seed 96-well culture plates (Greiner).  The plates were left at room temperature for 30 
minutes to allow even distribution of the cells throughout the wells and then the plates were 
incubated at 37C in 5% CO2 air for 24 hours.  HDACis treatment was carried out by 
carefully replacing the culture media with complete media containing the required 
concentration of the drugs (Table 3).  The plates were re-incubated at 37C in 5% CO2 air 
and the viability of the cells was measured after 72 hours from the treatment for the ‘dose 
response analysis’ and at 24, 48, and 72 hours for the ‘sensitivity’ experiment.  The 
proliferation rate was measured at 24, 48, 72 and 96 hours or every 24 hours over a period 
of 7 days.  All the measurements were performed using the colorimetric MTT assay 
(section 2.2.6).   
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Table 3:HDACis concentrations used to produce the dose-response curves  
SAHA (µM) MS-275 (µM) MI-192 (µM) Apicidin (µM) VPA  (mM) 
0.003  0.01  0.003  0.003  0.3  
0.01  0.03  0.01  0.01 1  
0.03  0.1  0.03  0.03 3  
0.1  0.3  0.1  0.1  4  
0.3  1  0.3  0.3  5  
1  2  1  1  10  
2  3  2  2  12  
3  4  3  3  13  
4  5  4  4  14  
5  6  5  5  15  
Concentrations used to study the effect of REST expression modulation 
5 µM 5 µM 3 µM 3 µM 10 mM 
 The MTT Assay 
The principle of this assay depends on the activity of mitochondria in viable cells to convert 
tetrazolium MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) dye to 
formazan colour by Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 
oxidoreductase enzyme.  The MTT stock solution was prepared by dissolving 5 mg of the 
MTT powder (Sigma, M5655) in 1 mL of PBS.  The solution was then stored in 500 µL 
aliquots at -20°C.  The MTT working solution (0.5 mg/mL MTT) was prepared by 1:9 
dilution using culture media.  The MTT assay was performed by gently aspirating the 
culture media using a multichannel pipette and adding 50 µL of the 0.5 mg/mL MTT 
working solution.  Subsequently, the plates were re-incubated for 90 minutes at 37C in 
dark.  The solution was then replaced with 100 µL of acidified isopropanol solution (0.04 
M HCL) and the plates were covered with foil and placed on an orbital shaker (~ 300 rpm, 
Stuart SSM1) at room temperature for 15 minutes.  The absorbance of the MTT was 
measured at 590 nm wavelength with a reference filter of 720 nm using a 
spectrophotometer plate reader (FLUOstar Omega, BMG Labtech).   
The cellular viability was calculated by subtracting the blank value (720 nm) from the 
formazan absorbance (590 nm).  At least, 6 biological repeats with 3 technical replicates 
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were performed for each condition and the average of all the biological replicates was used 
to represent the cells responses.   
 Calculating the Doubling Time 
The doubling time of the Daoy wildtype, REST knockout and knockdown cells was 
estimated using the results of the MTT assay.  The calculation was performed by 
subtracting the time value of the 0.8 MTT absorbance on the proliferation curve from the 
time value of the 0.4 MTT absorbance.  
 Modulation of REST Expression  
 Knockout REST Expression Using the CRISPR/Cas9 System  
The CRISPR/Cas9 system was used to disrupt REST gene expression.  Two guide RNA 
sequences (gRNA) were designed using the OriGene Technologies CRISPR/Cas9 tool, 
(gRNA1: 5′- CGCACCTCAGCTTATTATGC-3′, and gRNA2: 5′- TGGCAAATGTGGC 
CTTAACT-3′) 122.  Both sequences were followed by (TGG) PAM sequence and cloned 
into pCas-Guide vector (pCas-Guide1 [OriGene, KN211570G1], pCas-Guide2 – 
[OriGene, KN211570G2]) in additional to the antisense strand of the later gRNAs 
sequences.  A negative scramble-targeting (control) vector (OriGene, GE100003) of 20 bp 
sequence, which does not target any sequence, was included in the transfection reactions.   
The transfection reactions were performed in 6-well culture plates (Nunc Cell-Culture 
Plate) with a cell confluence of 50-70%.  The transfection solution was prepared by gently 
pipetting up and down 6 µL of Lipofectamine 2000 transfection reagents (Invitrogen, Life 
Technology) in 250 µL of the Opti-MEN media and the tubes were incubated at room 
temperature for 20 minutes.  The vectors (pCas-Guide1, pCas-Guide2, and Scramble 
control) mixtures were prepared by diluting 2 µg of vector in 250 µL of a pre-warmed 
Opti-MEN serum reduced medium (Gibco, 31985062) and left at room temperature for 5 
minutes.  The diluted DNA was then added into the lipofectamine solution using a 1:1 
ratio.  Prior the transfection, the cells were washed with sterile PBS for two times and 1 
mL of basal DMEM media was added into each well.  The transfection mixture was added 
in a dropwise manner and the plate was gently rocked back and forth and incubated at 37C 
incubator in 5% CO2 air.  After 4 hours, the transfection media was replaced with 2 mL 
complete DMEM media and the plate was re-incubated for 48 hours. 
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Monoclonal cell culture was established by seeding 96-well plates with a cell concentration 
of 1 cell/100 µL of the CRISPR/Cas9 transfected cells.  After 5 days from the seeding, 
wells with monoclonal cell growth were identified microscopically and left to grow for 
two weeks with replacing the media every 7 days.  After 14 days from the seeding, a 
daughter plate was prepared by harvesting the cells as described previously (see section 
2.2.1) using 25 µL of Trypsin-EDTA, and 70 µL of the culture media was pipetted up and 
down to detach the cells.  From each well, 30 µL of the cells was then transferred into a 
new 96-well culture plate containing 70 µL of complete media and the cells were re-grown 
to 90-100% confluency.   
The screening for the genome editing was performed by sequencing REST exon 2 using 
the DNA Sanger sequencing facility at Beckman Coulter Genomics service (Stortford).  
The efficiency of the knockout was verified using Western blot and SYBR green qPCR 
analysis and the cells with genome editing were propagated for further analysis.   
 Knockdown REST Expression using the shRNA System 
To knockdown REST expression, two shRNA sequences were designed using human 
homologue sequences of previously used mouse shRNA sequences (Gao et al., 2011) 23.  
The homologous human sequences were; 5’-AGTGTAATCTACAGTATCAC-3’ which 
targets REST exon4; and 5’-AGCAGAATCTGAAGAACAGT-3’ which targets exon2.  
The designed sequences were; shREST1:  5’-AGCTAAAAACAGTGTAATCTACAGT 
ATCACTTCTCTTGAAAGTGATACTGTAGATTACACT-3’, and shREST2: 5’-AGC 
TAA AAAAGCAGAATCTGAAGAACAGTTTCTCTTGAAAACTGTTCTTCAGATT 
CTGCT-3’. 
2.2.8.2.1 The shRNA Sequence Annealing 
Annealing the forward and reverse sequences of the two shRNA was performed by mixing 
1 µL of the forward and the reverse sequences (100 µM) with 48 µL of annealing buffer 
(100 mM NaCl, and 50 mM HEPES pH7.4).  The mixture was incubated at 95°C in a 
heating block to denature the oligoes and after 5 minutes the heating block was turned off 
and left to cool down at room temperature in order to allow the oligo to anneal.   When the 
block temperature reached 40ºC the tubes were transferred into ice and 100 µL of sterile 
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distilled water was added into each tube.  The oligos were either used directly in ligation 
reactions or stored at -20°C.   
2.2.8.2.2 The pSUPER-Puro Plasmids Preparation and Linearization  
pSUPER-Puro plasmid was prepared by streaking a loop-full suspension from glycerol 
stocks on ampicillin LB agar plates (2 % of LB Broth [Sigma] in H2O supplemented with 
1.5 % agar [Melford] and 100 µg/mL ampicillin [Sigma]) and incubated at 37°C.  After 24 
hours, a single colony was cultured in 100 mL LB broth (2 % of LB Broth [Sigma] in H2O, 
supplemented with 100 µg/mL ampicillin) and incubated at 37°C in a shaker incubator.  
The plasmid was extracted after 24 hours using HiSpeed plasmid midi kit (Qiagen; 12663) 
and processed according the manufacturer’s instructions.   
pSUPER plasmid was linearized using HindIII and BamHI restriction digestion enzymes.  
All restriction digestions were carried out in a reaction mix of 10 µL containing; 5 units of 
the restriction enzymes (New England BioLabs), 1 µL of 10x restriction enzyme buffer, 1 
% BSA (supplied by the enzyme manufacturer), 5 µL of the pSUPER-Puro DNA, and the 
volume was brought up to 10 µL using ddH2O.  The reactions were incubated at 37°C for 
one hour and then stored on ice.  The restriction digestion products were analysed on a 
1.2% agarose gel via electrophoresis.  
2.2.8.2.3 The shREST-pSUPER Plasmid Construction  
The annealed shREST1 and shREST2 molecules were cloned into the linearized pSUPER 
plasmid using; 1 µL of T4 DNA ligase enzyme (New England BioLabs), 1 µL of 10X 
ligation buffer (supplied by the enzyme manufacturer), 2 µL of the annealed 
oligonucleotides (~ 40 nM), 1 µL of the linearized pSUPER, and 5 µL of sterile distilled 
water.  The cloning reactions were performed by incubating the tubes at room temperature 
overnight.  A negative control containing the linearized vector and no insert was included 
with each ligation reaction.   
2.2.8.2.4 The shREST-pSUPER Plasmid Transformation 
Transformation into E. coli competent bacteria was performed using a heat-shook 
transformation reaction.  The reaction was performed by thawing competent cells (XL1-
Blue Subcloning-Grade, Agilent Technologies) on ice for 10-15 minutes and 50 µL of the 
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bacteria were transferred into a pre-chilled 14 mL BD Falcon tube and kept on ice.  A 
volume of 2 µL of the cloning products were gently mixed with the cells by pipetting up 
and down for few times and the tube was incubated on ice for 20 minutes.  The cells were 
then heat-shocked at 42°C for 45 seconds and immediately incubated on ice for 2 minutes.  
A volume of 900 µL preheated (42°C) SOC medium (Thermo-Fisher) was added into each 
tube, and the cells were then revived at 37°C in a shaker incubator (~230 rpm, Sanyo orbital 
incubator MIR-220RU) for one hour.  The transformed bacteria were then grown on pre-
warmed ampicillin (100 µg/mL) LB agar (5g Tryptone, 2.5g Yeast extract, 2.5g NaCl, 
1.5% Agar, ddH2O to 500 mL, media was autoclaved and stored in 4C, the mixture was 
autoclaved, supplemented with 100 µg/mL ampicillin and poured into plates) plates by 
spreading all the transformation mixture evenly around the surface of the agar and the plate 
was left upright to dry with the lid was slightly off.  After 10 minutes, the plate was 
incubated upside down at 37°C for overnight.   
In the following day, six random colonies from the LB culture plate were picked up using 
200 µL pipette tip and cultured into in 5 mL LB broth (5g Tryptone, 2.5g Yeast extract, 
2.5g NaCl and ddH2O to 500 mL, media was autoclaved and stored in 4C) medium 
supplemented with ampicillin (100 µg/mL) and incubated at 37°C in a shaker incubator 
(~230 rpm, Sanyo orbital incubator) for overnight.   
2.2.8.2.5 The shREST-pSUPER Plasmid Isolation 
After the overnight incubation, 1.4 mL of the LB broth cultured cells were transferred into 
1.5 mL tube and the cells were pelleted by centrifugation at 28000 g for 1 minute, whereas, 
the remaining volume of the LB broth was stored at 4C.  After removing the LB culture 
media, the cells were lysed in 100 μL lysis buffer (50 mM Tris-HCl, 10 mM EDTA, and 
100 μg/mL RNase A pH 8.0 (Sigma, Ribonuclease A from bovine pancreas, R4875).  The 
DNA was released and isolated by adding 200 µL of (1% SDS, and 0.2 M NaOH) buffer 
and then 50 μL of pre-chilled potassium acetate buffer (3.0 M, pH 5.5) was added.  After 
5 minutes of incubating the tubes on ice, a 400 µL of isopropanol was added into each tube 
to precipitate the DNA, and the tubes were incubated for 2 minutes at room temperature 
and centrifuged at 28000 g for 3 minutes.  The isopropanol was removed and 200 µL of 70 
% ethanol was added to remove the salt.  The tubes were further centrifuged at 28000 g for 
3 minutes, the ethanol was removed, and the pellet was air dried at room temperature for 
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5 minutes.  After complete drying of the pellet, the DNA was suspended in 30 µL of TE 
buffer (10 mM Tris-HCL, 1 mM EDTA, pH 8.0).  Enzymes restriction digestion was used 
to screen for successful cloning and it was performed as described previously (2.2.8.2.2).  
The products of the restriction digestion reaction were separated by electrophoresis in 1.2 
% agarose gels at 100 volts.  Constructs that showed the correct digestion product size 
were sequenced using Sanger sequencing facility at Beckman Coulter Genomics service.  
Plasmid with correct cloning sequence was then propagated in 50 mL LB broth for 
overnight and the plasmid isolation was performed using QIAprep Miniprep (QIAGEN) 
according to the manufacturer’s instructions.  
 The shRNA Transfection Reactions 
2.2.8.3.1 Transfection Optimisation 
The amount of the DNA needed to induce an optimal transfection level of the Daoy cells 
was established by transfecting the cells with the pCMV-Beta plasmid expressing β-
galactosidase. This plasmid contains LacZ gene upstream a CMV promoter which 
produces β-galactosidase enzyme.  When lactose (X-gal) is added, the β-galactosidase 
enzyme catalyses the X-gal and produce blue colour (5-bromo-4-chloro-3-hydroxyindole) 
which can be used to represents the transfection efficiency.  The effect of the transfection 
on the cell survival was evaluated microscopically and the transfection efficiency was 
measured by calculating the ratio of the stained to non-stained cells.   
The analysis was performed by transfecting the Daoy cells (80-100 % confluency) with 
the pCMV-Beta plasmid at concentrations of 125, 250 and 500 ng, using Lipofectamine 
2000 transfection reagents (Invitrogen, 11668-027) at ratios of 1:2, 1:3, and 1:4.  Both of 
the DNA and the transfection reagents were suspended in 1X Opti-MEM media (Gibco, 
31985062) and the transfection mixture was incubated at room temperature for 20 minutes.  
The cultured cells were washed with sterile PBS for two times and each transfection 
reaction was prepared by adding one part of the transfection mixture and 4 parts of Opti-
MEM media.  Culture plates were incubated at 37 °C in a 5% CO2 air incubator for 4 hours 
before replacing the transfection media with complete DMEM media.   
After 48 hours from transfection, the cells were washed three times in PBS and fixed in 
100 µl X-Gal Fixative Solution (2% v/v formaldehyde, 0.2% v/v glutaraldehyde) for 5 
minutes.  The cells were washed in PBS for three times and then overlaid with 150 µL of 
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X-Gal solution (5mM Potassium ferricyanide, 5mM Potassium ferrocyanide, 2mM MgCl2 
in PBS).  X-Gal [1mg/mL] was added freshly.  The efficiency of the cell transfection was 
analysed using a bright field microscope after an overnight incubation at 37 ºC.  
2.2.8.3.2 Transfection with the shREST-pSUPER and Establishing the Stable Cell 
Clones   
The transfection with the shREST-pSUPER vectors was performed as described previously 
(section 2.2.8.1) using 2.25 µL of Lipofectamine 2000 with 750 ng of the DNA vectors.  
After 48 hours from the transfection, the culture media was replaced with complete DMEM 
media supplemented with 5 µg/mL of puromycin.  A non-transfected (wild type Daoy) 
control was included in the selection assay and treated with puromycin.  The culture was 
then incubated at 37C and the media was replaced every 3 days with fresh media 
containing the puromycin.  The cells were examined microscopically on a daily basis and 
the selection for stable expression of the vector was assumed to be  completed when all the 
cells in the non-transfected control had been killed.  REST knockdown monoclonal cell 
clones were then established as described earlier in the knockout approach (2.2.8.1).  
 Study the Effect of REST-Modulation on the Daoy Cells Migration 
Using Wound Healing Assay 
The Daoy cells were cultured in 6-well plates using complete DMEM culture media at a 
cell density of 1x105 cell/mL and incubated at 37C in 5% CO2 air.  After 24 hours the 
growth was examined under an inverted microscope and the cells monolayer (90 - 100% 
confluency) was scratched by passing a sterile 200-μL pipette tip across the middle of the 
well in a vertical and horizontal directions.  The well was then gently washed for two times 
with PBS, fed with either 1% FBS-media or FBS-free media, and imaged at the intersection 
between the vertical and horizontal scratches.  A second image was taken 24 hours from 
wounding and the wound closure was analysed using TScratch software (CSElab, Zurich, 
Switzerland) (http://www.cse-lab.ethz.ch.) 123. 
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 The Flow Cytometer Analysis  
 Cell Cycle Analysis using Propidium Iodide  
The samples for cell cycle analysis on flow cytometry (FACS) were prepared by harvesting 
the cultured cells when they reached 80 - 90 % confluency for single time-point analysis 
or at 24, 48, 72 hours (time-courses analysis) using trypsin-EDTA as described in section 
(2.2.1). The cells were fixed in 9 mL of 70% cold ethanol with gentle vortex while adding 
the ethanol dropwise and the tubes were stored at -20C for at least 24 hours.  Prior the 
flowcytometry analysis, the ethanol was removed by centrifuging the cells at 400 g for 5 
minutes and the pellet was washed twice with ice cold PBS.  The cells were then 
resuspended in 250 µL PBS supplemented with 12.5 µL of RNase A (0.5 mg/mL) and 
incubated at 37C for 1 hour.   To each tube, a 12.5 µL of Propidium iodide (PI) (50 µg/mL, 
Sigma, P4170) was added and the samples were kept on ice in dark until the analysis. 
The cells were analysed on a flow cytometer (FACSAria II, Becton Dickinson 
Biosciences) using low-flow rate mode and the PI fluorescein was detected using 488 nm 
excitation.  The parameters of signal detection were; Forward Scatter-Area (FSC-A), Side 
Scatter-Area (SSC-A), SSC-H (Hight), and Phycoerythrin (PE-A, has an excitation 
wavelength (488 nm) similar to Propidium iodide).  The ‘gating’ was performed using 
FSC-A vs SSC-A (to exclude debris), PE-A vs. FSC-A (shows cellular material stained by 
PI), and PE-A vs. PE-H (to discriminate between singlets and doublets). 
The results were presented as DNA content frequency histograms, and the percentages 
of the cells (represented by peaks) were estimated by deconvoluting the histograms 
using ModFit LT DNA analysis software (Verity Software House, version 3.2).  The 
percentage in G1, S and G2 phases was calculated using Sync-Wizard mode of the 
ModFit, which models the actual number of the events after filtering out cell aggregates 
and debris.  The G0-G1 marker in the synchronization wizard was adjusted to align the 
most frequent part of the peak with SD between 1.5 and 2.0; the G2-M marker was adjusted 
to face the highest part of the second visible peak; whereas, the G2/G1 ratio was adjusted 
automatically between 1.7 and 2.0.  These values were then used to generate PI histogram 
plot which was used to quantitate the percentage of the cells in each cell cycle phase.  The 
accuracy of the DNA measurements was assessed by evaluating the coefficient of 
variation (CV) of the G1 mean and the results were accepted when their CV value is 
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less than 6% 124.  The average of the biological replicates was used to calculate the 
percentages of cells within each cell cycle phase. 
 Apoptosis Detection using Annexin V and PI 
The Daoy cells were cultured at 3.5 x 104 cell/mL in 6-well plates using complete DMEM 
culture media and the wells were labelled as 42, 36, and 30 and the plates were incubated 
at 37C in 5% CO2 air.  Prior harvesting the cells by 42, 36, and 30 hours, the cells were 
treated with a single dose of the HDACis by carefully replacing the culture media with a 
complete media containing the required concentration of the drug (Table 3).  The cells 
were harvested by collecting both floating and attached cells as described in section 2.2.1, 
and kept on ice. 
The apoptosis analysis was performed using FITC Annexin V Apoptosis Detection Kit I 
(BD Pharmingen, 556547) according to the manufacturer’s recommendations.  Briefly, the 
cells were washed twice in 1 mL of PBS and once in 600 µL of 1X Annexin V Binding 
Buffer and the cells were pelleted by centrifugation (400 g for 5 min).  For each sample, 
four tubes (Eppendorf, 1.5 mL) were prepared (labelled as Annexin V–/PI–, Annexin 
V+/PI–, Annexin V–/PI+, and Annexin V+/PI+) and a cell number of ~1 x 105 was 
transferred into each tube.  The cell staining was performed by adding 5 µL of Annexin V-
FITC and 5 μL of PI and the tubes were gently vortexed and incubated for 15 min at room 
temperature in the dark.   
The flowcytometry analysis was performed on CytoFLEX S (Flow Cytometry, Beckman 
Coulter) and the acquisition settings were customised to acquire FSC, SSC, FITC-green 
and PI red fluorescence.   The compensation algorithm was performed using cells treated 
with HDACis for 36 hours and stained with Annexin V–/PI–, Annexin V+/PI–, or Annexin 
V–/PI+.  The ‘gating’ for the apoptotic analysis was performed by using (FSC-A vs. SSC-
A) to remove debris (lower left corner of the plot), (SSC-A vs. SSC-H) to sort-out doublets 
(the cells off the diagonal population).  The percentages of the viable, necrotic, apoptotic 
(early/late) cells were interrogated using CytExpert 2.2 software (Beckman Coulter) using 
FITC vs. PE plot and applying a quadrant gate.  The quadrant location on the plot was 
adjusted using Annexin V–/PI–, Annexin V+/PI–, Annexin V–/PI+ controls and the cells 
percentages were represented by bar diagram.   
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 The Single Cell Next Generation Sequencing (scNGS) 
 Cell Treatment and Cryopreservation  
The Daoy cell (Passage 1) and the human neurons were seeded into 6-well culture plates 
at a cell density of 1.5 x 105 cell/mL and ~2.5 x105 cells/well, respectively.  The culture 
was performed as described in section (2.2.1 and 2.2.2).  The cells were then treated with 
by replacing the culture media with fresh media containing 5 µM of SAHA and MS-275 
and DMSO controls were included with each cell line.  The plates were incubated in 5% 
CO2 air incubator at 37C for 36 hours.  The cells were harvested as described in section 
(2.2.1 and 2.2.2), resuspended in 1 mL of cryopreservation media (Daoy: 10% DMSO, 
20% FBS in DMEM media, the neurons: 10% DMSO in NM medium) and transferred into 
1.8 mL cryogenic vials (nunc).  The vials were placed in Mr Frosty freezing container 
(Thermo Scientific) and the container was stored at – 80C for 8 hours and then the vials 
were stored in liquid nitrogen.  The vials were transferred to the MRC Weatherall Institute 
of Molecular Medicine (University of Oxford) in liquid nitrogen where the scNGS analysis 
was performed.  Within the facility, the vials were stored on dry ice until the cells were 
processed.   
 The scNGS Sample Preparation  
The samples for the scNGS analysis were rapidly thawed in a 37°C water bath for ~2 
minutes.  A small volume of the untreated neurons was transferred to a sterile microscope 
culture flask and they were checked microscopically for clumps.  Due to the presence of 
clumps, the neurons were centrifuged at 250 g for 3 minutes and the supernatant was 
removed without disrupting the cell pellet.  The neurons were resuspended in 200 µL of 
TrypLE Express and incubated in 37C water bath.  After 2 minutes, the cells were gently 
mixed with a pipette and re-incubated at 37C for another 2 minutes.  During the incubation 
time, the Daoy cells were thawed in a 37°C water bath at for 2 – 3 minutes.  To each 
neurons tube, 1 mL of the neuron media was added, the cells were gently pipette mix for 5 
times and both the neurons and Daoy cells were pelleted by centrifugation at 250 g for 3 
min.  The supernatant was removed, and the neurons were washed twice using cold NM 
whereas, the Daoy cells were washed twice in cold PBS supplemented with 0.04% (w/v) 
BSA.  The supernatants were removed, and the neurons were suspended in 500 µL of NM 
by gentle pipetting for 10 – 15 times.  The Daoy cells were suspended in 500 µL PBS 
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containing 0.04% (w/v) BSA.  The cells were then stained with DAPI (5%) and stored on 
ice for cell sorting.   
Sorting and isolation of viable cells was performed using FACSAria II SORP (Becton 
Dickinson Biosciences) at the MRC Weatherall Institute of Molecular Medicine 
(University of Oxford) using BD FACSDiva (8.0.1) software.  The sorting was performed 
using the FSC-A vs. DAPI to gate for the viable cell population 1 (P1) (located in the lower 
part of the plot).  The P1 was then further deconvoluted using a FSC-A vs. SSC.A plot to 
minimize cellular debris and to gate for the cells of interest (P2).  The doublets in P2 were 
excluded using FSC-A vs. FSC-H plot and the singlets (P3) were isolated.  For each sample 
at least 2000 events from P3 were sorted out into 1.5 mL tube containing 2 µL of 10% 
(w/v) BSA for the Daoy cell or NM for the neurons and the tubes were stored on ice.   
 The scNGS GEMs Preparation and RT-PCR 
The single cell next generation sequencing was performed using the 10x Genomics 
technology (Chromium Single Cell 3’ Reagent Kits v2) and the work was performed by 
the 10x team of the MRC Weatherall Institute of Molecular Medicine (University of 
Oxford).  Briefly, the single cell master mix for loading the cells into a Chip A Single Cell 
was prepared by mixing the contents of the Chromium Single Cell 3’ Library & Gel Bead 
Kit v2, 4 rxns (PN-120267 (Per sample; 50 µL of RT Reagent Mix, 3.8 µL of RT Primer, 
2.4 µL of Additive A, and 10 µL of RT Enzyme Mix) and approximately most of the sorted 
cells were transferred into the master mix tubes.  The unused wells of the chip were filled 
with 50% glycerol solution apart from the recovery wells and 90 µL of the master mix was 
transferred into row #1 of the chip.  Row #2 of the chip was filled with 40 µL of Single 
Cell 3’ Gel Beads whereas the row #3 was filled with 270 µL of Partitioning Oil.  The chip 
was then assembled using a 10x Chip Holder and the 10x Gasket was placed on the 10x 
tray. The GEMs were generated using Chromium Controller for 6.5 minutes.  A volume of 
100 µL of the GEMs was transferred into an emulsion-safe plate and the plate was heat 
sealed with pierceable foil at 185°C for 6 seconds.  The plated was loaded into a thermal 
cycler (Proflex Veriti MiniAmp, Applied Bio System, Thermo Fisher) and the GEM-RT 
was performed at 53C for 45 minutes, 85C for 5 minutes and the reaction was terminated 
at 4C. 
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 Post GEMs-RT Clean-up  
Post GEM-RT clean-up was performed by adding 125 µL of Recovery Agent (P/N 220016) 
into each well and the entire volume transferred into an 8-tube strip and centrifuged at 250 
g for 30 seconds.  A volume of 125 µL of the Recovery Agent/Partitioning Oil (pink) was 
removed from the bottom of the tube and discard.  Into each well, 200 µL of Dynabeads 
Cleanup Mix (182 µL of Buffer Sample Clean Up, 4 µL of Dynabeads MyOne SILANE, 
9 µL of Additive A, and 9 µL of nuclease-free water) was added and the tubes were 
incubated at room temperature for 10 minutes.  A volume of 100 µL of Elution Solution 
was added (98 µL of Buffer EB, 1 µL of 10% Tween 20, and 1 µL of Additive A) and the 
tubes were then placed on 10x Magnetic Separator in the High position until the 
supernatant is clear.  The supernatant was then discarded and a total volume of 300 μL of 
freshly prepared 80% ethanol was added to the pellet while on the magnet and stood for 1 
minute.  The ethanol was then carefully discarded and 200 µL of 80% ethanol was added 
and carefully removed after 30 seconds. The tubes were centrifuged and returned to a 10x 
Magnetic Separator in the low position and the samples were air dried for 1 minute.  The 
tubes were then removed from the magnet and the beads were resuspended in 35.5 µL of 
Elution Solution I and incubated at room temperature for 1 minute.  The tubes were then 
placed in a 10x Magnetic Separator in the low position until the solution is clear and 35 
µL of the purified GEM-RT product were transferred into a new tube strip.   
 The cDNA Amplification, Purification and Quality Check  
The cDNA amplification was prepared by adding 65 µL of cDNA Amplification Reaction 
Mix (50 µL of Amplification Master Mix, 5 µL of cDNA Additive, and 2 µL of cDNA 
Primer Mix) to the 35 µL of purified GEM-RT product and the cDNA was amplified on 
Proflex Veriti MiniAmp cycler using 90C for 3 min, and 12 cycle of 98C for 15 sec, 
67C for 20 sec, 72C for 1 min, and a final extension step of 72C for 1 min. 
The amplified cDNA was cleaned up using 60 µL of SPRIselect Reagent to each sample 
and the tubes were incubated at room temperature for 5 minutes.  The tubes were then 
placed in a 10x Magnetic Separator in the high position until the solution is clear, and the 
supernatant was carefully discarded.  The pellet was then washed three times using 200 µL 
of 80% ethanol and the samples were air dried for 2 minutes.  The tubes were then removed 
from the separator and 40.5 µL of Buffer EB was added and left for 2 minutes at room 
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temperature.  The tubes were then placed in a 10x Magnetic Separator in the high position 
until the solution is clear and 40 µL of sample was transferred into a new tube.  The quality 
of the cDNA amplification was evaluated using the Agilent Bioanalyzer D5000 
ScreenTape High Sensitivity chip (5067-5592).   
 The cDNA Fragmentation, End Repair and A-tailing  
The fragmentation of the amplified cDNA was performed by mixing 15 µL of the 
Fragmentation Mix (5 µL of Fragmentation Buffer, and 10 µL of Fragmentation Enzyme 
Blend) with 35 µL of the purified cDNA.  The fragmentation reaction was performed on 
Proflex Veriti MiniAmp cycler at 32C for 5 minutes.  The reaction was then followed by 
end repair & A-tailing step thus, the temperature was increased to 65C for 30 minutes and 
the reaction was stopped at 4C.   
The products of the fragmentation reaction were isolated by adding 30 µL of SPRIselect 
Reagent to each sample and the mixtures were incubated at room temperature.  After 5 
minutes, the tubes were placed in a 10x Magnetic Separator in the high position until the 
solution is clear.  A volume of 75 µL of the supernatant was transferred to new tubes and 
10 µL of SPRIselect was added to each tube.  The tubes were placed in a 10x magnetic 
separator in the high position until the solution is clear and then 80 µL of the supernatant 
was removed and discarded.  The pellets were then washed as described in the previous 
step using 125 µl of 80% ethanol and 50.5 µL of Buffer EB.   
 Adaptor Ligation   
The ligation reaction was performed by mixing 50 µL of the purified fragments with 50 
µL Adaptor Ligation Mix (20 µL Ligation Buffer, 10 µL DNA Ligase, and 2.5 µL of 
Adaptor Mix).  The reaction was incubated at 20C for 15 minutes, and the products were 
cleaned using SPRIselect as described in the previous step using 200 µL of 80% ethanol 
and 30.5 µL of Buffer EB.   
 Sample Indexing (i7) 
Sample indexing was performed by mixing 60 µL of the Sample Index PCR Mix (50 µL 
of Amplification Master Mix, 2 µL of SI-PCR Primer, and 8 µL of nuclease-free water) 
with 30 µL of the ligation-reaction purified samples and 10 µL of Chromium i7 Sample 
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Index was added into each sample mix.  The indexing reaction was performed on the 
Proflex Veriti MiniAmp cycler (98C for 45 sec, and then 12 cycles of 98C for 20 sec, 
54C for 30 sec, and 72C for 1 minutes, the reaction was followed by an elongation step 
of 72C for 1 minute).  The reaction products were clean using SPRIselect as described 
previously using 200 µl of 80% ethanol and 35.5 µL of Buffer EB.  A volume of 35 µL of 
sample was transferred into a new tube and the quality of the library construction was 
evaluated using Agilent Bioanalyzer High Sensitivity chip.  The samples were sequenced 
using Illumina NextSeq 500/550 High Output Kit v2.  The sequencing analysis was carried 
out at the MRC Weatherall Institute of Molecular Medicine (University of Oxford) using 
the following run parameters: Read 1-26 cycles, Read 2 - 98 cycles, Index 1-8 cycles.  
A sequencing depth of approximately 50,000 reads/cell was aimed for each 
sample. 
 Sequencing Data Demultiplexing  
 Installing the required Software 
The data demultiplexing was performed on Advanced Research Computing 3 (ARC3), part 
of the High-Performance Computing facilities at the University of Leeds, UK 
(http://www.arc.leeds.ac.uk).  The access to ARC3 was through using the MobaXterm 
software (https://mobaxterm.mobatek.net/download.html) and secure remote login (Secure 
Shell protocol).  The CellRanger V3.0 software was installed as per the 10x genomics 
instructions (https://support.10xgenomics.com/).  Into the same directory, the Human 
reference (GRCh38) data set was downloaded and the successful installation of CellRanger 
was verified and the site-checked file was uploaded to 10x support for future support.  
Further the Illumina bcl2fastq2 Conversion Software (v.20.0) was installed on the ARC3 
server.   
 Running the CellRanger mkfastq Pipeline 
The 10x scNGS Illumina sequencing data (Illumina raw base call (bcl) files format) were 
demultiplexed to FASTq (text files containing sequence data with a quality score for each 
base) files format using the CellRanger mkfastq pipeline.  The data demultiplexing was 
carried out by uploaded the data files to the ARC3 with the sample-index-set of each 
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sample (csv.format).  The mkfastq pipeline was ran by defining the path to the CellRanger 
and the bcel2fasq files location using the following commands:  
Note: the texts in grey font are the variables where the italic texts   are the description of the command  
export PATH=/directory path/bcl2fastq2-v20.0.x/bin:$PATH 
export PATH=/directory path/cellranger-3.0.0:$PATH 
The bcl data files were then converted to fastq format using: 
cellranger mkfastq --id=directory_name \ 
--id= (creates a directory and call it as the defined after the = sign, the name should not be exist in the directory) 
--run=/nobackup/bsasa/rawdata/seq1/ \ 
--run= (the path to the location of the seq data)  
--csv=samplesheet.csv 
--csv= (the sample sheet ended with .csv, no need to include the path of the directory).   
 Running the CellRanger count Pipeline 
The generated files were aligned to GRCh38 reference genome, de-duplicated, filtered, 
and the UMIs were counted using the CellRanger count.  The pipeline was run using the 
following commands: 
cellranger count --id=sample_number \ 
--transcriptome=/path_to_ref_genome/refdata-cellranger-GRCh38-3.0.0 \ 
--transcriptome= (Path to the Cell Ranger compatible transcriptome reference) 
--fastqs=/path_to_fastq_files/outs/fastq_path \ 
--fastqs= (Path to the fastq_path folder generated by mkfastq) 
--sample=sample_no \ 
--sample= (Sample name as specified in the sample sheet) 
--chemistry=SC3Pv2 \ 
--chemistry= (Assay configuration) 
--expect-cells=3000  
--expect-cells= (Expected number of recovered cells) 
The commands were re-run for each sample and the output summary files were used to 
evaluate the quality of the 10x analysis and to generate a digital gene expression 
matrix.  Upon the cell quantification, single-cell specific quality control measures were 
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examined including the sequencing depth, the total read per cell, and the total number of 
genes detected per cell.   
 Running the CellRanger aggr Pipeline 
The generated data of all samples were aggregated and normalized using CellRanger count.  
The pipeline requires a (csv) format file which specify the list of the CellRanger count 
output files path (molecule_h5) and the library ID in order to label the output files.  The 
csv file was uploaded to the analysis directory and the pipeline analysis was performed 
using: 
cellranger aggr --id=cellaggr \ 
--id=(creates a directory and call it as the defined after the = sign) 
--csv=cellaggr.csv \ 
--csv= (Path to the csv file which contains a list of cellranger count) 
--normalize=mapped 
--normalize= (equalizes the read depth between samples before merging until all the samples have an equal number of 
mapped reads per cell) 
 Visualising the Data using Loupe Cell Browser  
The data generated by the CellRanger aggr were visualized using Loupe Cell Browser 
(V.3.0.1) on Windows environment.  The browser was used to visualize the cell 
dimensional reduction on t-distributed Stochastic Neighbour Embedding of the principal 
components (t-SNE) projector.  
 Analysing the scNGS Gene Expression using Seurat 
Seurat scNGS R Package (version 3.0) was used to filter out the dead, empty droplets, 
mitochondrial genes, and doublets from the data sets of the CellRanger count matrix files 
125.  The analysis was performed by uploading the raw data matrix files into Seurat using 
the (Read10X) function, and the (CreateSeuratObject) function was used to include all 
the genes that were detected in at least 3 cells.  Next, the gene numbers (nGene), the 
UMI counts (nUMI), and the percentage of the mitochondrial genes (percent.mito) of 
each sample were counted and the results were visualized on violin and scatter plots.  
The plots were then used to identify the cells with a clear outlier number of genes and 
they were assumed as potential multiplets.  The cells with fewer than 300 genes were 
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also assumed as dead, or empty droplets and they were filtered out using (FilterCells) 
function.  Next, the gene expression values of each cell were normalized to the total 
expression using (LogNormalize) function which multiplies the values by a scaling 
factor of (1x104) and the values were then log-transformed.  Further, the cell to cell 
variations, the nUMI, and the percent.mito expression were regressed out using 
(ScaleData) function.   
To find the correlations between the genes and the cellular phenotypes, the genes with 
high variance were identified using Seurat (FindVariableGenes) function.  In Seurat, the 
highly variable genes were defined as significantly expressed genes with greater than 
zero at a false discovery rate (FDR) of 5% (i.e. getting false positive) and they were 
calculated based on the gene average expression and the dispersion level 126.  These 
genes were proposed to drive the heterogeneity across cells in a population and were 
used to cluster the cells 126.  The data were scaled to regress out cell to cell variations in 
the gene expression which they could be generated from the technical noise, the reagent 
batch, the nUMI, and the percient.mito.  Further, the data were dimensionally reduced 
using the principal component analysis (PCA, statistical procedure used to convert a set 
of correlated variables into a set of linearly uncorrelated variables) of the highly variable 
genes and the results of the cells and the genes clustering were visualized on heatmap 
and JackStraw plots 127.  The plots were used to determine the number of the principal 
components that were included in the subsequent steps.  
The cells were then clustered using Seurat (FindClusters) function and the number of 
the included PCs was determined based on the JackStraw plots significant P-values.  
The (FindClusters) function mainly implements the graph-based clustering approach 
(construct a graph and then apply a clustering algorithm to partition the graph) based on 
the similarity of gene expression patterns between the cells 125.  The data sets were 
dimensionally reduced using the (RunTSNE) function, and the clusters were visualized 
on t-SNE plots.  The differential expression analysis was performed using Seurat 
(FindAllMarkers) function which identifies the positive and the negative markers of each 
cluster by comparing genes in a cluster of cells against genes in all other cells.  The genes 
that were; differentially expressed in at least 10% of cells within a cluster, and with more 
than 0.25 log fold change and P-value of less than 0.01 were considered as marker genes. 
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With the tumour cell only, as the phase of the cell cycle has a major impact on the gene 
expression, each cell was subjected to cell cycle gene expression classification using Seurat 
(CellCycleScoring) function.  This function calculates the S and G2/M phase scores for 
each cell using a pre-set of genes that showed significant cell cycle–dependent expression 
128.   The selection of these genes was based on their anticorrelated expression thus, the 
cells expressing these markers should not be in G1 or quiescent (G0) phases.  The clusters 
of each sample were renamed based on the cell cycle phase and displayed on t-SNE 
projectors.  As HDACi induced a significant effect on the expression of cell cycle genes, 
the analysis was conducted by merging the three Daoy conditions in one Seurat object 
using (MergeSeurat) function.   
With the human neurons only, the identified markers were loaded into the Cell-type 
Specific Expression Analysis (CSEA) website manning server 
(http://genetics.wustl.edu/jdlab/csea-tool-2/) in order to identify the cell-type of each 
cluster 129.  The cell-type of the neurons was determined based on the expression of 
specific neuronal markers and the identity of the cells was assigned based on the 
significance of the P-value (Appendix 11).  The clusters of the neurons in each sample 
were renamed based on the cell identity and displayed on t-SNE plots.   Further, to study 
the effect of SAHA and MS-275 on the normal neurons, the analysis was carried out by 
extracting the data sets of each cell type cluster and the clusters of the same identity were 
merged in a single Seurat object. 
The Daoy and the neurons Seurat objects were normalized, dimensionally reduced, and the 
new dimensional reduction was visualized on non-linear t-SNE plots.  Further, the merged 
objects were subjected to the Seurat (FindClusters) function which cluster the cells based 
on their new PCA values.  The data were then subjected to Seurat (FindAllMarkers) 
function which calculates the average log expression of a gene in a single cluster and 
compared it to all other cells.  Also, it calculates the percentage of the cells in each group 
and uses these values to calculate the P-values. 
 Gene Functional Annotation and Gene Set Enrichment Analysis 
The functional annotations of the differentially expressed genes were investigated using 
the online GenCLiP v2.0 web-based text-mining server 
(http://ci.smu.edu.cn/GenCLiP2/analysis.php) 130.  The enquiries were made by 
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uploading a list of genes IDs and the enrichment of the Gene Ontology (GO) were 
evaluated based on the GenClip enrichment scores.  
The gene set enrichment analysis was performed using java Desktop Gene Set Enrichment 
Analysis (GSEA) Application (v3.0) of the Broad Institute 131.  The analysis was carried 
out by ranking the upregulated and downregulated genes as per the decrease in their fold 
change values and the ranked lists were analysed using the Run-GSEA-Preranked tool.  
The analysis was performed using the gene sets databases of Hallmark (gene symbols 
v.6.2), BioCarta (gene symbols v6.2), KEGG (gene symbols v6.2), and Reactome (gene 
symbols v6.2).  The gene sets with less than 15 genes and more than 500 genes were 
excluded and the statistical significance of the enrichment score (ES) was estimated by a 
permutation test with 1000 replications.  The pathways with a false discovery rate (FDR) 
q-value <0.25 and nominal P-value <0.01 were chosen as significantly enriched.  The 
upregulated pathways were defined by a positive normalized ES and described as positive 
phenotype and the downregulated pathways were defined by a negative normalized ES and 
described as negative phenotype.     
 Pathway Analysis  
The PathViso (version 3.3.0) pathway visualisation and analysis software 
(http://www.pathvisio.org) was used to examine the over-representation of the 
differentially expressed genes and visualized the pathway 132.  The homo sapiens pathways 
were downloaded from the WikiPath and were used for searching the overrepresentation 
of the genes 133.  The search for the pathway was performed by defining the a criterion that 
select all the differently expressed genes in a pathway (e.g. log2FC > 0.2 AND log2FC < 
-0.2) and the pathway was selected based on the highly significance of the P-Value and the 
results of the GSEA analysis.  
 Basic Molecular Biology Procedures 
 Extracting DNA from 6-Well Culture Plates  
The DNA extraction was performed using cells cultured in 6-well culture plates.  After 
removing the culture media, the cells were washed in sterile PBS buffer and scrapped into 
a 1 mL sterile PBS.  With the DNA fragmentation assay, both of floating and attached cells 
were used for the DNA extraction.  The cells were pelleted by centrifugation (12000 g for 
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5 min) and re-suspended in 400 µL of TE buffer (10 mM Tris pH 7.6, and 0.5 mM EDTA 
pH 8.0), 100μL of 10% SDS (10 g of sodium dodecyl sulfate in 100 mL H2O), and 20 μL 
of Proteinase-K (Sigma,10 mg/mL).  The tubes were mixed by gentle inversion for 3 
minutes and were incubated at 55 ºC for overnight.  To precipitate the DNA, 50 μL of 2.5 
M NaCl solution was added into each mixture followed by adding 400 μL of 100% ethanol, 
and the tubes were incubated with rotation for 10 minutes at room temperature.  The DNA 
was picked by pipet tip (when it is contact) and transferred into 1.5 mL tube contains 400 
μL of 70% ethanol.  The DNA that is not condense and not observable was precipitated by 
centrifugation at 28000 g for 10 minutes.  Next, the DNA was washed for two times in 400 
μL of 70% ethanol, the ethanol was removed by centrifugation at 28000 g for 3 minutes, 
and the pellet was air-dried at room temperature for 5 minutes.  The DNA was then 
dissolved in 50 µL TE buffer and the DNA concentration was measured using NanoDrop 
2000c (ThermoScientific) at 260 nm.  The purity of the total DNA was evaluated by the 
ratio of A260/A280 (between 1.8 and 2.0).  
 DNA Extraction from 96-Well Culture Plates 
The DNA extraction from 96-well plate was performed by removing the culture media by 
flipping the plate, and the wells were washed once with PBS.  A volume of 50 µL of (40 
µL TE, 10 µL of 10% SDS, and 2 µL Proteinase K [10 mg/mL] stock solution) buffer was 
added into each well and the plate was mixed on a plate mixture for 1 minute and incubated 
at 60 °C for overnight in humidified chamber.  Next, a 20 µL of NaCl was added into each 
well using a multichannel pipette followed by 130 µL of 100% ethanol, and the plate was 
mixed on a horizontal rotator for 5 minutes and incubate at room temperature.   After 30 
minutes, the plate was centrifuged at 2400 g  (Eppendorf Centrifuge 5810R) for 15 minutes 
and the supernatant was removed using a multichannel pipette.  The precipitated DNA was 
washed with 150 µL of 70% ethanol, centrifuged for 3 minutes at 2400 g, and the ethanol 
was removed with a multichannel pipette.  The precipitated DNA was left to dry at room 
temperature for around 15 minutes and was suspended in 30 µL of TE buffer and stored at 
-20 °C. 
 Extracting Total RNA from Cultured Cells 
The RNA was extracted from cells cultured in 6-well culture plates.  The cultured cells 
were washed in sterile PBS buffer and harvested using trypsin-EDTA for 5 minutes.  The 
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cells were then washed off the plate using 1 mL ice-cold PBS, transferred into a sterile 1.5 
mL tube, and pelleted by centrifugation at 12000 g for 3 min at 4 C (Heraeus Fresco 
centrifuge).  The RNA extraction was performed by suspending the pellet in 1 mL of cold 
TRI-reagent (Sigma-Aldrich, 93289) and the cells were homogenized by passing the lysate 
several times through a 1 mL pipette tip, then vortexed for 1 minute and incubated on ice 
for 10 minutes.   Into each tube, 200 µL Chloroform (Arcos Organics, 158210250) was 
added and the suspension was vortexed for 1 minute and incubated on ice for another 10 
minutes.  The mixture was centrifuged at 28000 g for 10 minutes at 4 ºC and the upper 
aqueous phase was transferred into a fresh 1 mL tube.  Total RNA was precipitated by 
adding 600 µL of isopropanol (Sigma, 59300-M) and the suspension was kept at – 80 ºC 
for at least 1 hour.  The samples were then thawed on ice and centrifuged at 24000 g for 
20 minutes at 4 ºC.  The supernatant was removed, and the pellet was washed with 200 µL 
of 70 % ethanol, centrifuged at 28000 g for 5 minutes, and the ethanol was removed.  The 
pellet was air dried at room temperature for 5 minutes and the RNA was dissolved in 50 
µL TE buffer.  The RNA concentration was measured using NanoDrop 2000c 
(ThermoScientific) at 260 nm, and the purity of the total RNA was evaluated by the ratio 
of A260/A280 (between 1.8 and 2.0). 
 The Nuclear Protein Extraction from Cultured Cells 
Cultured cells in 6-well plates were washed in sterile PBS buffer and harvested using 
trypsin-EDTA for 5 minutes.  The cells were then washed off the plate using 1 mL ice-
cold PBS and transferred into a sterile 1.5 mL tube.  The cell suspension was then pelleted 
by centrifugation at 12000 g for 3 minutes at 4C and washed twice with cold PBS.  After 
removing the supernatant, the pelleted cells were resuspended in 1 mL of ice-cold Triton 
Extraction Buffer (TEB, consists of PBS containing 0.5% Triton X100 (v/v), 0.02% (w/v) 
NaN3, the buffer was sterilized by filtration and supplemented with 1 mM 
Phenylmethanesulfonyl Fluoride (PMSF) (Cell Signal, 8553S) dissolved in isopropanol) 
using up and down pipetting for at least 10 times.  The lysate was incubated on ice for 30 
minutes with vortex every 10 minutes and clarified by centrifugation at 12000 g for 10 
minutes at 4 C.  After removing the supernatant, the nuclei were resuspended in 100 µL 
of Nuclear Lysis Buffer (NLB; 20 mM HEPES-KOH pH 7.9, 25% glycerol, 420 mM 
NaCL, 1.5 mM MgCL2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM PMSF, Protease 
Inhibitor Cocktail powder (Sigma, P8465) [prepared by suspending the powder in NLB 
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buffer and aliquoted in 100 µL], dithiothreitol, PMSF and the inhibitor was added freshly) 
and incubated on ice.  After 20 minutes, the mixture was centrifuge at 28000 g for 2 
minutes at 4 C, and the supernatant, which contains the proteins, was transferred into a 
new a 1.5 mL tube and stored at -20 C until further analysis.   
The concentration of the protein was measured using Pierce BCA Protein Assay Kit 
(ThermoScientific, 23221) as per the manufacturers’ instructions for 96-well plates. 
Briefly, 10 µL of; samples, BSA standards, and blank were mix with 200 µL of BCA 
Working Reagent (50 parts of BCA Reagent A with 1 part of BCA Reagent B).  The plate 
was mixed for 30 seconds and incubated at 37°C for 30 minutes.  The plate was then cooled 
down to room temperature and the absorbance was measured at 562nm wavelength 
(FLUOstar Omega, BMG Labtech).  Protein concentration was determined by plotting the 
average blank-corrected 562nm measurement for each BSA standard against its 
concentration in µg/mL. 
 Polymerase Chain Reaction (PCR) 
The DNA was amplified using 1 µL of the DNA, 0.5 µL of 10 mM dNTPs (Bioline, 
39028), 0.5 µL of 10 µM forward and reverse primers (NHEJ-FWD:5’-GCGATGTG 
GTTTTAAGCCAGT-3’, NHEJ-REV: 5’-GTTATCCCCAACCGGCATCA-3’), 0.2 unit 
of Taq DNA Polymerase and 2 µL of 5X PCR reaction buffer (Thermo Fisher Scientific, 
M7122).  The volume was completed to 10 µL with sterile distilled water.   
The DNA amplification was performed on Eppendorf PCR machine (Mastercycler EP 
Gradient 5341) under the following conditions: denaturation at 95 ºC for 2 minutes, 
followed by 30 cycles of 95 ºC for 30 seconds, annealing at 60 ºC for 30 seconds, extension 
at 72 ºC for 1 minute.  A post-PCR incubation step of 10 minutes at 72 ºC was performed 
to complete the synthesis of the PCR products.  The extension temperature was adjusted 
according to the primers melting time and the PCR efficiency, and all the reactions 
included positive and negative controls. 
 Quantitative Polymerase Chain Reaction (qPCR)  
The total RNA was reverse-transcribed using 1 µg of the total RNA, 0.1 µg Oligo (dT) 15 
Primer (Promega, C1101), and 0.2 µg of Random Primers (Promega, C1181).  The volume 
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was then completed to 15 µL with sterile distilled water and incubated at 65 ºC for 5 min 
and quenched on ice for 1 minute.   Next, each reaction mixture was supplemented with 4 
µL of MMuLV RT 5x Buffer (Promega, M1701), 8 units of RNasin inhibitor (Promega, 
N2111), 1mM dNTPs (Bioline, 39028), and 40 units of MMuLV RT (Promega, M1701) 
in a final volume of 20 µL.  The reaction was incubated at 37 ºC for 1 hour, and then at 4 
ºC for 10 minutes and a volume of 30 µL of sterile distilled water was added into the 
reaction.  
The Sybr Green quantitative PCR was performed in Rotor Gene 6000 (Corbett series) 
using 2X SensiMix SYBR & Fluorescein reagent (Florescencein kit, BioLine, QT615-05).  
The reactions were performed in 10 µL volume containing 2.5 µL of the reverse transcribed 
product, 5 µL of the 2X SensiMix SYBR & Fluorescein, 1.9 µL distilled water, and 0.3 µL 
of forward and reverse primers (10 mM) :(REST; FWD: 5’-ACTTTGTCCTTACTC 
AAGTTCTCAG-3’, REV: 5’-ATGGCGGGTTACTTCATGTT-3’, SNAP25; FWD: 5’-
CGTCGTATGCTGCAACTGGTTG-3’, REV: 5’- GGTTCATGCCTTCTTCG ACACG-
3’, Synapsin FWD: 5’-AGATTTTTGGGGGACTGGAC-3’, REV: 5’-TGTCTT 
CATCCTGGTGGTCA-3’, SCG10 FWD: 5’-TGAAGTCGTTTCTCCCCAAC- 3’, REV: 
5’-TCACAGCTTGCTCACAATGA-3’, GluR2 FWD: 5’-TTGACTTCTCAAAGCCCTT 
CA-3’, REV: 5’-GGCTAAAGGATCAAGAAAGGAA-3’, REST Bi-allelic genome 
editing FWD: 5’-GCAACATTGGAATGGCCCTG-3’, REV 5’- ATGGCGGGTTACTTC 
ATGTT-3’, REST4 FWD: 5’ ACTTTGTCCTTACTCAAGTTCTCAG 3’, REV: 5’ 
GGTATGGATACCATTTGGTAATA 3’).  Each gene expression reaction was performed 
in duplicate and the cDNA amplification was performed under the following real-time PCR 
conditions: Taq polymerase activation at 95 ºC for 10 minutes, followed by 40 cycles of 
95 ºC for 10 seconds, annealing at 60 ºC for 15 seconds, and extension at 72 ºC for 20 
seconds.  The reaction was followed by a melting step ramping from 72 °C to 95 °C with 
1 ºC increment and 5 seconds wait for each step which was later used to confirm the 
specificity of the amplification.  The expression of the RNU6 (RNA, U6 Small Nuclear 1) 
housekeeping gene (FWD:5’-CTCGCTTCGGCAGCACA-3’, REV: 5’-AACGCTTCAC 
GAATTTGCG T-3’) was measured for each sample and was used to normalize the 
expression level of the measured gene/s.  The qPCR expression analysis was performed 
using the Rotor Gene 6000 Series Software, and the expression level was presented by 
calculating the power of two exponent.   
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 Agarose Gel Electrophoresis  
The agarose solution was prepared by dissolving 1.2 % (w/v) of agarose (Sigma, A9539) 
in a volume of Tris-acetate-EDTA (TAE: 2M Tris base, 5M EDTA, and 5.71 % glacial 
acetic acid, pH8.0) and the agarose mixture was melted in a microwave oven.  The agarose 
gel was prepared by pouring the agarose solution into an electrophoresis chamber.  The 
PCR products were mixed with loading dye and 12 µL were loaded into the gel alongside 
of a pre-stained DNA ladder (New England, BioLabs, N3236).  The DNA was 
electrophoresed at 100 volts in 1X TAE buffer until the first migrating band had reached 
the end of the gel.  The DNA was stained with ethidium bromide (Sigma, E1510) and 
imaged using the Bio-Rad ChemiDoc XR system.  
 Western Blot Analysis  
To study protein expression, 30 µg of the total protein were mixed with 10 µL of 2X SDS 
loading buffer (Tris-HCL 0.5M pH 6.8, 20% glycerol, 4 % SDS, and 0.1% bromophenol 
blue, and 0.2 M DTT was added freshly), denatured at 95 ºC for 10 minutes, and incubated 
on ice.  SDS polyacrylamide gel electrophoresis was prepared by pouring a (5%) stacking 
gel over a pre-casted (8%) resolving gels in a 1.5 mm thickness vertical casting plates 
(SDS-PAGE, Mini-PROTEIN Tetra Cell, Bio-Rad) (Table 4).  The samples were loaded 
into the gel using 80 ng of the protein alongside a colour-coded prestained protein Marker 
(Cell Signal, 14208).  The electrophoresis was performed using 40 mA constant current in 
electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS, and dH2O) until the fast 
migrating band (~ 10 kDa) had migrated off the gel, and the resolving gel was separated 
from the staking gel prior western blotting.  
The protein was wet transferred to a Hybond-P PVDF 0.45 μm membrane (Amersham, 
GE10600100).  Before the transfer, the membrane was hydrated in 100 % methanol for 1 
minute, rinsed in H2O for 5 minutes and then equilibrated in transfer buffer (25 mM Tris, 
192 mM Glycine, and 20 % methanol) for 10 minutes.  The wet transfer of the protein was 
performed in XCell II Blot Module (Invitrogen) electrophoresis chamber by sandwiching 
the membrane between the SDS-PAGE gel, filter papers, and support pads with keeping 
the transfer membrane facing the node.  The XCell chamber was filled with the transfer 
buffer and the transfer was performed at 30 V (Start: at ~170 mA, and End: ~110 mA, and 
~ 5W) for 1 hour and 15 minutes.  The Membrane was blocked with 5 % milk (prepared 
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in 1 X PBS, and 0.1 % Tween 20) at room temperature for 1 hour on a roller mixer.  
Immunoblotting with primary antibody was carried out at 4 C overnight on a mixer using 
1:500 rabbit anti-REST antibody (OriGene, TA330562) and mouse anti-β-actin (1:10000, 
Sigma, A1978) antibody.  The membrane was washed three times in (1 X PBS and 0.1 % 
Tween 20) for 15 minutes on a roller mixer.  The detection with the secondary HRP-
conjugated antibodies was performed at room temperature for 1 hour using a mixer of anti-
rabbit (1:20000) and anti-mouse (1:40000) (Cell Signalling Technology, 7074 and 7076, 
respectively).  The membrane was washed three times in (1 X PBS and 0.1 % Tween 20) 
for 15 minutes.  The immunoreactive bands were visualized using 1 mL of Amersham ECL 
Western Blotting Detection reagent (RPN2209) and the membrane was scanned using 
LAS-3000 intelligent dark-box (Fujifilm). 
Table 4: SDS-PAGE Preparation  
  
 Evaluating Gene Expression using the GEO-NCBI Data Sets 
To explore the expression of REST, Synapsin, Synaptosome Associated Protein 25 
(SNAP25), Superior Cervical Ganglion-10 Protein (SCG10) and glutamate Ionotropic 
Receptor AMPA Type Subunit 2 (GluR2 also, known as GRIA2) in human 
medulloblastoma and normal cerebellum, I used the Gene Expression Omnibus (GEO, 
NCBI) data sets; [GSE85217 for medulloblastoma 41, GSE109403 134, GSE13162 135,  
GSE42658 136, GSE68776 137, and GSE86574 138 were used for normal human cerebellum, 
and GSE34101 139, GSE20492 140, GSE77947 141 for the Daoy cell gene expression]142.  
The data were downloaded and analysed using ExAtlas software 
(https://lgsun.irp.nia.nih.gov/exatlas/) 143.  The analysis was performed by transforming the 
Constituents 8% Resolving 5% stacking gel 
Water 3.33 mL 3.3 mL 
30% Acrylamide/Bis-acrylamide 
(Severn Biotech, 29:1) 
2.7 mL 1.02 mL 
1M Tris pH 8.8 3.8 mL - 
0.5M Tris pH 6.8 - 1.5 mL 
10% SDS 100 µL 60 µL 
10% Ammonium persulfate 100 µL 60 µL 
TEMED 
(Tetramethylethylenediamine) 
8 µL 6 µL 
Total volume 10 mL  6 mL 
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values into log2 and the correlation between the selected samples data was performed by 
normalizing the values using a set of pre-selected housekeeping genes.  The quality of the 
normalized samples were assessed by the standard deviation (SD) and ANOVA with error 
variance adjustment (also, known as empirical error variance) 143. 
 The Statistical Analysis and Visualization  
The normal distribution of the data was examined using Shapiro–Wilk test and P-values 
of >0.05 was used to show that the data may follow a normal distribution.  Significant 
differences between the means were evaluated using the Unpaired t-test and the One-Way 
ANOVA, and the two tailed and the P-values of <0.05 were considered significant and the 
measures were presented as means ± standard error of the mean (SEM).  Statistical analysis 
was performed using the GraphPad Prism version 8.0.1 for Windows, GraphPad Software, 
La Jolla California USA, (www.graphpad.com).   
The heatmaps were generated using the Heatmapper web server tool 
(http://www2.heatmapper.ca/expression/) 144 or the Seurat R function of heatmap.3.  The 
violin plots were generated using the ggplot2 R package, and the t-SNE plots were 
generated using the Seurat (TSNEPlot) function.  The Venn diagrams were produced using 
Venny online tool (v.2.1) (http://bioinfogp.cnb.csic.es/tools/venny/index.html). 
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Chapter 3 
3 Results I 
(Investigating the contribution of REST in Medulloblastoma) 
3.1 Preface  
 The aim and the Objectives of the Study  
This study aimed to investigate the contribution of REST in the medulloblastoma Daoy 
cell proliferation, cell cycle, migration, and to identify if HDACis induce their therapeutic 
action through the HDACs that are recruited in REST repression complexes.   
 The objectives of the study 
• Identifying the difference in REST expression between the medulloblastoma 
tumours and the normal brain tissue and across the medulloblastoma subgroups and 
subtypes 
• Modulating REST expression in the Daoy medulloblastoma cell line using both 
CRISPR/Cas9 and shRNA systems, and investigate the effect of REST depletion 
on the expression of the RE1-containing genes, on the cell proliferation, and on the 
migration ability  
• Investigating whether the HDACis induce their therapeutic action through the 
HDACs that are recruited in REST repression complexes 
 The Roadmap   
To address the research questions, the expression of REST in the Daoy cell line was 
modulated using the CRISPR/Cas9 and the shRNA systems to knockout and knockdown 
REST expression, respectively.  The effect of REST modulation was then examined; on 
the expression of the cell proliferation, the cell cycle, and on the migration ability of the 
cell.  Also, the sensitivity of the cells to HDACis was examined before and after REST 
modulation.  Additionally, the study used the GEO-NCBI gene profiling data of 
medulloblastoma patients’ tissue samples to explore the expression difference of REST 
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between the medulloblastoma tumours and normal cerebellum, and between the 
medulloblastoma classes (Figure 10).  
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Figure 10: Schematic representation of the research workflow  
The research started by optimizing the experimental condition of the cell seeding density, 
the HDACis dose response curves, Daoy transfection optimization, and measuring the 
effect of HDACis on the cell growth and the cell cycle.  REST expression was then 
modulated using the CRISPR/Cas9 and the shRNA systems.  The conformation of REST 
modulation was carried out by the DNA sequencing, measuring REST mRNA and protein 
expression, and the expression of some RE1-containing genes.  The contribution of REST 
modulation on the Daoy cell growth, the cell cycle, the cell migration, and the cell response 
to HDACis was then examined.   
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3.2 The Results 
 Investigate REST Expression using Published Microarray Gene 
Expression Data 
Elevated REST expression has been reported in approximately 80% of the 
medulloblastoma tumours 11, 14, 50.  However, it is not known if all the subgroups and the 
subtypes display an elevated REST expression.  In this analysis, the Gene Expression 
Omnibus (GEO, NCBI) microarray database was used to examine the variations in REST 
expression between the medulloblastoma tumours and normal brain cerebellum 142.  Also, 
the expression of REST and its functional effect on the RE1-containing genes was 
evaluated in the Daoy cell line.   
 REST Expression is Higher in Medulloblastoma Tumours Compared to 
Normal Cerebellum  
To examine the difference in REST expression between the medulloblastoma tumours and 
normal cerebellum, the GSE85217 data set was compared to normal cerebellum samples 
using the ExAtlas tool 41.  This data set contains 763 fresh-frozen primary medulloblastoma 
tissue samples which were originally classified according to their genetic and the 
methylation signature into the 4 subgroups and the 12 subtypes of the medulloblastoma 
classes 41.  The analysis was performed using the ExAtlas tool which normalizes the values 
between the data sets using a set of pre-selected housekeeping genes 143.   
Comparison of REST expression between the medulloblastoma groups and the normal 
cerebellum showed a significant (P<0.0001) increase in REST level in the tumour samples 
by 0.3-fold change (Figure 11 A).  On the level of the medulloblastoma subgroups, the 
expression of REST showed some differences between the subgroups.  For example, the 
WNT subgroup showed the highest expression of REST whereas, the Group 3 and the SHH 
subgroups showed relatively equivalent expression with an extensive variation between 
the samples of the SHH subgroup.  In contrast, the mean of REST expression of the Group 
4 was the lowest among all the subgroups however, around 50% of the samples displayed 
a relatively similar REST expression to the SHH and Group 3 (Figure 11 A).   
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Further, I clustered the samples according to the proposed medulloblastoma twelve 
subtypes in order to demonstrate the expression difference of REST between and within 
the subtypes 41.  The analysis revealed that the WNT β subtype displayed the highest REST 
expression though, the difference in the mean between WNT β and α was not significant 
(P=0.531).  Also, the results revealed a statistically significant difference between the 
means of the SHH subtypes as determined by one-way ANOVA (p<0.0001) (Figure 11 
B).  Both of the SHH α and β subtypes displayed an elevated REST expression compared 
to γ and δ subtypes.  Whereas, the expression of REST was comparable between Group 3 
subtypes as determined by one-way ANOVA (P=0.0539).  Group 4 showed a significant 
difference between the means of the α and β subtypes compared to the γ subtype (ANOVA 
P<0.0001) and they demonstrated the lowest expression of REST in all medulloblastoma 
classes (Figure 11 B). 
In order to evaluate the effect of REST expression, I extracted the expression values of 
some REST-regulated genes that are known by their high sensitivity to the modulation in 
REST expression and the high occupancy of REST to their RE1 sites (Synapsin (regulates 
synaptogenesis), SNAP25 (is a membrane fusion and involved in neurotransmitter release), 
SCG10 (helps in regulate the microtubule dynamic and stability) and GluR2 (is a 
neurotransmitter receptors)) 145.  The expression of Synapsin and SNAP25 was low 
(P<0.0001) in the medulloblastoma subtypes compared to the normal cerebellum.  Also, it 
was lower in the subtypes that display elevated REST expression such as the WNT 
subtypes when compared to the subtypes with low REST expression such as the Group 4 
subtypes (Figure 11 C and D).  Unexpectedly, the expression of SCG10 and GLuR2 was 
high in the medulloblastoma subtypes compared to the normal cerebellum apart from the 
GLuR2 (P<0.001) in the WNT and Group 3 subtypes (Figure 11 E and F).   
Taken together, the expression of REST in the medulloblastoma tumours is variable 
between the subtypes and within each subtype and it showed an elevated expression with 
the WNT and SHH pathways.  The WNT subgroups showed the highest REST expression 
whereas, the Group 4α and β subtypes exhibited the lowest expression among all subtypes.  
These findings may indicate that the contribution of REST in medulloblastoma could be 
different between the subgroups.  
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Figure 11: The expression of REST and some selected RE1-containing genes in 
medulloblastoma and normal cerebellum tissue samples 
The expression of REST in the medulloblastoma subgroups (A) and the subtypes (B), and 
expression of SNAP25 (C), Synapsin (D), SCG10 (E), and GluR2 (F) was extracted from 
the GEO NCBI database using ExAtlas tool.  The expression values were represented by 
the circular dots and the difference between the means was calculated using the two tailed 
Student’s t-test (the * in E and F is P<0.001) and the One-Way ANOVA (SHH subtypes 
(F(3, 143) = 29.61, P<0.0001), Group3 (F(2, 102) = 6.305, P=0.003), and Group4 (F(2, 
221) = 75.07, P<0.0001)), and the error bars are SEM.   
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 REST Expression is Elevated in the Daoy Medulloblastoma Cells 
Compared to Normal Cerebellum 
Elevated REST expression in the Daoy cell has been reported previously in several studies 
11, 14, 115.  In this study, I used the GEO gene expression data to identify the expression 
difference of REST between the Daoy cell and normal cerebellum.  The result showed that 
the expression of REST was almost 1.8-fold change (P<0.0001) higher in the Daoy cell 
compared to the normal cerebellum (Figure 12 A).  To evaluate if the increase in REST 
expression has a significant functional effect on the RE1-containing genes, I compared the 
expression of the aforementioned genes between the Daoy cell and the normal cerebellum.  
The results showed that the expression of the genes in the Daoy is at least one-fold 
(P<0.0001) less compared to the normal cerebellum (Figure 12 B).  
 
Figure 12:  The expression of REST and RE1-containing genes in the Daoy cell and 
normal cerebellum 
(A) Shows the expression of REST in the Daoy cell and the normal brain cerebellum.   (B) 
Shows the functional effect of REST expression on the expression of the RE1-containing 
genes. The expression values are represented by the circular dots and the differences 
between the means was calculated using t-test and the error bars are SEM.   
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 The Experimental Optimization to Examining REST contribution in 
Medulloblastoma   
 Daoy Seeding Density of 3.5 x 104 cell/mL Reaches 100% Confluence by 
72 Hours 
Daoy is a highly proliferative cell with a population doubling time of around 29.8 hours 7.  
Generally, the confluency of the cells could have a major impact on the cell response to 
the treatment which may affect the comparison between the biological replicates.  Hence, 
I started by identifying the cell count that yields 90 to 100 % confluency by 72 hours.   This 
experimental condition was selected in order to study the sensitivity of the cell to HDACis.  
The confluency was defined as the proportion of the culture surface that was covered by 
the cells at the time of measurement thus, a confluency of 50 % means half of the culture 
surface was covered by cells.   
To identify the seeding density that gives the former experimental condition, several 
dilutions (1 x 104, 2 x 104, 5 x 104, and 1 x 105 cell/mL) of the Daoy cell were prepared in 
volumes of complete culture media and cultured in 6-well culture plates.  The confluence 
of the cells was assessed at 24, 48, and 72 hours using an inverted microscope and the cells 
at each time point were also counted using haemocytometer cell counter.  
During the first 24 hour, both the 5 x 104 and 1 x 105 densities showed an increase in the 
cell count in comparison to the seeding time by more than 40% and 20%, respectively.  
Microscopically, the 5 x 104 cells started to show high confluency by the 48 hours, and at 
the 72 hours they showed an increase in the number of the detached cells and a decline in 
the number of the living cells by around 20%.   This outcome could be due to the high cell 
number which led to the consumption of the media nutrients and possibly affected the other 
cell functions.  In contrast, the 2 x 104 and 1 x 104 densities have reached a confluence of 
50% and 20% at 72 hours and their count increased by 30% and 15%, respectively (Figure 
13 B).  As the 1 x 105 and 5 x 104 showed high confluence after 48 hours whereas, the 2 x 
104 did not reach the required confluence, I used a cellular density of 3.5 x 104 cell/mL for 
all the subsequent experiments.  
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Figure 13: Identifying the Daoy cell count that yield 90 – 100% confluence after 72 
hours from culturing 
Different densities (1 x 104, 2 x 104, 5 x 104, and 1 x 105 cell/mL) of the Daoy cell were 
prepared in a complete culture media and seeded into 6-well culture plates.  The 
confluence of the cell (A) was evaluated microscopically every 24 hours from the seeding 
by assuming a confluency of 50% as half of the culture surface is covered by the cells.  The 
cells at each time-point were counted and the percentage of the growth was calculated by 
assuming the concentration of 1 x 105 cell/mL at 48 hours (the highest reading) as 100% 
and the other readings were proportioned to its value (B).   
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 Generating the Cell Dose-Response Curve for HDACis  
HDACis are a family of anticancer drugs that inhibit the deacetylation of the histone and 
non-histone proteins leading to change the gene expression, the cell metabolic activity, and 
the cell cycle which ultimately result in stimulating apoptosis 81.  Both the in vivo and in 
vitro analysis demonstrated the high sensitivity of the transformed cells to HDACis 
compared to normal cells 75, 146.  Based on the distinct chemical structure of the HDACis, 
they have been grouped into four main classes.  In this study, I examined, at least, a drug 
from each of the four structural groups (SAHA is hydroxamic acid structural groups, MS-
275 and MI-192 are bibenzimides, Apicidin is cyclic tetrapeptide, and VPA is classified 
under the Short-chain fatty acids group).   
The analysis was started by generating Daoy cell dose-response curve for each inhibitor.  
The dose-response analysis was performed by seeding the cell at 3.5 x 104 cell/mL in 96-
well culture plates and after 24 hours from the culturing, the media was replaced with 
ranges of the inhibitor’s concentrations.  Untreated and DMSO controls were included with 
each measurement and the anticancer effect of the drugs was measured after 72 hours from 
the exposure using the MTT assay.  The colorimetric results of this assay were presented 
as percentage by assuming the value of the Daoy untreated control at 72 hours as 100% 
and the values of the other reading were proportioned to its value. 
The absorbance of the untreated Daoy control showed robust growth and reached a plateau 
at 72 hours.  The DMSO control did not show any significant cytotoxicity and the cell 
continued to grow with very minimal difference to the untreated cell.  In contrast, the 
HDACis treated cells showed a progressive reduction in the cell viability in a 
concentration-dependent manner (Figure 14).  SAHA, MS-275, MI-192 and Apicidin have 
induced their antiproliferative effect in sub-micromolar concentrations with complete cell 
death at the highest concentrations apart from SAHA which showed some viable cells at 
10 M.  In contrast, VPA induced a slight increase in the cell proliferation rate at the 
0.03mM concentration.  With higher concentrations, VPA showed a concentration-
dependent effect and exhibited more than 95% cell death with the 15  mM concentration.   
The generated dose-response curves were also used to estimate the IC50 (half maximal 
inhibitory concentration) of the cell at 72 hours (Figure 14).  The subsequent analysis were 
carried out using [SAHA (5 µM), MS275 (5 µM), MI192 (3 µM), APICIDIN (3 µM), and  
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HDACis Used Concentration 
SAHA 5 µM 
MS-275 5 µM 
MI-192 3 µM 
Apicidin 3 µM 
VPA 10 mM 
Figure 14: The Daoy cell dose-response curves showed a concentration-dependent 
effect of HDACis on the cell growth   
The Daoy cells were seeded at 3.5 x 104 cell/mL into 96-well plates, and after 24 hours 
incubation the media was replaced with ranges of the HDACis concentrations; SAHA 
(0.003 µM to 5 µM) (A), MS-275 (0.01 µM to 6 µM) (B), MI-192 (0.003 µM to 5 µM) (C), 
and VPA (0.03 mM to 15 mM) (D).  The viability of the cells was measured after 72 hours 
from the treatment using the MTT assay.  The results are the average of three independent 
replicates and presented in percentage by assuming the value of the vehicle control at 72 
hours as 100% and the values of the other reading were proportioned to its value.  The 
error bars are SEM.  Table (F) shows the used concentrations in the subsequent analysis.  
(F) 
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VPA at (10 mM)] concentrations which induce a significant cell death at 72 hours.  These 
concentrations have been reported to induce tumour cell death though, they do not affect 
the viability of normal cells  147, 148, 149.  
 HDACis Showed Variable Anticancer Activity and a Time-dependent 
Effect  
As most anticancer drugs, HDACis have been reported to reduce the tumour cell growth 
and stimulate apoptosis in a time-dependent manner 65, 150.  In this study, the difference in 
the anticancer activity between the used inhibitors was investigated in a time-course 
manner.  The analysis was performed by treating the cell with a single concentration of 
SAHA (5 µM), MS-275 (5 µM), MI-192 (3 µM), Apicidin (3 µM), and VPA (10 mM) and 
the viability of the cell was measured at 0, 12, 24, 36, 48, 60 and 72 hours from the exposure 
using the MTT assay.  Untreated controls were included with each time-point which were 
used later to normalize the results of the treated cells.   
The MTT results exhibited the ability of HDACis to induce a progressive reduction in the 
cells count in a time-dependent manner yet, the anticancer activity was slightly different 
between the drugs (Figure 15).  For instance, the viability results of MI-192 showed a rapid 
and statistically significant (P ≤ 0.05) decline in the total number of the cells by more than 
15% at the 12-hours measurement and it continued to eradicate the cell by around 50% 
between a time-point and the subsequent time-point (P ≤ 0.001) (Figure 15 C).  Whereas, 
the effect of SAHA, Apicidin and VPA started at the 24-hours with more than 20% 
reduction (P≤0.001) in the total count of the cells.  The Apicidin effect was more 
progressive and it reduced the cell number by more than 60% at the 36-hour (P ≤ 0.001).  
The SAHA effect was gradual with around 20% reduction between the time-points 
whereas, the VPA effect was slightly low compared to the other inhibitors and it showed 
around 15% reduction between a time-point and the subsequent point (P≤0.001).  In 
contrast, MS-275 did not show any significant anticancer effect during the first 24 hours 
of the exposure though, at the 36-hours it started to show a significant reduction (P ≤ 0.001) 
in the cell number by more than 20% and it eradicated most the cells at the 72 hours.   
The results were further used to measure the amount of the dead cells at each time point 
by calculating the difference between the value of a time point and the time point before 
it.  These investigations may appear as an inverse to the above cells viability results though, 
Chapter 3Chapter 5  Results I 
81 
 
it was used to show the anticancer effect of HDACis from two sides (Figure 15 F).   The 
results of the dead cells clearly showed that all the inhibitors induce their anticancer effect 
after the first twelve hours, apart from MI-192 which showed a rapid increase in the dead 
cell at the 12-hours reading by around 13% and it reached to more than 30% at the 36-
hours.  SAHA and Apicidin showed more than 20% dead cell at the 24-hour time point 
though, the Apicidin anticancer effect continued to increase and reached to 40% at the 36-
hours (Figure 15 F).  The anticancer activity of 10 mM VPA concentration was relatively 
equivalent to the micromolar-concentration of the other inhibitors yet, its anticancer 
activity during the first 48-hours was lower in comparison with the other inhibitors (Figure 
15 F).    
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Figure 15: HDACis induce a time-dependent antiproliferative effect   
A time course analysis of the HDACis anticancer effect.  The Daoy cells were seeded at 
3.5 x 104 cell/mL into 96-well plates and after 24 hours the cells were treated with a single 
dose of SAHA (5 µM) (A), MS-275 (5 µM) (B), MI-192 (3 µM) (C), Apicidin (3 µM) (D), 
and VPA (10 mM) (E).  Untreated controls were included with each time point.  The 
viability of the cell was measured at 12, 24, 36, 48, 60, and 72 hours using the MTT assay 
and the results of each time point was normalized to the untreated control (not displayed 
in the graphs).  The dots represent the values and the P-value was calculated using the two 
tailed Student’s t-test (* P ≤ 0.05, *** P ≤ 0.001) by comparing the values of a time point 
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to the untreated control of the same time-point which was considered as 100%.  The error 
bars are SEM.  The amount of the dead cell (F) for each time point was measured by 
calculating the difference in the MTT absorbance between a time point and the time point 
before it.  The results are the average of three independent replicates and represented in 
percentage.   
 HDACis Induced a Prolonged Cell Cycle Delay and not a Complete Cell 
Cycle Arrest 
HDAC enzymes have a considerable role in regulating several cellular functions 
including the cell cycle.  In several studies, HDACis have been claimed to cause cell 
cycle arrest at G2 phase yet, this conclusion was based on the results of a single time-
point analysis 151, 152, 153, 154.  In this study, the effect of HDACis on the Daoy cell cycle 
was investigated by treating the cell with HDACis in a time-course manner (at 6, 12, 
24, 48 and 54 hours from culture).  This approach helps in showing the dynamic and the 
duration of each phase and aids in revealing if HDACis induce a complete cell cycle 
arrest.   
The distribution of the cells in each phase can be assessed by staining the cells with PI 
and assay them on FACS 155.  The concept of this analysis depends on the amount of the 
DNA in each phase, and the fluorescence intensity of the PI is presumed to be 
stoichiometric relationship to the DNA content 155.  For example, in G1 and G2 phases 
the DNA is uniform and it is equivalent to the DNA ploidy index (DI) of 1.0 for G1 and 
2.0 for G2/M, where the DI in S phase is between 1.0 and 2.0 156. 
The results of this analysis displayed that the untreated cell have an active cell cycle 
profile (Figure 16).  Whereas, the results of the treated cells showed a non-stopping cell 
cycle with a prolonged delay in the progression between the phases however, there was 
no evidence for the cell cycle arrest.  The results of SAHA and Apicidin showed a 
relatively similar pattern.  For instance, they show more than 30% increase in the cells 
of the G2 phase at the 24-hours however, the accumulation slightly decreased at the 48 
and the 54-hours (Figure 16).  MS-275 showed different pattern of cell cycle delay.  At 
the 6-hours, it showed ~10% increase in G1 phase accumulation and it reached to more 
than 70% at the 24-hours.  This accumulation was associated with a decrease in S and 
G2 phases cell count (Figure 16).  Similarly, MI-192 also showed different pattern of 
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cell cycle delay however, its effect started at the 6-hours with ~15% accumulation in G1 
phase.  At the 24-hours, it induced an increase in cells accumulation in G2 by ~30% yet, 
at the 54-hours it increased the accumulation in S phase by more than 40% compared to 
the untreated cell (Figure 16).  The effect of the VPA started at the 24-hours with around 
20% increase in G2 phase though, it did not last for long and the distribution of the cell 
in the S phase started to increase at the 48-hours (Figure 16).  
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Figure 16: HDACis induced a prolonged cell cycle delay though, it did not arrest the 
cell cycle 
The effect of HDACis on the distribution of the cells in the cell cycle phases.  The cells 
were treated with the HDACis and harvested at 6h (A), 12h (B), 24h (C), 48h (D), and 54h 
(E) from the treatment.  The cells were fixed in 70% ethanol and stored at -20C for at 
least 24 hours.  Before the analysis, the cells were treated with RNase A, stained with PI, 
and analysed on FACS.  The cell distribution results are the average of 3 biological 
replicates and the accuracy of the DNA measurements was assessed by the CV value of 
the G1 mean ( 6) 157.  The error bars are SEM. 
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 Optimizing the Transfection of the Daoy Cell 
In order to identify the optimal ratio between the Lipofectamine transfection reagent and 
the plasmid DNA concentration, I used three concentrations (125, 250 and 500 ng) of the 
pCMV-β-gal plasmid with a Lipofectamine reagent ratio of 1:2, 1:3, and 1:4 to transfect 
the Daoy cell.  The results showed that the transfection ratio of 1:2 DNA to Lipofectamine 
was not enough to introduce the DNA into the cells and it did not cause any noticeable cell 
death.  Whereas, the 1:4 ratio showed more than 40% efficiency with all the DNA 
concentrations, but it induced more than 60% cell death.  The 1:3 ratio showed more than 
20% transfection efficiency with the 125 and 250 ng of the DNA, with the 500 ng the 
transfection efficiency reached to around 30% and the cell death was less than 30% (Figure 
17).  As the 1:3 ratio showed the lowest cell death and generated around 30% transfection 
efficiency with the 500 ng hence, the transfection reactions of the shRNA knockdown were 
prepared using 1:3 ratio with 750 ng of the DNA.   
 
Figure 17:  Daoy Cell Transfection optimization  
The X-Gal assay was used to optimize the lipofectamine transfection reaction.  The Daoy 
cell with 60 - 80% confluency was transfected with the pCMV-β-gal plasmid using 125, 
250 and 500 ng of the plasmid DNA to Lipofectamine reagent at ratios of 1:2, 1:3, and 
1:4.  After 48 hours from the transfection, the cells were exposed to X-gal solution and 
incubated overnight for colour development.  The effect of the transfection on the cell 
viability was evaluated under inverted microscope, and the transfection efficiency was 
measured by identifying the proportion of the stained to non-stained cells.   
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 Modulating REST Expression in the Daoy Cell  
To study the effect of REST ‘loss-of-function’ on the Daoy cell and to investigate whether 
HDACis induce their action through the HDACs recruited in the REST repression 
complexes, I disrupted REST expression using the CRISPR/Cas9 and shRNA systems.   
 Modulating REST Expression Using CRISPR/Cas9  
With the CRISPR/Cas9 system, two guide RNA (gRNA) sequences were used to 
selectively target the sense and the anti-sense strand of REST exon 2 (Figure 18 A).  The 
off-target effect for each gRNAs was examined using NCBI-blast and the analysis 
displayed the 100% sequence identity and covary of the gRNAs to the human REST 
mRNA transcription variant 1 and 2 (NCBI Reference Sequence: NM_005612.4 and 
NM_001193508.1).  The E value, which represents the number of hits that is expected to 
be found in the NCBI blast search, was 0.017 (the closer to zero the more significant the 
match is).  The shortest sequence compatible with other genomic sites is 18 bp for gRNA1 
and 16 bp for gRNA2 and they aligned to ZNF91 (a zinc finger protein of the KRAB 
(Kruppel-associated box) and NEAT1 (a long non-coding RNA), respectively.  The 
shortest sequence of the scramble control that is compatible with other genomic sites was 
15 bp with E-value of 9.1.  These results demonstrate the low probability of the two gRNA 
sequences to induce off-target effect.  In order to isolate cells with complete knockout of 
REST expression, the CRISPR/Cas9 transfected cells were grown as a single cell per 
culture to produce a monoclonal cell growth.  The cells were screened for the genome 
editing by amplifying the editing sites and the products were analysed using Sanger 
sequencing.  The sequencing results of 140 monoclonal cell growths showed the presence 
of 6% of the cells with mono-allelic genome editing in forms of a single nucleotide deletion 
and/or insertion in REST exon 2 (Figure 18 B).   
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Figure 18: CRISPR/Cas9 induced mono-allelic genome editing 
(A) A schematic diagram of the REST gene regulatory regions, the exons, the genome 
target site of gRNA1 (green) and gRNA2 (blue) at exon 2, and the PAM sites (TGG) which 
are the located immediately following the gRNA sequence.  (B) Examples of the mono-
allelic genome editing in form of insertion (AT, T, C, or GAAAA) or deletion 
(TGTGGCCTTA).  
Interestingly, the PCR screening revealed a cell clone (hereinafter referred to as KO) with 
a single PCR product of more than 1500 bp and no amplification product at 326 bp (the 
expected product size) which may suggest that the genomic editing in this clone could 
involve all REST alleles (Figure 19).  Sequencing of the KO cell clone has identified a 
homologues recombination of more than 1500 bp DNA insert at the editing site.  The NCBI 
blast analysis of the inset referred the sequence to a highly conserved E. coli enzyme, 
known as triphosphoribosyl-dephospho-CoA synthase (citrate fermentation enzyme).   
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Figure 19: CRISPR/Cas9 has induced homologous recombination genome editing 
Agarose gel electrophoresis (1.2%) shows the PCR amplification products of the 
CRISPR/Cas9 editing sites.  REST exon 2 was amplified using specific primers to amplify 
the editing sites.  The cell clone KO showed a single PCR product of more than 1500 bp 
and did not show the expected product size (~ 326 bp).  
With the knockout approach, to achieve functional knockout both copies of a gene should 
be mutated (biallelic mutation).  Hence, to confirm the biallelic editing of REST in the KO 
cell, the editing site was amplified using SYBR green qPCR.  For efficient SYBR green 
amplification signal, the recommended amplicon length should be between 50-150 bp.  
Amplifying longer fragments of cDNA mostly leads to loss of the qPCR efficiency in 
detecting the florescence single which it could be due to the inability of the reaction to 
produce completed PCR products that can be used as templates in further cycles 158.   
Accordingly, this reaction is expected to show amplification with the wildtype and if the 
editing in the KO cell involved one allele (monoallelic editing) as the size of the product 
is 188 bp.  If all the REST alleles in the KO cell were edited the qPCR should show no 
amplification due to the long fragment of the insert (~1500 bp).  As this reaction generates 
negative results (no amplification), a positive control that amplifies REST exon1 (known 
here as E1) was included.  In this study, I used U6 Small Nuclear 1 RNA (RNU6, also 
known as RNU6-1) as an endogenous control to normalize the qPCR results.  This gene 
has been widely used to normalize the qPCR results due to its consistent high expression 
in transformed cells compared to healthy controls also, it characterized by its narrow 
standard deviation 159, 160, 161. 
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The qPCR results showed an amplification with the Daoy, the scramble control, and the 
E1 control.  The KO reaction did not show any amplification signal, which could confirm 
the genome editing of all REST alleles in the KO cell (Figure 20).  Further, the expression 
of REST protein in the KO cell clone was examined using western blot analysis (section 
3.2.2.4).   Also, the expression of the RE-1 containing genes was examined using the qPCR 
analysis (section 3.2.4.2). 
 
Figure 20: CRISPR/Cas9 induced bi-allelic genome editing in the KO cell clone 
qPCR amplification of the REST editing site.  The qPCR was performed by reverse-
transcribing 1.0 µg of the total RNA and the SYBR green qPCR reactions were performed 
using a pair of primers that specifically amplifies the CRISPR/Cas9 editing site (188 bp).  
A positive control that amplified REST exon 1 (E1) was included to verify the no-
amplification of the KO reaction and the qPCR was performed using the standard 
amplification conditions.  The measurements were performed in duplicate and the results 
are the average of 6 repeats normalized to RNU6 housekeeping gene.  The expression 
values are log2 transformed and represented by the circular dots, the P-value was 
calculated using the two tailed Student’s t-test, and the error bars are SEM. 
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 Modulating REST Expression Using the shRNA Knockdown System 
As CRISPR/Cas9 has not been used previously to knockout REST expression, the shRNA 
knockdown approach was used to validate the knockout results.  With the knockdown, two 
shRNA sequences were used to target REST exon 2 and exon 4.  The selection for stable 
shRNA-expression cells was performed by culturing the cells in puromycin selective 
medium.   
Ahead of this work, the puromycin killing curve was generated by treating the Daoy cell 
with various concentrations of puromycin and the viability of the cells was evaluated using 
the MTT assay at day 4 and day 7 from the start of the treatment (Figure 21).   The result 
of this analysis showed that the puromycin concentration of 5 µg/mL was sufficient to 
eradicate the Daoy cell within 7 days of treatment.  
To select for the stable shRNA expression, the transfected cells were treated with 5 µg/mL 
of puromycin and the selection was completed when all the cells in the non-transfected 
control had been killed.  The survived cells were then grown as a single cell per culture to 
produce a monoclonal cell growth.  Screening for the pSUPER-puro genomic integration 
was performed using the PCR amplification and the clones that showed shRNA plasmid 
integration were further analysed with western blot analysis.   
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Figure 21: 5 µg/mL of Puromycin was used to select for stable expression of the 
shRNA 
Puromycin kill curve for the Daoy cell.  The cell was seeded at 3.5 x 104 cell/mL and after 
24 hours the media was replaced with range of puromycin concentrations (0, 1, 0.5, 1, 2, 
3, 4, 6, and 8 ug/mL).  The viability of the cell was measured after 4 days and 7 days from 
the treatment using the MTT assay.  The results are the average of three independent 
replicates and presented in percentage by assuming the value of the untreated control at 
72 hours as 100% and the values of the other reading were proportioned to its value.  The 
error bars are SEM.  
 Confirm the Modulation of REST Expression 
 Modulating REST Expression Resulted in a Significant Reduction in REST 
mRNA and Protein levels 
To further confirm the modulation of REST, Western blot with anti-REST polyclonal 
antibody was used to examine the KO cell clone and to screen the stable shRNA cell clones 
for REST expression.  The immunoblotting analysis of the KO cell did not show the 
expression of REST protein (122 kDa) (Figure 22 A).  With the shRNA knockdown 
system, I found a cell clone (hereinafter referred to as KD) showed approximately 80% 
reduction in the REST protein expression compared to the wild type cell (Figure 22 A and 
B).  It should be noted that the other immunoreactive bands may be incompletely reflecting 
the different REST isoforms due to: the specificity of the anti-REST antibody, not all REST 
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protein isoforms have been experimentally verified, and the post-translational 
modifications of the isoforms can substantially alter their apparent molecular weight when 
resolved on western blots 162.  These factors make difficult to determine whether an 
unknown immunoreactive band is non-specific or a REST isoform.  See (Appendix 6) for 
more information. 
Figure 22: REST modulation has induced a significant reduction in REST protein 
Western blot analysis of REST protein expression in the KO and KD cells.  The nuclear 
protein was immunoblotted with anti-REST polyclonal antibody (1:1000) and anti-β-actin 
antibody (1:20000) (A).  The Bar chart (B) is the densitometric quantification of the 
western blot membrane using Image J.  The dots represent the REST expression relative 
to β-actin value and the P-value was calculated using the two tailed Student’s t-test and 
the error bars are SEM. See (Appendix 6) for complete western blot image and comment.  
The mechanism of the shRNA knockdown is based on the sequence-specific degradation 
of the host mRNA which results in decreasing the mRNA level and accordingly the REST 
protein expression.  To study the functional effect of the shRNA, the expression of REST 
mRNA was examined using a qPCR reaction that amplifies part of exon 3 and 4.  The 
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results of the KD cell showed a significant reduction (P<0.0001) in the REST mRNA level 
by more than 50% compared to the control (Figure 23).   
 
Figure 23: The shRNA resulted in a significant reduction in the KD REST-mRNA 
level  
The qPCR amplification of REST-mRNA in the KD cells.  The mRNA (1.0 µg) was reverse-
transcribed and amplified using a pair of primers that specifically amplifies part of REST 
exon 3 and 4.  The measurements were performed in duplicate and the results are the 
average of seven repeats normalized to the RNU6 housekeeping gene.  The expression 
values are log2 transformed and represented by the circular dots, the P-value was 
calculated using the two tailed Student’s t-test, and the error bars are SEM. 
 Modulation of REST Expression Derepresses the Expression of the RE1-
Containing Genes  
REST expression is typically associated with repressing the expression of the RE1-
containing genes conversely, depletion of REST expression results in the derepression of 
the REST-regulated genes 23.  To study the impact of REST modulation, I measured the 
expression of the four RE1-containing neuronal genes (Synapsin, SNAP25, SCG10 and 
GluR2) that are known by the high occupancy of REST to their RE1 sites and showed 
sensitivity to the modulation in REST expression 145.   
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The qPCR results revealed a significant upregulation in the expression of these genes by 
more than 5-fold change in the KO and KD cells compared to the wild type (Figure 24).  
The expression in the KO cell was almost 2-fold higher than the KD, apart from SCG10, 
which showed a higher expression in the KD cell (Figure 24 C).  It is not clear why the 
SCG10 expression is elevated in the KD cell however, it could be due to the SCG10 
function in regulating neurite outgrowth and branching during the neuronal cell maturation.  
This may suggest that despite the general repression effect of REST on most RE1-
containing genes however, there could be concomitant regulations that precisely adjust the 
expression of a gene according to the internal regulations.  Collectively, these results 
confirmed that REST expression is elevated in the Daoy medulloblastoma cells and 
demonstrated its functional impact on the expression of the RE1-containing genes.  The 
results also verify the efficiency of the knockout and knockdown systems to modulate 
REST expression.    
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Figure 24: Modulation of REST expression resulted in increasing the expression of 
the RE1-containing genes  
The expression of Synapsin (A) SNAP25 (B) SCG10 (C) and GLuR2 (D) in the KO and KD 
cell clones.  The total RNA was (1.0 µg) was reverse-transcribed to cDNA and amplified 
using SYBR green qPCR.  The measurements were performed in duplicate and the results 
are the average of seven repeats normalized to the RNU6 housekeeping gene.  The 
expression values are represented by the circular dots, the P-value was calculated using 
the two tailed Student’s t-test, and the error bars are SEM. 
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 Study the Effect of REST Modulation on the Daoy Cell 
In brain cancers, REST has been proposed as an oncogene due to its ability to govern the 
expression of the neuronal differentiation genes.  In a number of previous studies, the 
oncogenic property of REST was investigated through knockdown REST expression.  
Such studies have claimed the direct involvement of REST in reducing the tumour cells 
growth and stimulating apoptosis 4, 11, 12, 13, 14.  However, this study has moved further to 
examine REST contribution in cancer through using the knockout approach as the partial 
expression of REST in the knockdown approaches may maintain some repression on 
different subsets of the neuronal genes. 
The following sections will present the functional effect of REST modulation on the Daoy 
cell proliferation rate, cell cycle, and the cell migration ability, and if HDACis induce their 
action though the HDAC recruited in REST repression complexes. 
 REST Deficiency does not Strongly Inhibit the Cell Proliferation Rate  
In cancer, unrestrained cell proliferation depends mostly on bypassing at least, a 
checkpoint pathway however, there is a large number of oncogenic factors that may 
contribute in maintaining the self-renewal potential of tumour cells.  To study the effect of 
REST knockout on the cell growth, the MTT assay was used to measure the viability of 
the cells at 24, 48 and 72 hours from seeding.   
The analysis showed that blocking REST expression did not induce a significant effect on 
the self-renewal potential of the KO and KD cells though, it slightly decreased their 
proliferation rate compared to REST expressing cells (Figure 25 A & B).  However, due 
to the small difference in the KO and KD growth to the control cells, the MTT analysis 
was performed over a period of 7 days.  The results of the 7 days culture showed a decrease 
in the KO and the KD cells growth by around 20% compared to the REST expressing cell 
(Figure 25 C).    
In addition, the proliferation curves were used to calculate the doubling time of the cells 
by subtracting the time value of 0.8 MTT absorbance from 0.4.   The calculated doubling 
time for the Daoy cells was around 27.9 hours, and for the KO cell it was 29.5 hours, and 
the KD cell was 29 hours (Figure 26).  
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Figure 25: Modulating REST expression slightly reduced the proliferation rate in the 
KO and KD cells 
The proliferation rate of the KO and KD cells.  The Daoy cells were seeded at 3.5 x 104 
cell/mL in complete culture media and the growth was measured using the MTT assay at 
24, 48 and 72 hours (A & B) and at day 7 (C).  The results are the average of three 
replicates and the percentage in the graph (C) was calculated by assuming the control 
value (the highest reading) at 72-hour and 7 days as 100% and the other readings were 
proportioned to it.  The error bars SEM. Further experiments are required to establish the 
effect of REST on the proliferation of the Daoy cells.  
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Figure 26: The doubling time of the KO and KD cells was slightly longer than REST 
expressing cells 
The doubling time was calculated from the proliferation curves by subtracting the time 
value of 0.8 MTT absorbance from 0.4.  (A) Daoy doubling time (DT) ~ 27.9 Hour, (B) the 
KO DT~ 29.5 Hour, and (C) the KD DT~ 29 Hour.  Further experiments are required to 
establish the effect of REST on the doubling time of the Daoy cells. 
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 Modulating REST Expression Increased Cells Accumulation in G1 Phase of 
the Cell Cycle 
The proliferative advantage of a tumour cell arises from its ability to bypass the 
quiescent state of the parent G1 phase as a result of alterations in the cell molecular 
regulations.  These changes generally disturb the mitogenic signalling and affect the cell 
cycle regulation.  In tumour cell, there is a large number of factors that may contribute in 
evading the quiescent state.   
In this study, the effect of REST modulation on the KO and KD cell cycle was 
investigated by isolating the cells in two conditions: when their growth reached 80-
100% confluency (single time-point), and in a time-course manner (at 24, 48 and 72 
hours from culture).  The single time-point analysis helped in giving an overall view about 
the percentage of the cells in each phase of cell cycle, but it does not show the kinetic of 
the cell cycle.  Whereas, the time-course method helped in revealing the dynamic of each 
phase. 
The results of the single time-point showed the active cell cycle profile of the Daoy cells 
wildtype with progression throughout the phases of the cell cycle.  However, the KO 
and KD cells displayed about 10% accumulation (P<0.0001) at G1 phase with a 
concomitant reduction in the cells proportion at S phase compared to the control cell 
(Figure 27 A).  The time-course analysis revealed that the accumulation of the KO cells at 
G1 phase continued for 48 hours before the progression of the cell cycle became 
moderately similar to the control cells at the 72-hour time point.  With the KD cell, the 
progression in the cell cycle was relatively comparable to the KO cell at the 24-hour time 
point yet, at the 48-hour the proportion of the cells within each phase became similar to 
the control cells (Figure 27 B, C, and D).   
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Figure 27: Modulating REST expression increased the KO and KD cells 
accumulation in G1 phase  
The effect of REST modulation on the distribution of the cells in the cell cycle.  The cells 
were grown in standard culture conditions and harvested when they reached 80-100% cell 
confluence (A) or at 24h (B), 48h (C), and 72h (D) from the seeding.  The cells were treated 
with RNase A, stained with PI, and subjected to flow-cytometry analysis (10.000 evens 
were recorded for each sample).  The distribution of the cells was presented as frequency 
histograms of the DNA content (E).  The results are the average of 3 biological 
replicates and the accuracy of the DNA measurements was assessed by the CV value of 
the G1 mean ( 6).  The dots represent the values and the P-values were calculated 
using the two tailed Student’s t-test and the error bars are SEM.  
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 Knockout REST Expression Significantly Reduced Cells Migration 
Migration of cancer cells represents a major challenge in medulloblastoma treatment and 
has been associated with poor clinical prognosis and outcome 163, 164.  In this study, the 
wound healing assay was used to investigate the effect of REST modulation on the KO and 
KD cells migration ability.  The concept of this assay depends on creating a scratch in a 
confluent cell monolayer which allows the migration of the cells in the edge of the gap 
toward the opining until the cells contact is re-established again.  This assay has been 
widely adapted to study the cell migration ability under several experimental conditions, 
including the modulation of gene expression 165.   
The analysis was performed, initially, by culturing the cells after creating the scratch in 
1% FBS-containing media.  In order to ensure the acquisition of reliable and reproducible 
results, the assay was evaluated by measuring the difference between several biological 
repeats.  The results showed a considerable difference between the repeats and within the 
results of the same cell clone which resulted in high standard deviation values (Figure 28).  
These variations could be due to the 1% FBS which could induce some effect on the cell 
growth.  Hence, in order to minimize the cell growth effect on the analysis, the experiment 
was carried out using FBS-free media.  Microscopically, growing the cells in FBS-free 
media did not show any observable cell death during the first 24 hours and the number of 
dead cells started to show a noticeable increase after 72 hours from the culture (Figure 
28A).  The results of the biological repeats of this work showed more consistent results 
with relatively low SD.  The migration results showed a significant difference between the 
means of the Daoy to the Scramble and EmpVec controls.  However, the difference 
between the KO and KD cells and their controls was also statistically significant 
(P<0.0001) and the cells were less efficient in migration and closing the gap by around 
40% compared to the controls (Figure 28 B and C).  
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Figure 28: The effect of 1% FBS on the wound healing assay results  
The relative cell migration in 1% FBS-containing media.  The cells were cultured in 6-well 
plate and after 24 hours the cells were scratched by passing a sterile pipette tip throughout 
the middle of the well in a vertical and horizontal directions.  Images were taken at the 
time of creating the scratch and after 24 hours and were analysed using TScratch software 
(CSElab, Zurich, Switzerland).  The dots represent the values, the boxes represent the 
upper and lower quantiles, the middle line of the box represents the median, the (x) 
within the box represents the mean, the whiskers indicate the variability and the SD is 
the standard variation.  
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Figure 29: Modulating REST expression resulted in reducing the cells migration 
ability  
The relative cell migration in FBS-free media.  The images (A) are a representation of 
culturing the cell in FBS-free media for 3 days.  (B) The bar chart is the average of three 
biological replicates, the dots represent the values, the P-values were calculated by the 
two tailed Student’s t-test, and the error bars are SEM.  The images (C) are a 
representation of the in vitro wound healing assay (a single biological repeat).  See 
(Appendix 8) for the ‘Tscratch’ analysis images.    
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 Disrupting REST Expression did Not Reduce the Sensitivity of the Cells to 
HDACis 
The mechanism of action of HDACis is not completely well known though, they may 
depend on the HDACs complexes and/or the non-histone proteins to induce their lethal 
effect 80, 166, 167.  REST repression complexes recruit several of HDAC enzymes which 
deacetylate histone and assist REST in repressing genes expression 168.  Tumours with 
elevated REST expression such as medulloblastoma are often highly sensitive to HDACis 
which may suggest that these agents may induce their action through the HDACs in REST 
repression complexes.  
In order to examine this assumption, the KO and the KD cells were treated with a single 
dose of the HDACis and the sensitivity of the cells was measured over a period of 72 hours 
using the MTT assay.  The results showed that the rate of the cell death in the KO and KD 
cells was equivalent to the control cells (Figure 30).  This finding may suggest that REST 
repression complexes are not the primary element for HDACis to induce their action and 
indicates that they may act through other HDAC complexes.   
Collectively, the results of this part of the research showed that the absence of REST 
expression alone is not the main factor of reducing cellular multiplication or inducing 
differentiation.  In addition, despite the elevated expression of REST in Daoy though, its 
repression complexes are not the main component for HDACis to induce their action and 
they may induce their action through other histone or non-histone proteins.    
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Figure 30: Disrupting REST expression did not affect response of the Daoy cells to 
HDACis 
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The sensitivity of the KO and KD cells to HDACis.  The cells were seeded at a 
concentration of 3.5 x 104 cell/mL and the MTT absorbance was measured after 24 hours 
from the seeding.  The cells were then treated with a single dose of the inhibitors (SAHA 
[5µM] (A & B), MS-275 [5µM] (C & D), MI-192 [3µM] (E & F), Apicidin [3µM] and 
VPA [10mM] (G & H) and the absorbance of the MTT was measured every 24 hours from 
the treatment for 3 consecutive days.  The percentage was calculated by assuming the 72-
hour untreated control value (the highest reading) as 100% and the other readings were 
proportioned to it.  The results are the average of five experiments and the samples in each 
experiment were tested in triplicate and the error bars are SEM. 
 The Daoy Cells Express REST4 Isoform   
REST4 isoform is an alternative splice form of REST full-length protein with a poor 
transcriptional repression role as it only retains five of the eight zinc fingers of REST and 
does not have the CTD.  Hence, when REST4 binds to an RE1 site it does not efficiently 
recruit the repression complexes which causes an increase in the expression of REST target 
genes in neuronal cells 7.  Accordingly, REST4 has been suggested to regulate the 
transcriptional repression by opposing REST function.  In cancer, high expression of 
REST4 has been associated with several of non-neuronal tumours such as neuroblastoma, 
breast, and small cell lung cancers however, its expression in brain cancer is not well 
known 7.  Also, the molecular regulation of REST4 expression is not fully understood.  
However, it has been reported that several of the RE1-containing genes such as SRRM4, 
ChAT, and VAChT may regulate REST4 expression which suggest REST regulation of 
REST4 18, 169.  In this work, it was suggested that the Daoy cells may lack the expression 
of REST4 due to the domination of REST full length repression which may downregulate 
REST4 expression.  
To investigate the expression of REST4 in the Daoy cells, the mRNA was amplified using 
REST4 exon-specific primers.  The reaction included an mRNA sample of SH-SY5Y 
neuroblastoma cell line as a positive control as this cell line has been reported to express 
REST4 170.  The results of the PCR amplification showed bands of 88 bp with the Daoy, 
the KO, the KD, and the SH-SY5Y cell (Figure 31).  This finding demonstrates the 
expression of REST4 in the Daoy in the existence of REST full length.  
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Figure 31: Daoy medulloblastoma cells expresses REST4 
Gel electrophoresis of the RT-PCR products of REST4.  Total RNA was reverse-
transcribed and amplified using REST4 exon-specific primes.  The reaction included a 
reaction for SH-SY5Y cell line as a positive control for REST4 amplification.  The PCR 
products of REST4 (88 bp) were electrophoresed on 2% agarose gel alongside with a DNA 
ladder and visualized using ethidium bromide. The negative control is N.CTRL.  
 HDAC Inhibitors Decrease Cell Viability Independent of DNA 
Fragmentation 
The results of this study have demonstrated the ability of the used HDACis to decrease the 
Daoy medulloblastoma cells viability which is possibly through the activation of the 
intrinsic apoptotic pathway.  One of the key features of apoptosis is the activation of the 
endogenous endonucleases which fragment the DNA into small oligonucleosomal 
fragments and irreversibly drive the cell death.  The fragmentation of the DNA forms 
laddering when electrophoresed on an agarose gel however, not all cancer cells show the 
DNA ladder when treated with anticancer drugs.  In here, the study examined if the DNA 
fragmentation is the end products of the HDACis-induced cell death.  
The analysis was performed by treating the cells with a single dose of the HDACis for 48 
hours and the DNA was extracted from both of the attached and floated cells in order to 
capture the DNA fragmentation.  To retain the small molecular weight fragments of the 
DNA, the extraction was performed by releasing the nuclear DNA without performing the 
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salt precipitation step.  The HeLa cell was included as a positive control as it has been 
reported to form DNA ladder when treated with HDACis 171.  The electrophoresis results 
of this work showed a smeary band with the HeLa treated cells whereas, the Daoy did not 
show the laddering feature (Figure 32).  This finding may suggest the presence of a 
different molecular regulation that regulates the Daoy cell death. 
  
 
Figure 32: HDACis induced Daoy cell death independent of DNA fragmentation 
DNA gel electrophoresis of the HDACis treated cells.  The Daoy and HeLa cells were 
treated with a single dose of the HDACis (SAHA [5µM], MS-275 [5µM], MI-192 [3µM], 
Apicidin [3µM] and VPA [10mM]) for 48 hour and the DNA was extracted from both the 
attached and floated cells without performing the salt precipitation step.  The DNA was 
electrophoresed on 2% agarose gel alongside with a DNA ladder and visualized using 
ethidium bromide. 
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3.3 Discussion 
Medulloblastoma is a group of cerebellum tumours branded by elevation of REST 
expression in most of its subgroups.  In literature, there has been some disagreement about 
REST contribution in cancer.  For example, the in vitro analysis has shown that knocking 
down REST in human medulloblastoma cell lines such as Daoy and D283 resulted in 
repealing the tumorigenic potential of the cells, upregulating the expression of neuronal 
genes, and ultimately triggering the apoptosis regulation 11, 14, 50.  Whereas, exogenous 
induction of REST into normal neuronal progenitors cells claimed to stimulate tumour 
formation and maintain the self-renewal potential of the tumour stem cells 53.   
In contrast, several of gene expression profiling studies were performed using primary 
human medulloblastoma specimens to study the whole image of the genetic involvement 
39, 41, 44, 103.  However, none of these studies have proposed REST involvement, or at least, 
the exclusive repression of the RE1-containing genes.  Despite the considerable research 
work that associated REST expression with medulloblastoma however, the 
medulloblastoma sequencing studies have not identified any direct or indirect link between 
the identified mutations which could contribute in increasing REST expression 42, 104.  This 
was further supported by a recent study which revealed that knocking down REST 
expression resulted in inhibiting the glioblastoma cells migration yet, it did not stimulate 
cell death 12.   
The main aim of this study was to identify the contribution of REST in medulloblastoma.  
In this research, I used GEO-NCBI gene profiling database to identify the difference in 
REST expression between the tumour and normal brain cerebellum and between the 
medulloblastoma subgroups and subtypes.  I modulated REST expression in the Daoy 
medulloblastoma cells using the CRISPR/Cas9 and the shRNA approaches.  Then I 
examined the effect of REST modulation on; the expression of the REST-regulated genes, 
the cell proliferation, the cell cycle, and the migration ability of the cells.  Also, I examined 
the sensitivity of the REST-negative and REST expressing cells to HDACis.   
The results of the GEO data analysis have revealed the elevated REST expression in the 
medulloblastoma subgroups compared to normal cerebellum.  Whereas, the evidences 
from the research work of this study showed that blocking REST expression resulted in 
slightly reduction in the cell growth rate, increased the cell accumulation in G1 phase and 
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decreased the cells migration ability.  However, it did not stimulate apoptosis.  The results 
also demonstrated the high sensitivity of the Daoy medulloblastoma cells to the used 
HDACis yet, the HDAC enzymes in REST repression complexes were not the primary 
elements for the inhibitors to induce their action.  
The following sections, will discuss the findings of the study, compare them to what it has 
been known and draw a final conclusion based on the evidences I have.  
  
The Discussions main points 
• WNT Medulloblastoma Subtype Exhibits the Highest REST Expression  
• REST Repression of RE1 Genes is not Equivalent between the Subtypes  
• Medulloblastoma Daoy Cell Showed High Sensitivity to HDACis 
o MI-192 Induced a Significant Cell Death within 12H of the 
Treatment 
o Apicidin Induced a Progressive Cell Death 
o MS-275 Showed a Significant Delay in Inducing Cell Death 
o SAHA Did not Completely Eradicate the Cell 
o Daoy Cell Showed Concentration-Dependent Sensitivity to VPA 
• HDACis Induced a Prolonged Cell Cycle Delay and not a Complete Arrest 
• Blocking REST Expression in Medulloblastoma did not Stimulate 
Apoptosis Mechanism 
• Modulating REST Expression Slightly Reduced Cell Proliferation and 
Increased the Accumulation of the Cell in G1 Phase 
• Modulation of REST Expression Significantly Reduced Cell Migration 
• HDACs Recruited in REST Repression Complexes are not the Primary 
Element for HDACis to Induce Their Action 
• Daoy Medulloblastoma REST4 Expression 
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 WNT Medulloblastoma Subtype Exhibits the Highest REST 
Expression  
Medulloblastoma is a cohort of heterogenous tumours which depends on specific cellular 
mechanisms to maintain its proliferation and tumorigenesis.  Based on the genetics 
profiling, four distinct subgroups of medulloblastoma have been identified and each 
subgroup characterized by a domination of a specific cellular mechanism 39.  Due to the 
high heterogeneity within each subgroup, twelve subtypes have been recently 
characterized based on the methylation and expression signatures 41.  In this study, I aimed 
to identify the subgroup and subtype that exhibit the highest expression of REST, which 
possibly helps in identifying the most possible pathway that mediates REST upregulation.   
The findings of this study revealed the high expression of REST in medulloblastoma 
tumour compared to the normal brain tissue.  Also, it showed that the medulloblastoma 
tumours enriched with WNT and SHH pathways displayed the highest expression of 
REST.  The highest expression of REST was in the WNT β and WNT α subtypes  whereas, 
the SHH subtypes showed variation in REST expression between moderate in the SHH β 
and SHH α subtypes to low in SHH γ and δ.  The lowest expression of REST was identified 
in Group 4α and β.  Moreover, the expression of some of the RE1-containing genes was 
inversely correlated with the level of REST expression however, not all RE1-containing 
genes were equally repressed.  
High expression of REST has been reported in most brain tumours including glioblastoma 
and medulloblastoma 4, 13, 14.  However, the molecular mechanisms that control and 
maintain REST expression in cancers has not yet been known.  In this study, the observed 
association of high REST expression with WNT and SHH pathways may reveal part of the 
regulations that maintain high REST expression.  As REST is elevated in WNT and SHH, 
I will focus on these two mechanisms in attempt to identify the mechanism that enhances 
REST expression. 
The WNT pathway is a signalling cascade, consists of a family of nineteen secreted 
glycoproteins that play a major role in regulating cell proliferation, migration, survival, 
and the self-renewal in stem cells 172.  Any perturbation in the WNT pathway level during 
neuronal stem cell proliferation can result in embryonic defect and may affect defining 
midbrain/hindbrain boundary, from which the cerebellum is developed 172.  
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Overexpression of the WNT genes, in particular WNT1 and WNT3, causes acceleration in 
neural progenitor growth.  WNT medulloblastoma subgroup was proposed to arise from a 
group of embryonic stem cells located below the cerebellum.  The majority of this 
subgroup tumours have been found to harbour CTNNB1, TP53, and DDX3X mutations, 
and loss of chromosome 6 39.   
One of the WNT pathway functions is to stabilize β-catenin (CTNNB1) protein and 
activate CTNNB1-dependent transcription 172.  β-catenin is transcriptional coactivator and 
central component of the WNT pathway and its expression is elevated during neuronal 
differentiation.  The expression of WNT stabilizes β-catenin, also it assists in translocating 
β-catenin/TCF complex into the nucleus where it activates the transcription of its target 
genes.  In medulloblastoma and several of other cancers, the regulation of β-catenin 
expression fails when CTNNB1 gene contains mutations that prevents proteasomal 
degradation of β-catenin 173.  In addition, APC (adenomatous polyposis coli, a human 
tumour suppressor factor) which downregulates β-catenin, has been frequently found 
mutated in cancers 172.   
Two proposed mechanisms have been reported for the β-catenin/TCF complex which 
contribution in cancer.  The first, the β-catenin/TCF complex has been found to activate 
Cyclin D1 (CCND1), which requires for neuronal stem cells progression through G1 phase 
to S phase 173.  The second mechanism is that the Exon1a of REST contains a DNA 
conserved sequence that works as a putative binding site for β-catenin/TCF.  Binding of   
the β-catenin/TCF complex to this site enhances REST transcription 174.  Therefore, it 
could be concluded that the high REST expression in the WNT pathway could be due to 
the activation of REST transcription by β-catenin/TCF complex dependent mechanism and 
this warrant further investigation.    
In contrast, the mechanism that upregulate REST expression in SHH is not fully identified.  
The SHH pathway plays a fundamental role in the carcinogenesis of the SHH enriched 
medulloblastoma subgroup.  It consists of several Hedgehog (Hh) proteins that regulate 
embryonic cell proliferation and differentiation, and they orchestrate the development of 
the granular neuronal precursors in the cerebellum.  During normal embryogenesis, Hh 
expression is upregulated, and when the cells reach their early postnatal stage the Hh 
expression is downregulated 175.  However, in some tumours the expression of SHH 
enhances the stem cell self-renewal in the presence of other tumour pathways, which has 
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been suggested to give rise to medulloblastoma 175.  One of the common features of the 
SHH medulloblastoma is the PTCH1 gene mutation in additional to several of other 
mutations in Smo, SuFu, Gli and N-myc.  PTCH1 gene encodes a transmembrane protein 
(PTCH1) that works as a receptor for the SHH pathway.  Binding of an activated Hh protein 
to PTCH1 results in releasing a proliferation cell signal protein, known as smoothened 
(Smo).  Hence, mutated PTCH1 protein cannot block Smo proliferation signal leading to 
activation of Gli1 (glioma-associated oncogene) and Gli2 transcription factors and 
increases the expression of cell proliferation genes such as cyclin D, cyclin E, and MYCN 
(a proto-oncogene protein) 176.  The interplay between SHH and REST is unclear however, 
many of the Gli1/2 target genes overlap with the β-catenin target genes, which may lead to 
elevate REST expression.  Recently, it has been proposed that WNT/β-catenin and SHH 
may collectively regulate the expression of mSin3 REST corepressor 177.   
The expression of REST in Group3 and 4 was relatively lower than the WNT and the SHH 
subgroups, conversely, the expression of some RE1-containing genes was moderately 
higher than the WNT and the SHH subgroups.  Several pathways have been reported in 
Group3 tumours such as photoreceptor, protein translation, and telomere maintenance 
pathways 44.  Whereas, Group 4 has been reported to be enriched for MAP Kinase (a signal-
regulated kinases), fibroblast growth factor receptor 1, and cell migration pathways 41.  
However, it is not completely known what factors maintains the proliferation of Group 3 
and 4.   
 REST Repression of the RE1-containing Genes is not Equivalent 
between the Subtypes  
REST is a transcriptional repressor recruits several chromatin and histone modifiers at the 
RE1 sites, leading to chromatin condensation and transcriptional repression.  Elevated 
REST expression is predicted to cause an extensive repression of the RE1-containing 
genes.  However, the expression analysis of the used microarray data showed that REST 
repression of RE1-containing genes was not even across the selected genes.  For example, 
despite the elevated REST expression in the SHH subtypes yet, some subtypes such as 
SHH γ showed wide variations in the RE1-containing genes expression between the 
subtypes and among the RE1-containing genes as well.  These variations could be referred 
to the heterogeneity of REST repression function.  It has been reported that more than half 
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of REST binding sites showed low recruitment of REST corepressors which results in 
insufficient transcriptional repression 178.  While, some RE1 sites showed more efficient 
binding and contain varying number of corepressors 178.  Also, it has been proposed that 
some of the RE1 genes, which have a postsynaptic role in synaptic plasticity such as 
GluR2, are highly depending on the SHH regulation rather than the repression of REST 
179, 180.  This may suggest that the regulation of the RE1-containing genes is not limited to 
REST repression machinery and possibly there are several of other pathways that have 
more superior control on their expression.   
 Medulloblastoma Daoy Cell Showed High Sensitivity to HDACis 
Many tumours showed high sensitivity to HDACis however, the sensitivity is often 
different from one inhibitor to another and between the different types of the same cancer.  
The results of this study demonstrated the ability of the HDACis to induce a progressive 
reduction in the Daoy cell number in a time-dependent manner though, the anticancer 
activity was slightly different between the drugs.  In this research, I used at least a drug 
from each chemical group of the HDACis.  Some of these drugs are pan-inhibitors and the 
other are more selective.  All the sensitivity analyses were performed within 72 hours as it 
has been reported that continuous treatment with HDACis for more than 72 hours could 
lead to a dramatic effect on cells viability due to the cytotoxicity rather than the acetylation 
status 91.   
The most noticeable difference between the inhibitors was the exposure time needed for 
an inhibitor to induce its anticancer effect.  Based on the time-course analysis, MI-192 
showed a significant cell death after 12 hours from the treatment.  SAHA, Apicidin and 
VPA showed a significant anticancer effect after 24 hours from the treatment.  Whereas, 
MS-275 showed some delay in its anticancer activity.  
 MI-192 Induced a Significant Cell Death within 12 Hours from the 
Treatment 
MI-192 is a member of benzamide class of HDACis with a high selectivity to HDAC3 and 
HDAC2 and it showed more than 60% higher selectivity to HDAC3 than MS-275 95.  In 
this study, MI-192 showed a rapid, progressive, and significant cell death which started 
after 12 hours from the treatment.  MI-192 is one of the promising anticancer drugs 
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regrettably, no pharmacokinetic data were reported on this unique compound and its 
anticancer regulation is not well addressed 95.  A single study that was performed on 
cholangiocarcinoma (bile duct cancer) cell line reported that MI-192 significantly inhibited 
the activity of HDAC3, also it caused an elevation in the p53 expression which could 
promote apoptosis through the expression of BAX gene 147.   
HDAC3 has been found to take part in regulating the cell proliferation in a large number 
of cancers and its elevated expression been correlated with poor overall survival in breast, 
colon, lung, cervical, prostate and several of other cancers 96.   In medulloblastoma, the 
expression of HDAC3 has been reported to show a relatively similar level between normal 
cerebellum and the four medulloblastoma subgroups 54.  The elevated expression of 
HDAC3 has been reported to enhance the stability of β-catenin (a downstream element in 
WNT signalling pathway) which could maintain the growth of cancer stem cell in several 
tumours 96.  Knocking down the HDAC3 expression has been found to suppress the 
expression of the PI3K/Akt-mediated signalling pathways (promotes survival and growth 
in response to extracellular signals) and increase the caspases activity through  
downregulating the anti-apoptotic genes and upregulating the pro-apoptotic genes 181.  In 
clinical trials, selective inhibition of HDAC3 in solid tumours was more effective and 
helped in reducing the toxicity produced by inhibiting several HDAC enzymes 80.   
HDACis containing benzamide moiety such as MI-192 have been found to possess higher 
affinity to HDAC3 than other compounds 96.  The advantages of MI-192 in inducing a 
rapid and progressive cell death over the other used inhibitors may suggest the importance 
of using selective inhibitors in cancer therapy.  Also, suggest the significance of exploring 
the pharmacokinetic of this inhibitor, which require further investigation.      
 Apicidin Induced a Progressive Cell Death 
Apicidin is a selective inhibitor with a higher affinity to HDAC3 and HDAC2 93.  The 
finding of this study showed that treating with Apicidin for 24-hours resulted in reducing 
the cell viability by around 20%, and it induced a progressive anticancer activity which 
reached to more than 50% at the 36-hours measurement.  
The anti-proliferative activity of Apicidin has been reported in many cancers.   In cervical 
and ovarian cancer cells, Apicidin has been reported to induce HeLa and SK-OV-3 
(cervical and ovarian cancer cell line, respectively) cells death through altering the 
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expression of p21WAF1, cyclin A and E-cadherin 182, 183.  It also showed an apoptotic activity 
in the human promyelocytic leukaemia cell line (HL60) through activation of the 
mitochondria-dependent caspase pathway 150.  In this study, the concentration used to treat 
the cell was the same between Apicidin and MI-192 (3 µM), both inhibitors show 
progressive cell death however, the difference was in the high kinetic binding of the MI-
192.  Though, Apicidin has higher inhibition for HDAC3 and HDAC2 than MI-192 184.  
Collectively, the dynamic anticancer activity of MI-192 and Apicidin and their selectivity 
to HDAC3 may suggest HDAC3 as a potential therapeutic target in this tumour.  
 MS-275 Showed a Delay in Inducing Cell Death  
MS-275 is a selective inhibitor and it showed a high selectivity to HDAC1 and to lesser 
extent, HDAC2 and HDAC3 55.  Compared to the other inhibitors MS-275 showed a delay 
in its anticancer activity as it did not induce any significant reduction in the cell number 
after 24-hours from treatment.  Though, at 36-hours it showed rapid and progressive cell 
death by more than 30%.  This delay in stimulating the cell death has been referred to the 
slow binding and dissociation kinetic of MS-275 91.  The chemical structure of MS-275 
contains a lipophilic aromatic ring which necessitates the disruption of most hydrogen 
bonds that connect a HDAC protein structure in order to accommodate this inhibitor, and 
when it binds it showed a long residence time 91.  However, the observed progressive cell 
death after the 36-hours may suggest that MS-275 has induced its action through 
stimulating specific cellular pathway that induced the rapid cell death.   
The efficiency of MS-275 to block medulloblastoma cells growth has been reported in the 
in vitro and the in vivo analysis hence, it becomes one of the current potential treatment for 
medulloblastoma tumour 81.  In previous studies, the effect of MS-275 was evaluated on 
several paediatric solid tumours and has been found to increase histone acetylation and 
p21WAF mRNA level however, it showed diverse effect on cell cycle.  For example, in some 
cells MS-275 led to increase the accumulation in the G1 and the G2 cell cycle as it is the 
case with the Daoy cells whereas, in some other cell lines it stimulated apoptosis 81.  It is 
not completely known how MS-275 stimulate apoptosis however, the upregulation in the 
death receptor (Fas) expression has been suggested as a possible factor 185.  
Fas is a cell membrane surface receptor that stimulates apoptosis when binds to a 
transmembrane protein known as Fas ligand (FasL) and activates apoptosis through 
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caspase-8 activation.  Downregulation of Fas receptor expression by HDAC1 and HDAC3 
has been reported in several cancers 185.  Similarly, the low expression of CASP-8 has also 
been reported in more than 70% of medulloblastoma tumour samples, and it has been 
associated with unfavourable survival outcome in childhood medulloblastoma 186.  
Furthermore, the expression of cellular FLICE-inhibitory protein (c-FLIP) Fas inhibitor 
protein is upregulated in most cancers 185.  All of these factors could lead to increase the 
resistance of cancer cells to death-receptor mediated apoptosis pathway 187.  Nevertheless, 
treatment with MS-275 disrupts the former cancer strategies by selectively inhibiting 
HDAC1 and HDAC3 leading to increase the expression of Fas receptor on cell surface and 
upregulate the expression of CASP-8 gene 186.  Also, MS-275 downregulates the 
expression of c-FLIP which results in redistributing the Fas receptors on cell surface and 
sensitizing the cells to FasL 185.  These changes, in turn, elevate Caspase-8 activity, 
stimulate Bax release, and initiate apoptosis downstream signalling pathway 34, 81.   
Another possible explanation of the high sensitivity of medulloblastoma cell to MS-275 is 
through increasing the acetylation of H3 and H4 at the DR4 (also known as TRAIL receptor 
1 (TRAILR1)) promoter which results in increasing the expression of the DR4 receptor 
and stimulating apoptosis.  Interestingly, in many medulloblastoma tissue samples and in 
the Daoy cell-line the expression of DR4 has been reported to be consistently 
downregulated compared to normal cerebellum 34.  Collectively, this may explain the high 
sensitivity of the Daoy cells to MS-275. 
The high sensitivity of the Daoy cells to MS-275 does not necessarily suggest the 
sensitivity of other medulloblastoma cell lines to this drug.  In a previous study, the D283 
medulloblastoma cell line was included in the analysis and it showed a minor sensitivity 
to this drug 34.  This may suggest the contribution of the tumour cell regulation in defining 
the sensitivity to the HDACis treatment.  Also, it is not well known why the 
medulloblastoma cells exhibit different sensitivity to the HDACis in general and to MS-
275 in particular.  However, the low sensitivity of some cancer cells to MS-275 has been 
referred to the overexpression of an endoplasmic reticulum (ER) stress regulator, known 
as glucose-regulated protein 78 (GRP78).  GRP78 is an antiapoptotic factor with ability to 
chaperon newly-synthesized proteins across the ER membrane 188.  Downregulation of 
GPR78 expression by HDAC1 has been reported in many cancers.  It has been suggested 
that MS-275 inhibiting of HDAC1 may result in increasing the expression of GPR78 which 
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relieves the ER stress and blocks apoptosis.  As a result, this mechanism could be a 
potential machinery for HDACis resistance 189.   
 SAHA Did not Completely Eradicate the Daoy Cells 
SAHA at 5 µM has induced a significant anticancer effect at the 24-hours of treatment 
which increased to more than 50% at the 48-hours measurement.  However, SAHA did not 
completely eradicate the Daoy cells at the 72-hours even with 10 µM concentration, which 
was used to establish the dose response curve.   
SAHA is class I and class IIb pan-inhibitor with a high kinetic binding which can be 
observed by its relatively rapid induction of cell death.  A prior study has shown more than 
50% cell death when a similar concentration of SAHA was used to treat the D283 and the 
D341 medulloblastoma cell lines 190.  The ability of SAHA to induce cells death among 
different medulloblastoma cell lines could be due to the efficiency of SAHA to inhibit a 
wider range of HDACs.  Also, the antiproliferation effect of SAHA has been related to the 
post-transcriptional effect of SAHA on decreasing the REST protein level, which it could 
be through the proteasomal beta subunit (protein degradation) 14. 
SAHA has been found to activate both the extrinsic and the intrinsic apoptotic pathways.  
Activation of the extrinsic pathway was suggested to be through increasing the expression 
of Fas receptor on cell surface, which results in sensitizing the cell to FasL and initiating 
caspases downstream apoptosis pathway.  Whereas, the activation of the intrinsic pathway 
is initiated by cleaving some of the anti-apoptotic factors such as Bcl-2, IKKα, IKKβ, IKKγ 
and NFκB proteins, which increase the acetylation of H3 and H4.   
Consequently, this results in upregulating the expression of p21WAF1, releasing the 
cytochrome c, and ultimately inducing the cell death mechanisms 82, 191.  Also, SAHA is 
believed to increase the intracellular level of ROS which causes an excessive oxidative 
stress and stimulates the cellular death regulations 192.   
It is not completely well known why SAHA does not stimulate complete cell death 
however, it has been proposed that treatment with SAHA leads to increase the expression 
of the caspase inhibitors which pauses the death receptor apoptotic pathway and 
interrupting the SAHA-induced apoptosis.  However, this suggestion has been found to be 
a tumour cell-type dependent 82.  Also, it has been reported that treating cell lines with an 
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increasing concentration of SAHA yield to a non-reversible resistant in a subset of cells 
independent of the increase in HDAC1 or HDAC3.  Though, it is also tumour cell-type 
dependent 193.  Most SAHA-resistant cancer cells have been reported to highly express 
proliferation proteins such as cyclin A, surviving, ki-67, p21WAF1, and p53 which may 
hinder the anti-tumour effect of SAHA 194.  Collectively, this may explain why SAHA does 
not stimulate complete cell death. 
 The Daoy Cells Showed Concentration-Dependent Sensitivity to VPA 
VPA is a pan HDAC inhibitor that showed an inhibitory effect on class I and class IIα 
HDAC.  In this study, VPA showed a significant anticancer effect after 24-hours from the 
treatment.  Also, it showed a concentration-dependent effect.  At low concentrations, the 
cell continued to grow and did not show any significant cell death.  Yet, with the high 
concentrations, it induced a sharp decreased in cell growth by approximately 50% and the 
cells death became more noticeable.   It is not completely understood how VPA induces 
cellular death however, the increase in caspase 3 has been reported in some cell lines after 
72-hours from the treatment.  However, the cleavage of caspase 8 and caspase 9 was not 
detected in the analysed cell lines 195.  This may suggest that the VPA-induced apoptosis 
could be partially through a caspase-dependent pathway though, the activation of the 
caspases might not be through the classic apoptotic pathway 195.   
VPA has been reported to inhibit the growth of the tumour cell through increasing the 
acetylation of H3 and H4, decreasing the expression of GSK3β (neuronal cell development 
factor), and suppressing TP53, CDK4, and c-Myc which are important for the cell cycle 
progression.  Also, VPA has been found to increase the expression of p21WAF1 pathway, 
and activates β-catenin, which works as a blocker for cell division 196.  Likewise, it has 
been proposed that VPA induce degradation of RET-kinase (a proto-oncogene signalling 
molecules) resulting in inhibition of the RET downstream signalling pathway and 
interrupting the proliferation of cancer cells 197.    
It has been observed that VPA can induce a rapid histone acetylation in cell culture though, 
the process that regulate the chromatin condensation may require more than 48 hours to be 
completed 198.  Also, it has been claimed that treating with VPA often causes unexpected 
increase in REST gene expression, which could be due to the increase in the histone 
acetylation and the chromatin remodelling at REST promoter 14.  In this context, treating 
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cancer cells with low concentration of VPA may not inhibit the tumour cells growth due 
to the increase in REST expression which been proposed to drive cells proliferation 14.  
Therefore, it has been suggested that a higher concentration or a longer VPA exposure is 
needed to inhibit the tumour cell growth 14.  In normal cells, it has been reported that the 
effect of the VPA-induced apoptosis is mitigated by increasing the phosphorylation of 
extracellular signal–regulated kinases (ERK1/2), a regulator of cell cycle and 
angiogenesis) which could lead to increase the expression of BCL-2 antiapoptotic protein 
and inhibit the release of cytochrome c from mitochondria 199.   
Taken together, not all the medulloblastoma cells are highly sensitive to HDACis 
treatment, which may further prove the involvement of different molecular regulations in 
sustaining the tumour growth.  Hence, the efficiency of a specific HDAC inhibitor is 
largely depending on identifying these molecular markers and employing them to evaluate 
the efficiency of the treatment.  Also, it is observed that some HDACis that show a high 
selectivity for HDACs were more efficient in inducing cell death than the pan-HDACis.  
This could be due to the ability of the selective inhibitors to target the molecular regulations 
that specifically initiate the cellular death mechanisms.  Whereas, the pan-inhibitors may 
drive the re-expression of the apoptosis initiating and inhibiting genes, which diminishes 
their anti-cancer effect.  Moreover, it has been reported that the high selectivity of a HDAC 
inhibitor is considerably important to reduce the inhibition of inappropriate HDACs and to 
induce more anticancer action 91.      
Also, it has been reported that the activation or the repression of some genes are largely 
depending on the kinetic binding of HDACis.  Therefore, HDACis with low binding 
kinetics such as MS-275 may induce longer effect on genes that control cell proliferation 
and apoptosis compare to the HDAC inhibitor with fast dissociation kinetics such as 
SAHA.  This may suggest that the effect of HDACis on the cell viability may depend on 
the inhibitor-selectivity and the exposure length 91.   
 HDACis Induced a Prolonged Cell Cycle Delay and not a Complete 
Arrest 
Active progression in cell cycle is one of the cancer hallmarks and it is mediated by 
families of regulatory proteins including cyclin-dependent kinases (CDK), p21WAF1, 
p27KIP1, and p57KIP2, CDK inhibitors as well as other regulatory mechanisms known as 
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checkpoints proteins 200.  The HDAC enzymes are known to deacetylate a wide range of 
histone and non-histone proteins including those control the cell cycle.  In several studies, 
HDACis have been claimed to cause cell cycle arrest at G2 phase 151, 152, 153, 154.  In 
contrast, the research work that used the time-course analysis approach reported the 
ability of HDACis to delay the transition between the cell cycle phases and they do not 
induce cell cycle arrest 201, 202, 203.   
In this study, the effect of HDACis on the Daoy cell cycle was investigated using a time-
course analysis.  This approach helped in showing the dynamic and duration of each phase 
and aided in revealing if HDACis arrest the cell cycle.  The results of this study showed 
a wide variation between the inhibitors in their effect on the cell cycle progression. 
Though, the general theme was that the transition between the phases was less active in 
the HDACis treated cells compared to the untreated cell with transient cell accumulation 
between the phases.  Also, these was no significant similarity between the pan-inhibitors 
(SAHA & VPA) and between the selective-inhibitors (MS-275, MI-192 and Apicidin) 
though, SAHA and Apicidin showed relatively similar cell cycle accumulation.  This 
may suggest that each inhibitor may induce different molecular regulations that affect the 
cell transition in cell cycle.  
In most cancers, deacetylation of cell cycle genes is one of the factors in tumour cell 
proliferation.  The role of HDAC enzymes in this regulation is mainly involved in 
regulating the expression of some CDK and CDK inhibitors.  For example, HDAC1 and 
HDAC2 have been found to deacetylate p21WAF1, p27KIP1, and p57KIP2 genes promoters 
and negatively regulate their expression 200.  In variety of tumour cell lines loss of HDAC1 
and HDAC2 resulted in interrupting the cell proliferation potential and drives cell death 
in medulloblastoma, glioblastoma, and colon cancer 71, 204, 205.  HDAC3 is also important 
factor for the cyclin A stability which has a crucial role in S phase progression.  It has 
been suggested that during mitosis the HDAC3 complexes deacetylate histone 3 and 
condensate the chromatin through A-kinase anchor proteins (AKAP8 & AKAP8L).  
This may serve as an indicator for mitotic checkpoint to regulate proper cell division 206.  
Knocking down HDAC3 in HeLa cell reported to increase the accumulation in S and 
G2 phases 207.  HDAC10 is also regulates cell cycle progression via cyclin A and 
knocking down HDAC10 in non-small cell lung cancer resulted in cell accumulation in 
G2 phase 200.  
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Comparing the findings of the cell cycle to the cell proliferation results of this study 
showed some correlation between the results.  For example, MI-192 showed the fastest 
cell death and it also showed a significant decline in G1 phase and increase in S and G2 
phases at the 6-hours measurement.  Likewise, MS-275, which showed the slowest 
anticancer effect (36 hours), its effect on cell cycle was after 24 hours.  SAHA, Apicidin 
and VPA also showed a synchronous effect on the cell cycle and cell viability.  This 
correlation may suggest that the effect of HDACis is started by interrupting the cell 
cycle proliferation genes and simultaneously activating the cell death mechanism.    
Taken together, the results suggest that the cell death induced by HDACis is not due to 
arresting the cell division at specific cell cycle phase, and it could be due to the initiation 
of cell death mechanism.   
In this study, the cell cycle flow cytometry analysis can be improved by synchronizing 
the cell population using an agent such as vinblastine or colcemide or by serum 
starvation.  These agents have the ability to arrest the cell cycle progression at a specific 
phase.  This method could ensure that the cells begin cycling from the same phase which 
may help in improving the results of the time-course analysis 157.  However, the 
synchronization may interfere with normal cycling, growth of cells, gene expression, 
and can result in significant cell death.   
Additionally, the cell cycle effects of HDACis and REST can be further investigated using 
bromodeoxyuridine (BrdU).  BrdU staining of DNA takes advantage of the incorporation 
of BrdU into newly synthesized DNA during the S phase.  When the cells divide the 
fluorescence intensity of the BrdU is halved as a result of the decrease in the amount of 
BrdU per cell.  The reappearance of the BrdU fluorescence signal in S-phase is an 
indicative of a complete cell cycle and the time taken can be used to estimate the cell 
cycle kinetics 208.  The advantage of this method is that it allows to determine the 
duration of a cell cycle phase without the need to induce potentially toxic 
synchronization agents 208.   
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 Blocking REST Expression in Medulloblastoma did not Stimulate 
Apoptosis Mechanism 
In some studies, REST has been described as an oncogene in particular, in 
medulloblastoma and glioblastoma 4, 9, 11, 12, 13.  The claim behind the oncogenic property 
of REST originated from the ability of REST to repress the expression of neuronal 
differentiation genes which blocks the cell differentiation and maintains the self-renewal 
potential of cancer cells.  Therefore, modulating REST expression has been proposed as 
potential approach to treat cancer 4, 9, 11, 12, 13.  This conclusion was built based on using the 
knockdown tools to reduce REST expression in xenograft animal models.  Though, the 
partial expression of REST in the knockdown approaches may maintain some repression 
in different sets of neuronal genes which could affect the results interpretation.   
In this study, the knockout approach was used to study the effect of REST modulation on 
the Daoy medulloblastoma cells.  To the best of my knowledge, this is the first study that 
used CRISPR/Cas9 to knockout REST expression in a medulloblastoma cell line.  In 
addition, this study used the shRNA knockdown approach to approve the knockout results.  
However, the effect of REST modification was not limited to REST expression, and the 
impact was extended to a myriad number of REST-regulated genes.  Comparing the REST-
negative cells to the wildtype cell showed an increase in the expression of some RE1-
containing genes by more than 5-fold change however, it did not result in differentiating 
the tumour stem cell or interrupting the oncogenic regulation.  Noteworthy, the number of 
REST regulated genes has been estimated to exceed 2000 genes 3.  Despite these enormous 
changes though, the cells maintained their proliferative potential and did not show any 
morphological changes or cell death.  In a similar context, the absence of REST expression 
in embryonic stem (ES) cells has been reported to cause inappropriate upregulation of a 
cohort of genes that are important for neuronal cell differentiation and function 9.  Despite, 
the expression of brain-specific genes including Secretogranin III (SCG3), Complexin 1 
(Cplx1) and Stathmin 3 (Stmn3) however, it did not lead to the differentiation of the ES 
cells or affect their multipotent potential 9. 
Collectively, these findings may demonstrate the low importance of REST in regulating 
tumour cell proliferation and differentiation and could suggest the existence of other 
oncogenic regulations that maintain the self-renewal potential of the tumour cell.  Also, 
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the results may suggest the lack of the tumour cell the primary components that are required 
for employing the differentiation factors.  In addition, it may demonstrate the ability of the 
tumour regulation to avoid the progression in the maturation stages. 
 Modulating REST Expression Slightly Reduced Cell Proliferation and 
Increased the Accumulation of the Cells in G1 Phase  
Cancers, in general, sustain their growth through mutations that affect one or several cells 
pathways and the growth continues unless a main factor in proliferation pathway was 
targeted.  In this study, blocking REST expression resulted in reducing the growth of REST 
negative cells by approximately 20%, it also caused a slight accumulation in G1 cell cycle 
phase concomitant with a decrease in S phase.   
These findings are in agreement with a previous study that used shRNA to knockdown 
REST expression in the Daoy cells 52.  In the study, they found that loss of REST resulted 
in increasing the accumulation in G1 phase with a concomitant decrease in the S phase 
however, it did not lead to cellular apoptosis.  Also, they reported that loss of REST led to 
a decrease in the expression of MYCN (a proliferative marker) and an increase in the 
expression of certain antiproliferation makers such as p27 and UPS37 52.  This could 
suggest that REST may control the cellular proliferation through a p27-dependent 
mechanism 52. Similarly, several of gene expression analysis studies were performed using 
primary human medulloblastoma however, the elevated REST expression was not 
proposed as a factor in sustaining the cell growth 38, 39, 44, 41.   
In contrast, a number of other studies, have claimed that knocking down REST expression 
resulted in reducing the tumour cell growth and stimulated apoptosis 11, 50, 115, 209.  For 
example, some studies used REST-VP16 vector to knockdown REST expression in 
medulloblastoma cell lines.  According to Lawinger et al. REST-VP16 is a transcriptional 
activator form of REST that has the ability to compete with REST and upregulate the 
expression of the RE1-containing genes 115.  Also, it was used in some studies to 
differentiate the NSC and the myoblast C2C12 cell into neuronal cells 210.  REST-VP16 
was constructed by replacing both repressor domains of REST with herpes simplex virus 
activation domain (VP16) 115.  Lawinger et al. study has claimed that modulating REST 
expression in the Daoy, D341 and D283 medulloblastoma cell lines using REST-VP16 
resulted in a massive cell death within 96 hours, however, the results of the in vitro 
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apoptosis were not presented in the publication 115.  It has also been reported that 
transfecting a subcutaneously injected Daoy cells with REST-VP16 resulted in inhibiting 
the tumour growth, and the direct injecting of REST-VP16 into subcutaneously Daoy-
formed tumours resulted in about 50% reduction in the tumour growth 115.   In 2005, Fuller 
et al. have reproduced the former experiment on an intracranial Daoy-induced tumour, and 
they claimed the ability of REST-VP16 in blocking the tumour growth and stimulating 
apoptosis however, the study did not mention if the cellular death was observed in the in 
vitro analysis 11.   
In contrast, in three separate studies the expression of REST was knocked down in different 
glioblastoma cell lines using the shRNA system.  The studies reported the effect of REST 
knockdown in reducing the tumour cell proliferation rate and migration ability 4, 12, 13.  
Despite the similarity between the used cell lines, in particular, between Kamal et al. and 
Zhang et al. studies however, the apoptosis was only reported in the Kamal et al. and the 
Conti et al. studies 4, 13. The Zhang et al. study concluded that the apoptosis was not 
stimulated by REST knockdown 12.  It is not clear why the knockdown of REST in the 
former studies led to different outcomes.  However, the variation between the studies could 
be due the limitation in the techniques that were used to detect the cellular apoptosis.  For 
example, the TUNEL assay requires careful analysis of the stained cells, as the duration of 
the proteinase K in the pre-treatment step may generate false-negative or false-positive 
results due to the enzymatic under-digestion or over-digestion, respectively.  The published 
images of the TUNEL assay in Kamal et al. 2012 study did not clearly show the apoptotic 
cells and some of the green signals in the images may not related to apoptotic cells 
(Appendix 9).  In contrast, the FACS analysis in the Zhang et al. study did not identify any 
significant apoptosis events both at early and late stages of cells growth 12. 
Taken together, REST is not a primary factor for the Daoy cell growth and the cell may 
sustain its growth through other cellular mechanisms.  Blocking REST expression in this 
cell led to increase the expression of the neuronal genes and slight decline the cell growth 
however, it did not result in inducing the differentiation or cause cell death.   
 Modulation of REST Expression Significantly Reduced Cell Migration 
Migration is a critical factor in early progression of the tumour cell to metastasis, and it 
has been linked, in part, to elevated REST expression 211.  All medulloblastoma subgroups 
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have been reported to disseminate along the cerebrospinal fluid pathway with higher 
frequency in the Group 3 and 4 medulloblastomas 41.  To gain more insight into the 
implication of REST knockout on the Daoy cell migration, I used wound healing assay to 
evaluate if the absence of REST results in decrease the migration.   
The data showed that, knockout REST expression resulted in decreasing the migration 
ability of the Daoy cell.  This finding is further supported by a previous study that showed 
knocking down REST expression using shRNA led to inhibit glioblastoma cells migration 
12.  The migration inhibition has been referred to the upregulation of genes that are involved 
in migration and cytostasis (stopping cell growth) and some of these genes are regulated 
by REST such as BBC3 and DAXX 12.  This finding is in consistence with the concept of 
the neuronal stem cell development regulation.  During neurogenesis REST expression is 
upregulated in NSCs which may contribute in their migration.  Whereas, the mature 
neurons, which display low REST level, show very limited ability to migrate.   
 HDACs Recruited in REST Repression Complexes are not the Primary 
Element for HDACis to Induce Their Action  
Medulloblastoma has been classified into four main subgroups most of them showed 
elevated REST expression.  Interestingly, the tumours with elevated REST expression 
showed high sensitivity to HDACis.  In this study, we hypothesised that HDACis induce 
their effect through the REST repression complexes which recruits several of HDACs.  We 
found that disrupting REST activity alone did not affect the sensitivity of the cell to the 
HDACis.  This may indicate that these inhibitors do not mainly depend on the REST 
recruited HDACs and they possibly arrest cancer growth through other HDACs complexes 
and/or non-histone protein yet, this requires further investigation.  A previous study has 
suggested REST overexpression as a marker for HDACis treatment, although the findings 
of this study do not fully support this suggestion 14.   
HDACis are multitarget anticancer drugs, and they can act through acetylating histone and 
non-histone proteins.  In human cell, the acetylation sites are countless therefore, the 
cellular response to an inhibitor is very complex and most likely includes transcriptional 
and non-transcriptional regulations.   
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 Daoy Medulloblastoma REST4 Expression 
Comparing the expression of the RE1-containing genes between REST expressing and the 
REST modulated cells demonstrated the functional effect of REST on these genes.  The 
exact mechanism of REST upregulation in cancer is not yet known however, the extensive 
repression of neuronal genes may suggest the exclusive expression of REST full-length 
protein isoform in the absence of REST4 isoform.  REST4 is a transcriptional activator and 
it competes with REST full-length in binding to RE1 sites, resulting in upregulation of 
REST target genes in neuronal cells 7.  Remarkably, REST4 expression has been found 
upregulated in post-mitotic neurons and in non-neuronal cancers that express neuronal 
phenotype such as breast and small cell lung cancers 7, 18.  In contrast, in normal non-
neuronal cells the expression of REST4 has been reported to be downregulated as a result 
of downregulation of protein kinase A by CREB (cAMP response element-binding protein) 
pathway 30.  In this study, I proposed that the upregulation of REST expression in 
medulloblastoma could be due to the absence of REST4 expression in the Daoy cells.   
The result of PCR amplification of REST4 mRNA show the amplification product of 
REST4, which may propose that there is no direct association between the expression of 
REST and REST4.  This primary assumption is further supported by a recent glioma study 
which concluded that the expression of REST4 has no direct relation to REST expression 
and did not recommend the expression of REST4 as a prognostic biomarker due to its low 
expression 212.  Regulation of REST4 transcription is not entirely clear though, it has been 
suggested that the expression of REST4 in neuronal cells is directly promoted by a 
neuronal-specific splicing regulator, known as SRRM4 (Serine/Arginine Repetitive Matrix 
4, also known as nSR100), which activates the inclusion of the exon N 17.  Remarkably, 
SRRM4 gene has been reported to include an RE1 site in its promoter which may suggest 
the involvement of REST in regulating its expression 17.  Also, it has been reported that the 
expression of REST4 is increase when the expression of choline acetyltransferase (ChAT), 
and vesicular acetylcholine transporter (VAChT) genes is increased.  Both genes contain 
an RE1 site in their promoters and they are regulated by Protein kinase A, which increases 
the expression of REST4 isoform 169.  However, the regulation of REST4 expression is 
complicated and not completely clear and needs further investigation. 
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3.4 Conclusion 
The analysis revealed the elevated expression of REST in most the medulloblastoma 
subgroups and the highest expression of REST was identified in WNT subgroup.  Whereas, 
the Group 4α and β subtypes exhibited the lowest expression among all subtypes.  This 
study concluded that blocking REST expression in medulloblastoma Daoy cells has led to; 
increase the expression of some RE1-containing genes, increase the cells accumulation in 
G1 phase, slightly reduced the cell proliferation rate, and decrease cells migration ability.  
However, it did not stimulate apoptosis.  The results also showed the high sensitivity of 
the Daoy medulloblastoma cells to the used HDACis yet, the HDACs recruited in REST 
repression complexes are not the primary elements for the inhibitors to induce their action.   
This is the first study to undertake CRISPR/Cas9 knockout approach to study the 
contribution of REST in medulloblastoma cell growth.  This work has contributed in 
improving our understanding about REST involvement in cancer and it offers some 
important insights about REST contribution in cancer.  
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Chapter 4 
4 Results II 
4.1 Introduction  
This study aimed to investigate the anticancer mechanism of HDACis in the Daoy 
medulloblastoma cells and explore their effect on normal neurons. The analysis was 
performed at the transcriptome level using the single cell next generation sequencing 
(scNGS) as the gene expression is affected by the phase of the cell cycle in the Daoy cells 
and by the cell heterogeneity in the normal neurons.    
The objectives of this work  
❖ investigate the SAHA and MS-275 anticancer regulation in the Daoy 
medulloblastoma cells 
❖ identify the difference between SAHA (pan-HDACi) and MS-275 (selective 
inhibitor)  
❖ investigate the effect of SAHA and MS-275 on the normal human neurons   
The Roadmap  
In this analysis, the Daoy medulloblastoma cells and the normal human neurons were 
treated with SAHA and MS-275 at 5µM concentrations.  The untreated and treated cells 
were harvested into a single suspension and partitioned into nanolitre-scale reaction 
vesicles (GEMs) using the 10x Chromium 3” technology.  After reverse-transcribing the 
RNA, the cDNA libraries were sequenced and the scNGS data were used to study the gene 
expression differences between the untreated and the treated cells.  
In this study, I set off by establishing an appropriate HDACis treatment length to isolate 
the cells for the scNGS analysis.  I took into account the Daoy cell viability and cell cycle 
analysis results that were reported in the Results I .  I used the apoptosis Annexin V and PI 
assay to measure the proportion of the viable cells in each cell cycle phase.  I determined 
the treatment duration on the Daoy cells. As the neurons were postmitotic and limited in 
number, I used the Daoy treatment regime with them.  This chapter starts by showing the 
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results of the HDACis treatment length and then moves to present the scNGS analysis and 
findings. 
4.2 The Results 
 Assessing the Apoptosis Level in SAHA and MS-275 Treated Daoy 
Cells  
During apoptosis, cells pass through several stages of biochemical and gene expression 
changes which could result in externalization of the inward-facing phosphatidylserine (PS) 
on the surface of the cell 213.  The expression of PS is a hallmark during early and late 
stages of apoptosis and can be detected using Annexin V protein labelled with fluorescein 
isothiocyanate (FITC).  Annexin V is an anticoagulant protein with a high affinity to PS 
and has been used to study apoptosis 214.  Similarly, PI has been used to stain the DNA in 
late stages of apoptosis as the cell membrane permeability increases before cell death.  
Whereas, double staining with Annexin V-FITC and PI can be used to distinguish early 
apoptotic cells from late apoptotic cells using FACS analysis.  In early apoptotic cells, the 
externalization of the PS results in Annexin V-FITC (Annexin V+/PI-) binding which 
causes an increase in the ‘forward’ light scatter signal.  In late apoptosis, the PI passes the 
cell membrane and intercalates with DNA which results in increasing the PI ‘side’ scatter 
light signal (Annexin V+/PI+).  
To study the apoptotic effect of SAHA and MS-275, the Daoy cells were treated with 5µM 
of the drugs, harvested at 30, 36 and 42 hours from the treatment and analysed by FACS.  
The result of the untreated control (42 hours) showed that the majority of cells (87%) were 
viable with around 6% of cells being in the late stage of apoptosis as indicated by Annexin 
V and PI signals.  The treated cells showed a gradual reduction in the percentage of the 
viable cells associated with an increase in the ratio of the early and late apoptotic cells.  
The treatment for 30-hours resulted in reducing the percentage of the viable (Annexin V–
/PI–) cells to around 75% (Figure 33 A and B).  With the progression in the treatment, the 
percentage of the cells in late apoptosis stage (Annexin V+/PI+) showed a significant 
increase (P≤0.05) to ~25% and ~35% at the 36 and the 42-hours, respectively.   
Collectively, this analysis showed the presence of more than 65% viable cells at the time 
between the 36 and the 42-hours (Figure 33 A and B).   
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Figure 33: Evaluating the apoptosis level in SAHA and MS-275 treated cells  
The bar charts show the percentage of viable and apoptotic cells at 30, 36 and 42 hours of 
the Daoy SAHA (A) and MS-275 (B) treated cells (5µM concentration).  The cells were 
stained with Annexin V and PI and the results are the average of 4 biological replicates.  
The dots represent the values, the P-value was calculated using the two tailed Student's 
t-test (* P ≤ 0.05, ** P ≤ 0.01) by comparing the values of a time point to the untreated 
control, and the error bars are SEM.  The two-dimensional dots plots (C) are a 
representation of 30.000 events that were measured on FACS.  The viable cells are 
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(Annexin V-/PI-), early apoptotic cells are (Annexin V-/PI+), and late apoptotic cells are 
(Annexin V+/PI+).  
 Estimating the Treatment Length Based on the MTT and FACS 
Analysis   
The results of the cell viability reported in the Results I (section 0) showed that the 
minimum treatment time required for SAHA and MS-275 to reduce the cell viability is 
between the 24 to the 36 hours (Figure 34 A).  At this time frame the percentage of the 
viable cells was ~70%.  Similarly, the apoptosis analysis results showed the presence of 
more than 65% viable cells and around 30% dead cells at the treatment time between 
the 32 to 42 hours (Figure 34 C).  The results of the cell cycle analysis at this time frame 
(Results I section 3.2.2.4) suggested the presence of approximately 30% of the cells in G1, 
more than 15% in S, and around 40% in G2 phase in the cells treated with SAHA.  
Whereas, the MS-275 results showed the presence of more than 60% in G1 and around 
15% in each of S and G2 phases (Figure 34 B).    
Based on these results, the scNGS analysis was performed by treating the cells for the 
36 hours.  At this time point; there are more than 60% viable cells, there are enough cells 
to present each phase of cell cycle, and the anticancer effect of HDACis was observed in 
the apoptosis analysis (Figure 34).   
 
Chapter 4                                                Results II 
136 
 
 
Figure 34: Estimating the scNGS treatment duration length using the MTT and 
FACS results 
The pie charts present a summary of the MTT assay, the cell cycle, and the apoptosis 
results of the Daoy SAHA- and MS-275-treated cells (5 M).  The MTT assay (A) shows 
the percentage of viable vs. dead cell at the 24, 36 and 48 time points.  The cell cycle charts 
(B) (PI flowcytometry analysis) show the cells distribution in the cell cycle phases at 24 
and 48 hours.  The apoptosis (C) (Annexin V/PI flowcytometry) charts display the 
percentage of viable to early and late apoptotic cells at 36 hours.  
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 The scNGS Samples Preparation  
The scNGS analysis was performed by treating passage (1) Daoy cells and human neurons 
with SAHA and MS-275 for 36 hours.  In this study, six treatment conditions were analysed 
using the 10x Chromium single cell kit and the RNA libraries were sequenced on Illumina 
500 (Table 5).   
Table 5: Single cell samples identification Acronym 
Sample Number Condition Hereinafter referred to as 
1 Daoy Untreated D.Vehicle 
2 Daoy - SAHA D.SAHA 
3 Daoy -MS-275 D.MS-275 
4 Neurons Untreated N.Vehicle 
5 Neurons-SAHA N.SAHA 
6 Neurons-MS-275 N.MS-275 
 
As standard practice, all the cells were examined microscopically before and after the 36-
hours of the treatment.  The microscopic examination after the 36-hours showed a minor 
fraction of floating cells in the untreated Daoy and neurons cultures (estimated to be <3% 
of the total cell count).  Whereas, the treated Daoy cells showed a noticeable increase in 
the detached cells which estimated to be between 10% to 15%.  The neuron culture showed 
many small floated spherical cells compared to the untreated neurons yet, they can only be 
seen under microscope (Figure 35). 
At the time of the 10x Chromium preparation, the cells were stained with DAPI and the 
viable cells were collected by a FACS sorter after gating for the debris, dead, and doublet 
cells (Appendix 10).  This approach yielded approximately 5000 cells per each Daoy 
sample.  The counts of the sorted neurons were 2000 cells for the untreated, 5000 cells for 
SAHA, and 1200 cells for the MS-275 treated neurons.  The cells were then loaded into a 
10x chip and sequenced on an Illumina 500 platform.  See (Figure 36) for more information 
about the scNGS workflow.   
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Figure 35: Microscopic images for SAHA and MS-275 (-/+) Daoy and neurons at 36 
hours  
The Daoy cells and the normal human neurons were treated with 5µM concentration of 
SAHA and MS-275 for 36 hours.  The images were taken after 36-hours using inverted 
microscope.   
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Figure 36: Schematic representation of the scNGS analysis workflow 
The scNGS analyses were carried out by treating the cells with SAHA and MS-275 for 36 
hours.  After harvesting the cells, they were sorted on a FACS sorter (A).  The cells were 
loaded into a 10x Chromium chip to generate GEMs (Gel Bead in Emulsions) and the RNA 
was reverse-transcribed, amplified, and used to generate the cDNA libraries (B).  The 
libraries were sequenced on an Illumina 500, and the data were demultiplexed using the 
CellRanger pipelines.  Next, the data were analysed using the Seurat R package (C).  The 
data were passed through several stages of data filtration, normalization, and scaling, and 
the quality improved data were used in the subsequent analysis. (STAMPs is single-cell 
transcriptomes attached to microparticles).  The caption was adapted from (Macosko et 
al., 2015) 215. 
 scNGS data Demultiplexing 
The generated 10x scNGS data (Illumina raw base call (bcl) files format) were 
demultiplexed to FASTq (text files containing sequence data with a quality score for each 
base) files format using the 10x CellRanger mkfastq pipeline.  The CellRanger pipelines 
were used to demultiplex the Chromium scNGS data, align the reads to the reference 
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genome, generate barcode matrices, identify the gene count, and perform gene expression 
analysis.  Upon the data demultiplexing, several single-cell specific quality control 
measures were examined including the number of the targeted cells, the mean sequencing 
reads per cell, the mean genes per cells, the sequencing depth, and the Q30 of the bases.   
The output of this analysis showed that the number of the analysed Daoy cells was greater 
than 1700 in the D.Vehicle and in D.SAHA samples, and it reached to more than 2700 
cells with the D.MS-275 cells.  Whereas, the count of the untreated and treated neurons 
was between 1100 to 1300 cells (Figure 37 A).  The low count of the neurons is possibly 
due to the inaccurate counting of the neurons which resulted in loading fewer cells into the 
10x chip.  
With the sequencing depth, the recommended depth for the 10x scNGS analysis is > 95% 
saturation.  Yet, despite the several attempts of resequencing to a higher depth the sequence 
saturation of all the samples did not reach to the recommended level.  The sequencing 
depth of the D.MS-275 cells was 34% and it was lower than 18% in the D.Vehicle and 
D.SAHA.  Whereas, the sequencing depth of the neurons was between the 50% and 60% 
(Figure 37 B).  As a consequence, the low sequencing saturation affected the mean reads 
per cell and the number of the detected genes.  The number of the detected genes in the 
Daoy samples was between 3000 to 5000 genes, and the detected genes of the neuron 
samples were between 1000 to 1300 genes.   
In addition, the quality of the sequencing data was evaluated using the Q30 values on the 
level of; the barcode, the RNA, the sample index, and the UMI.  The Q30 value is defined 
as the probability of having an incorrect base call in 1000 bases (i.e. a Q30 of 99% means; 
every 1000 bp sequencing reads will likely containing an error).  The Q30 results of all the 
samples were more than 85%, apart from the Illumine barcode reads of the N.Vehicle and 
the N.MS-275 which were 63% and 52%, respectively. 
Collectively, these results showed that the sequencing depth was suboptimal in particular 
with the Daoy samples which could affect identifying some of the cellular regulations 
especially and the expression of the low abundant genes may be underrepresented in the 
data set.  Nevertheless, the number of the targeted cells and the quality of sequencing data 
could be sufficient, at least, to address some of the research questions of this thesis.  
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Figure 37: Statistical summary of the 10x scNGS data quality measures   
The sequencing data were demultiplexed using the CellRanger mkfastq and count 
pipelines.  The quality of the 10x libraries were evaluated on the level of; the number of 
the targeted cells (A), the sequence saturation (B), the mean read per cell (C), and the 
median genes per cell (D).  The quality of the data was also evaluated using the Q30 bases 
of the barcode, the RNA reads, the sample index reads, and the UMI reads (E).  
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 The Initial Visualization of the 10x scNGS Data 
The generate data of all the samples were further passed by several steps of data analysis 
(Figure 38).   First the data were processed through the CellRanger aggr which combined 
all the data and subjected them to dimensional reduction using t-Distributed Stochastic 
Neighbour Embedding (t-SNE) analysis.  t-SNE is a nonlinear dimensionality reduction 
technique used to visualize high-dimensional data in a low-dimensional space of two or 
three dimensions 216. 
In this stage, the t-SNE plot was used to demonstrate the transcriptome landscape for a 
sum of 10.262 single cells (Figure 39).  This primary analysis revealed a high-dimensional 
separation between the tumour and the normal cells and across the untreated and treated 
samples which may indicate the high transcriptome heterogeneity between the cells.  
However, it should be noted that the position of the cells and their clustering is significantly 
depending on the parameters that were applied in the dimensional reduction.  The 
dimensional distribution of the cells is also different from one analysis tool to another. 
In order to examine the heterogeneity, the fold change expression of the highly variable 
genes (P<0.001) of each sample was extracted and visualized on a heatmap plot (Figure 
39).  The heatmap plot revealed a considerable heterogeneity in the gene expression 
patterns between the untreated and the treated cells and across the tumour and normal cells.  
For example, the HDACis treated tumour and normal cells showed a distinct expression 
patterns to the untreated cells.  Also, there was a noticeable difference in the expression 
patterns between the tumour and normal cells.  Comparing the expression patterns between 
the SAHA- and MS-275-treated cells showed some similarity in both cell types (Figure 
39).                    
Further, the biological function of these genes was explored using GenCLiP 2.0 Gene 
Ontology (GO) mining server by annotating the genes of each condition.  The GO terms 
of the untreated Daoy cells showed a wide range of cell regulations including proteolysis, 
cell cycle, response to stress, and negative regulation of cell death.  The apoptotic 
regulation and cell death terms were more frequent with the HDACis treated Daoy cells.  
The untreated neurons showed a high enrichment in GO terms that encompass supporting 
normal cell growth, gene expression, and neuronal functions.  In contrast, the treated 
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neurons showed GO terms such as extracellular organelle and vesical, cellular response to 
stress, macromolecule catabolic, and neuronal differentiation process.   
Figure 38: Schematic representation of the data analysis workflow  
The quality improved data were processed through several steps of data analysis.  First, 
the expression of all the samples was visualized on two-dimensional t-SNE projector and 
the gene expression was presented on a heatmap.  Next, each of the Daoy and the neurons 
were processed independently.  The Daoy cells were analysed by clustering the cells based 
on their cell cycle phase and the cells were then subjected to GO annotation analysis.  As 
treating with HDACis affected the cells cycle clustering, all the treatment conditions were 
merged in one data set and the data were subjected to; clustering analysis, GO analysis, 
Gene Set Enrichment Analysis (GSEA), and differential expression analysis.  The analysis 
of the neurons established by identifying the identity of the cells in each cluster and the 
clusters of the untreated and treated cells were merged based on the similarity in their 
identity.  The data were then subjected GO analysis, GSEA, and differential expression 
analysis.      
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Figure 39: Visualization of the untreated and treated Daoy cell and neurons  
The t-SNE scatterplot (A) show the clustering of ~10.262 cells based on their gene 
expression.  The data sets of the 6 samples were processed using the CellRanger aggr 
pipeline and the gene expression of each cell was subjected to PCA and presented on a t-
SNE plot.  Interestingly the scNGS data revealed two populations of Daoy and neuronal 
cells which requires further investigation. Each dot corresponds to one single cell and the 
cells were coloured according to the sample.  The t-SNE plot was produced by CellRanger 
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Loupe.  (B) The heatmap shows the differential expression of the highly variable genes 
(P<0.001) of the untreated and treated Daoy and neurons.  The rows represent the genes 
and the columns represent the samples.  The colour and the intensity of the boxes are z-
score values and were calculated by centring the fold change expression values to zero 
mean and all the data were scaled to 1 SD.  The light green boxes indicate upregulated 
genes, the red indicate the lower expression and no differential expression is black.  The 
hierarchical clustering (left) is the average linkage and was calculated based on the 
similarity of gene expression patterns.  The heatmap was generated using the Heatmapper 
online tool 144.  
 Improving the Quality of the 10x scNGS Generated Data   
As the generated data from the CellRanger-pipelines contain high level of biological 
background signal (cell-free RNA noise) the data were subjected to several steps of 
filtration and quality improvement.  These analyses were performed using the Seurat R 
package which was also used to merge the data sets and visualize the DGE between the 
untreated and treated cells.  The first step in data quality improvement was to exclude the 
cells with fewer than 300 genes and the genes that were detected in less than 3 cells.  Next, 
Seurat was used to calculate the total number of the UMI (nUMI) counts, the percentage 
of mitochondrial genes (percent.mito) and the number of the genes (nGene) for each cell 
and the values were presented using violin and scattered plots (Figure 40).   
The number of the detected genes in the Daoy cells plots was between 3000 to 5000 genes 
however, there were some cells with more than 5000 genes.  Also, the percentage of the 
mitochondrial genes were around 0.2% of the sum of the detected genes.  With the neurons, 
the number of the detected genes in the majority of the cells was between 1000 to 1500 
genes yet, few cells displayed more than 2000 genes.  Whereas, the percentage of the 
mitochondrial genes was ≤0.05%.  With all the samples, the small subsets of cells with a 
clear outlier number of genes and UMIs were assumed as potential multiplets.  The 
elevated expression of the mitochondrial genes could be indicative of poorer cell quality 
and it may be a result of apoptosis and/or cell lysis.  
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Figure 40: Exploring the scNGS Data to improve the quality  
The number of the genes (nGene), UMI (nUMI) and the percentage of mitochondrial genes 
(percent.mito) were calculated for each sample using Seurat (CreateSeuratObject) 
function.  The data were presented as violin and scatter plots to show the subset of cells 
that have clear outlier number of nGene, UMIs, and percent.mito.  The violin plots show 
the calculated number of the gene (first column), UMI (second column), and percent.mito 
(third column) for each sample.  The scatter plots present the expression of the UMIs vs. 
percent.mito, and the UMIs vs. nGene.   
Hence, the cells with a clear outlier number of genes and the mitochondrial genes were 
filtered out.  Also, the cells with low gene count were considered as dying/dead, empty 
droplets and were filtered out, as well.  Next, the quality improved data of each sample 
was normalized, scaled, and subjected to clustering analysis.  The outputs of these 
analysis were dimensionally reduced and displayed on t-SNE plots and the data were used 
in the subsequent analysis.   
 Daoy scNGS Data analysis    
 SAHA and MS-275 Affected the Expression of the Daoy Cell Cycle-Specific 
Markers  
In this study, the scNGS data analysis was established by investigating each Daoy sample 
independently.  The principal component analysis (PCA) revealed the presence of 4 
distinct clusters in the D.Vehicle sample whereas, D.SAHA and D.MS-275 showed the 
presence of 5 and 6 clusters, respectively (Figure 41 A).   
Initially, and as the phase of the cell cycle is possibly the main source of the transcriptome 
heterogeneity within each sample also, it could be the driver of the cells clustering, the 
analysis was carried out by characterizing the cell cycle phase of each cell using Seurat 
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(CellCycleScoring) function.  The analysis was performed by calculating the S and G2/M 
phase scores for each cell using a pre-set of 97 genes that have a significant cell cycle–
dependent expression 128.   The scoring of each cell was based on the genes anticorrelated 
expression thus, the cells expressing these markers should be not be in G1 or quiescent 
(G0) phases (Figure 41 B).  
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(A)            Original Clustering (B)          Cell Cycle Scoring 
D.Vehicle 
0=625, 1=485, 2=435, 3=44 G1=567, G2M=517, S=505 
D.SAHA 
0=560, 1=505, 2=398, 3=157, 4=150 G1=962, G2M=327, S=481 
D.MS-275 
0=712, 1=667, 2=316, 3=300, 4=225, 5=191  G1=1080, G2M=839, S=492 
Figure 41: The clustering of the Daoy treated cells was independent of the cell cycle 
phase 
The t-SNE plots in column (A) show the original clustering-analysis results of D.Vehicle, 
D.SAHA, and D.MS-275.  The t-SNE plots in column (B) show the cell cycle scoring 
analysis results generated by the Seurat (CellCeycleScoring) Function.  The numbers 
below each projector are the cell count of each cluster.  
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The outcome of this analysis showed that the clustering of the D.Vehicle was mainly driven 
by the expression of cell cycle genes, apart from cluster 3 which showed a distinct cluster 
located outside the three main clusters (Figure 41 B).  In contrast, the cell cycle scoring of 
the D.SAHA and D.MS-275 cells showed extensive overlap between the different phases 
of the cells which may indicate the effect of SAHA and MS-275 on the cell cycle gene 
expression (Figure 41 B). 
Further, and in order to demonstrate the effect of HDACis on the expression of the cell 
cycle markers, the expression of the S and G2M specific genes of each cell was visualized 
using heatmaps.  The heatmaps of the D.Vehicle showed high, specific, and more frequent 
expression patterns of the S and G2M markers in the cells that were classified as either S 
or G2M phase, respectively (Figure 42 A and B).  Whereas, the expression patterns were 
different with D.SAHA and D.MS-275.  For instance, the expression of the S phase 
markers was not limited to the cells that were classified as S phase, and many of the G1 
and G2M classified cells showed the expression of these markers.  Similarly, the G2M 
markers were expressed in cells that were classified as S and G1 (Figure 42 A and B). 
To explore the variations between the clusters, I used the functional annotation analysis to 
annotate the upregulated and downregulated genes of each cluster.  The annotation results 
of the D.Vehicle showed some variations in GO categories between the four clusters.  For 
example, the upregulated genes in cluster (1, 2 and 3) showed wide range of GO terms 
including cell cycle transition, mitotic nuclear division, and G2/M transition of mitotic cell 
cycle.  Similarly, the downregulated genes showed a broad range of GO annotations such 
as cell differentiation, regulation of cell differentiation, and cell death.  Noticeably, cluster 
(3) which consists of 44 cells showed upregulation of more than 50 genes that were 
annotated as caspase-independent apoptosis (Table 6).    
With D.SAHA, there was wide variations in the GO terms between the clusters.  For 
example, the downregulated genes in cluster 1 and 2 showed an enrichment by GO terms 
such as regulation of (non-apoptotic) programmed cell death.  In contrast, cluster 4 showed 
upregulation of genes that were annotated as cell cycle phase transition, apoptosis 
inhibitors, and caspase-independent cell death (Table 6).    
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Figure 42: Visualization of the cell cycle markers in D.Vehicle, D.SAHA, and D.MS-
275    
The heatmaps visualize the expression of 97 cell cycle markers (43 genes for S phase (A), 
and 54 genes for G2M phase (B)) across the untreated and treated Daoy cells.  The rows 
represent the genes, the columns represent the cell cycle phase, and each column within a 
row represents a cell.  The green boxes indicate upregulated genes, the red indicate the 
lower expression and the no differential expression is black.   
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Likewise, the cluster (0) of D.SAHA showed an enrichment in GO categories that are 
highly relevant to cell death.  Cluster (3) showed an enrichment in categories of mitotic 
cell cycle, chromosome condensation, and DNA replication and downregulation of genes 
that were annotated as regulators of the extracellular exosome (Table 6).   
Also, D.MS-275 showed wide variations in GO terms between the 6 clusters.  For example, 
cluster (0) and (3) showed upregulation in the genes that are involved in RNA transcription 
and downregulation in cell proliferation genes.  Cluster (1) and (4) showed downregulation 
of genes that are involved in cell cycle transition and also, in the genes that function as 
negative regulators of apoptosis.  Cluster (2) and (5) showed downregulation of genes that 
regulate cell differentiation and upregulation in genes that were annotated as negative 
regulators of cell death (Table 6).   
Collectively, the GO results of the D.Vehicle suggest the expression of cell cycle genes 
whereas, some of the D.SAHA and D.MS-275 clusters showed GO terms related to the 
regulation of caspase-independent cell death.  Treating with SAHA and MS-275 resulted 
in affecting the expression of the cell cycle regulating genes which consequently affected 
the accuracy of the cell cycle soring analysis.  Based on this analysis, comparing the DGE 
between the untreated and treated cell of the same cell cycle phase is not possible under 
the current situation.   
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Table 6: Summary of the GO terms that were more frequent for each cluster   
D.Vehicle 
Cluster 
GO Annotation  
(Upregulated Genes) 
GO Annotation  
(Downregulated Genes) 
0 
negative regulation of cell cycle mitotic cell cycle 
cycle transition from G1 to S phase 
1 
mitotic cell cycle 
checkpoint 
negative regulation of cell cycle 
regulation of cell proliferation 
cell differentiation 
regulation of cell death 
2 
Progression in mitotic cell cycle 
DNA metabolic process 
negative regulation of cell cycle 
3 
programmed cell death 
positive regulation of apoptotic 
process 
mitotic cell cycle 
regulation of mitotic cell cycle 
D.SAHA 
0 
apoptotic process 
cell differentiation 
extracellular region 
1 
homeostatic process 
regulation of biological characteristic 
cell cycle 
regulation of (non-apoptotic) 
programmed cell death 
2 
membrane organization regulation of proteolysis activation of 
apoptosis 
regulation of (non-apoptotic) 
programmed cell death 
3 
mitotic cell cycle 
condensed chromosome 
DNA replication 
mitotic cell cycle phase transition 
extracellular exosome 
negative regulation of biological 
process (i.e. gene expression, protein 
modification) 
4 
apoptosis inhibitor activity 
caspase-independent cell death 
cell cycle phase transition 
mRNA metabolic process 
membrane organization 
intracellular transport 
protein synthesis elongation 
D.MS-275 
0 
regulation of transcription from RNA 
polymerase II promoter 
cell proliferation 
1 
 negative regulation of cell death 
(caspase-independent cell death) 
apoptotic process 
cell cycle phase transition 
2 
regulation of cell migration 
regulation of apoptotic process 
cell differentiation 
nervous system development 
3 extracellular organelle growth 
4 
mitotic cell cycle 
regulation of mitotic cell cycle phase 
transition 
negative regulation of cell death 
cell differentiation 
5 
negative regulation of programmed 
cell death 
apoptotic process 
extracellular organelle 
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 Merging the D.Vehicle, D.SAHA, and D.MS-275 Data Sets  
In order to study the anticancer effect of SAHA and MS-275, the three Daoy-cell 
conditions were merged in one Seurat object and the data were normalized, dimensionally 
reduced, and visualized on t-SNE plots (Figure 44 A).  The new dimensional scale of the 
merged data set displayed the D.Vehicle with high similarity to its original unmerged scale.  
Though, the dimensions of the D.SAHA and D.MS-275 cells showed some differences  
compared to their unmerged condition.  The plots did not show overlap between the three 
conditions and each sample maintained its own clustering identity with very few cells of 
the D.SAHA sample were overlapping with the other two conditions (Figure 44 A).  
Comparing the detected genes between the three conditions showed a considerable 
reduction in the number of the genes in the HDACis treated cells.   For example, 1724 
genes were detected in the D.Vehicle cells and the number reduced to 841 and 934 genes 
in D.SAHA and D.MS-275, respectively (Figure 43).   
Next, the merged data set was subjected to the clustering analysis based on the new PCA 
values.  The new clustering of the D.Vehicle did not result in a considerable difference 
when compared to the unmerged clustering yet, the number of the cells within each cluster 
was different when compared to the unmerged (original) clustering (Figure 44 B).  
Whereas, the number of the clusters of the D.SAHA and D.MS-275 was less than the 
unmerged condition.  For example, D.SAHA, was clustered into two clusters with 1563 
cells in the main cluster.  Also, the number of the D.MS-275 clusters was reduced to 4 
clusters with 1404 cells in the main cluster (Figure 44 B).  
Figure 43: Illustration of the number of detected D.Vehicle, D.SAHA, and D.MS-275 
genes 
The Venn diagram shows the number of 
the detected genes in D.Vehicle, D.SAHA 
and D.MS-275 that showed a significant 
differential expression.   
1724 Genes  841 Genes  
934 Genes  
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D.MS275=2411, D.SAHA=1770, D.Vehicle=1589 
 
0=1563, 1=1404, 2=639, 3=634, 4=542, 5=428, 6=218, 7=178, 8=117, 9=47 cells 
 
Figure 44: Merging the three conditions into one Seurat object to study the DGE 
The data sets of the D.Vehicle, D.SAHA, and D.MS-275 samples were merged, normalized, 
dimensionally scaled, and displayed on t-SNE plot (A).  Next, the merged data (A) were 
subjected to clustering analysis based on the new PCA of the three samples, and the new 
clustering was displayed on t-SNE plot (B).   
(A) 
(B) 
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To calculate the differential gene expression (DGE) between the untreated and the treated 
cells, the merged data set was subjected to Seurat (FindAllMarkers) function which 
calculates the log fold-change and the P-value for each differentially expressed gene.  The 
outcome of this analysis showed a significant (P > 0.001) upregulation and downregulation 
of more than 2600 genes across the three conditions.   
Further, the expression values of the genes that showed shared differential expression 
across the three conditions were used to explore the effect of SAHA and MS-275 on the 
Daoy cells.  The analysis identified 253 shared genes which were functionally annotated, 
and their expression was presented on a heatmap plot (Figure 45).   
The heatmap showed a considerable difference between the untreated and treated cells and 
across the treated cells, as well.  Treating with SAHA and MS-275 resulted in a significant 
(P> 0.001) downregulation of several genes families that were annotated as cell cycle 
regulators, cell cycle checkpoint, and positive regulators of cellular process (Figure 45).   
Also, the MS-275 treated cells showed the expression of more than 23 genes that were 
annotated as regulators for cell death (Figure 45).   
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Figure 45: The differential expression of the highly variable genes across the Daoy 
untreated and treated cells    
The heatmap shows the differential expression of 253 highly variable genes (P<0.001) 
shared between the untreated and treated Daoy cells.  The rows represent the genes, the 
columns represent the treatment-condition, and the terms on the right are the GO 
annotations terms.  The colour and the intensity of the boxes are z-score values and were 
calculated by centring the fold change expression values to zero mean and the data were 
scaled to 1 SD.  The light green boxes indicate upregulated genes, the red indicate the 
lower expression and the no differential expression is black.  The hierarchical clustering 
is the average linkage and was calculated based on the similarity in the gene expression 
patterns. 
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Further, the merged data set was used to study the anticancer regulation of SAHA and MS-
275 in the subsequent analysis.  However, as the clustering of the merged set was not 
similar to the clustering of the single sample, also as not all the clusters of the single sample 
analysis showed the anticancer effect of the drugs in the earlier analysis, the main cluster 
of D.SAHA (0) and D.MS-275 (1) were further subjected to the functional annotation 
analysis to determine if they include the clusters that displayed the cell death regulations. 
The results of D.SAHA cluster (0) upregulated genes showed several GO terms with > 
4.13 GenClip Enrichment Score ((GES), significant > 1) 130.  The terms were included the 
negative regulation of cell cycle and positive regulation of programmed cell death.  The 
downregulated genes showed high enrichment in GO terms of cell cycle transition, 
negative regulation of cell death, and cell differentiation (GES: > 20).  
Likewise, the upregulated genes of the D.MS-275 cluster (1) showed a significant 
enrichment in GO categories associated with cell death, response to stress, and cellular 
response to chemical stimulus (GES: >6).  Whereas, the downregulated genes revealed a 
significant enrichment in GO categories that were highly relevant to mitotic cell cycle 
process (GES: 14.89), negative regulation of apoptotic process (GES: 5.43), and 
programmed cell death (GES: 4.75).  Despite, the functional differences between all the 
previous GO terms yet, there was high similarity in the genes across the GO terms.   
Collectively, these findings suggest the anticancer effect of SAHA and MS-275 in cluster 
0 and 1 therefore, they were used in the subsequent analysis to study the anticancer 
molecular regulation.  Hereinafter the cluster (0) referred to as D.SAHA, and the cluster 
(1) referred to as D.MS-275.  
 Dissecting the Molecular Regulation of the Daoy Untreated and Treated 
Cells 
In order to study the anticancer regulation of the HDACis, the study started by exploring 
the molecular regulations of the D.Vehicle, D.SAHA, and D.MS-275 samples.  The 
analysis was carried out by examining the gene enrichment for each sample using the Gene 
Set Enrichment Analysis (GSEA) at Broad Institute 131.  The analysis was performed by 
ranking the upregulated and downregulated genes as per the decrease in their fold change 
values and the ranked lists were used to run the GSEA.  The GSEA define the genes at the 
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top of the ranked list as ‘positive phenotype’ and gives them a positive enrichment score 
(the majority of the genes are upregulated) whereas, it defines the genes at the bottom of 
the list as ‘negative phenotype’ and scores them with negative ES (majority of the genes 
are downregulated). 
The GSEA results of the D.Vehicle cells showed several cellular pathways with 
statistically significant ES [false discovery rate q-value (FDRq) <0.25, and nominal P-
value <0.01] (Table 7).  The majority of these pathways were largely related to the cell 
growth mechanisms.  For instance, the results of the positive phenotype displayed high 
enrichment in cell cycle, DNA replication, Myc and E2F targets pathways (Figure 46). 
Whereas, the negative phenotype showed high enrichment in TNFα signalling via NFκB, 
hypoxia, p53 pathway, MAPK and KRAS pathways which have significant role in 
regulating the cell growth, as well (Figure 46).  Interestingly, the analysis also revealed the 
presence of two different subsets of genes that showed negative phenotype and enriched 
with genes that were identified as regulators for apoptosis (Table 7).   
The results of the D.SAHA and D.MS-275 showed an inverse phenotype to the molecular 
regulations of the D.Vehicle sample (i.e. the positive phenotype in the D.Vehicle becomes 
negative in the D.SAHA and D.MS-275) (Figure 46).  For example, the results of D.SAHA 
and D.MS-275 negative phenotype showed a significant (FDRq <0.25, nominal P <0.01) 
enrichment with terms such as Myc (Targets V1), cell cycle, and p53 pathways.  Whereas, 
the positive phenotype results showed high enrichment with TNFα signalling via NFκB, 
p53 and, MAPK signalling pathways (Table 7).    
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Figure 46: GSEA enrichment plots of the highly enriched molecular regulations  
The GSEA was carried out by ranking the upregulated and downregulated genes based on 
the decrease in their fold change and the ES was calculated by walking down the ranked 
list.  In the above charts, the horizontal middle line in red and blue colours is the rank 
ordered list of the upregulated and downregulated genes, respectively, and the decrease 
in the intensity of the bar colour represents the decrease in the fold change.  The vertical 
black bars represent the gene hits, the vertical grey bars represent the ranking metric 
scores of the genes, the positive values indicate correlation with the phenotype profile and 
the negative values indicate the inverse correlation, and the green fluctuating curve shows 
the enrichment score.  The red framed-charts show the gene set enrichment at the top of 
the ranked list (Positive ES) and the green framed-charts display gene set enrichment at 
the bottom of the list (Negative ES).  
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Table 7: GSEA results of the highly enriched gene sets of the Daoy cells 
(Pathways) Size1 ES2 NES3 
NOM p-
val4 
FDR q-val5 
D.Vehicle 
Reactome_Cell_Cycle 141 0.437 3.585 0 0 
Hallmark_Myc_Targets_V1 108 0.390 3.020 0 0 
Hallmark_E2F_Targets 102 0.497 3.754 0 0 
Reactome_DNA_Replication 79 0.515 3.620 0 0 
Reactome_Apoptosis 44 0.379 2.250 0 0.0011 
Hallmark_TNFA_Signaling_Via_NFKB 54 -0.570 -3.222 0 0 
Hallmark_Hypoxia 41 -0.568 -2.958 0 0 
Hallmark_Apoptosis 41 -0.370 -1.952 0.001 0.042 
Hallmark_P53_Pathway 38 -0.376 -1.923 0.005 0.039 
Kegg_MAPK_Signaling_Pathway 27 -0.557 -2.533 0 3.70E-04 
Hallmark_KRAS_Signaling_Up 27 -0.542 -2.492 0 4.23E-04 
D.SAHA 
Hallmark TNFA Signalling Via NFKB 29 0.174 0.99 0.438 0.932 
Hallmark Myc Targets V1 73 -0.437 -2.36 0.000 0.001 
Reactome Cell Cycle 59 -0.445 -2.17 0.000 0.001 
Reactome Apoptosis 33 -0.317 -1.39 0.117 0.146 
Reactome P53 Dependent G1 DNA 
Damage Response 
25 -0.441 -1.81 0.015 0.019 
D.MS-275 
Hallmark_TNFA_Signaling_Via_NFKB 25 0.505 2.477 0 0.002 
Hallmark_MTORC1_Signaling 22 0.380 1.793 0.018 0.060 
Hallmark_P53_Pathway 18 0.448 1.985 0.002 0.019 
Kegg_MAPK_Signaling_Pathway 17 0.484 2.015 0.002 0.020 
Hallmark_Apoptosis 15 0.415 1.680 0.021 0.094 
Reactome_Cell_Cycle 44 -0.328 -1.938 0.005 0.016 
Hallmark_Myc_Targets_V1 36 -0.374 -2.018 0.003 0.010 
Reactome_Apoptosis 20 -0.516 -2.287 0 0.003 
The light red shaded rows show the positive phenotype and the light green display the 
negative phenotype. The statistically insignificant pathways are in dark red font colour. 
1 The number of the detected genes.  
2 Enrichment Scores. 
3 Normalized Enrichment Score (used to compare analysis results across gene sets). 
4 Nominal P-value (statistical significance of the enrichment score). 
5False discovery rate (the probability that the NES represents a false positive finding). 
  
Chapter 4                                                Results II 
163 
 
 Study the Differential Expression between the HDACis Untreated and 
Treated Daoy Cells 
The results of the GSEA revealed a significant change in several cellular pathways between 
the untreated and treated cells.  The changes in the HDACis treated cells involved the 
downregulation of genes that regulate the cell proliferation and upregulation of genes that 
are part of cellular pathways such as TNFα Signalling via NFκB, and Myc Pathways.  Also, 
the results showed a significant expression difference between subsets of genes that 
possibly have some contribution in regulating the apoptosis regulations.  In order to 
identify the most potential driver genes across the different pathways, the genes of each 
pathway were compared to the other pathways.  The investigation showed that each 
pathway has a conserved set of genes however, some of the genes were more frequent, in 
particular, across the cell cycle, Myc and the apoptosis pathways (Figure 47).  Also, 9 
genes were shared between the TNFα Signalling via NFκB and the apoptosis pathways 
(Figure 47).    
Figure 47: Representation of the genes that showed high enrichment scores across the 
identified pathways 
The genes that showed high ES in the TNFα Signalling via NFκB, cell cycle, Myc, and 
apoptosis pathways were compared to identify the shared genes between them.  The 
diagram was prepared by combining the genes that present each pathway in the untreated 
and treated cells.   
IER3  JUN SQSTM1 
ATF3  RHOB GADD45A 
MCL1  BTG3  GADD45B 
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4.2.6.4.1 TNFα Signalling via NFκB Molecular Pathways  
Further, to present the gene expression difference between the D.Vehicle, D.SAHA, and 
D.MS-275 cells, the fold change expression was extracted from the merged data set and 
presented on bar carts.  With the TNFα Signalling via NFκB pathway, the number of the 
detected differentially expressed genes across the three conditions was 62 genes, with 9 
genes showed shared differential expression (PHLDA2, ATP2B1, AREG, TUBB2A, 
CDKN1A, CCL2, FOSL1, CEBPD, and PLAUR) (Figure 48).  D.SAHA, showed the 
expression of 7 exclusive genes (EIF1, CD44, SAT1, SOD2, CXCL1, CCND1, and 
BIRC3) whereas, the expression of TRIB1 (reported to help in sensitizing cells to TRAIL-
induced apoptosis) 217 was only detected in the D.MS-275 cells.  The highest fold change 
between the SAHA and MS-275 treated to the untreated cells was in the upregulation of 
AREG (inhibits the growth of certain cancer cells)218 and downregulation of CCL2 
(support primary cell tumour growth and metastasis) 219 (Figure 49).   
 
Figure 48: Illustration of the DGE with high enrichment scores in TNFα Signalling 
via NFκB pathway  
The genes with high ES in the TNFα Signalling via NFκB pathway were compared in order 
to identify the shared genes between the HDACis untreated and treated cells.  The table 
shows the fold change expression of the shared genes across the three conditions, 
upregulated expression in red and downregulated expression in green.  
TNFα Signalling via NFκB pathway 
D.Vehicle D.SAHA D.MS-275
CCL2 1.572 -1.669 -1.145
CEBPD 0.776 -0.417 -0.408
FOSL1 -0.294 -0.289 0.340
PLAUR -0.476 -0.383 0.455
TUBB2A -0.522 -0.631 0.659
ATP2B1 -0.675 0.261 0.292
CDKN1A -1.014 -0.519 0.763
PHLDA2 -1.101 -0.787 0.985
AREG -1.804 -0.469 0.859
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Figure 49: Fold change expression of the TNFα Signalling via NFκB pathway  
The bar chart displays the fold change expression of 62 genes that showed high enrichment 
score in TNFα Signalling via NFκB pathway.  The red bars are the D.Vehicle, the green 
are the D.SAHA, and the blue are the MS-275. 
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4.2.6.4.2 Treating with SAHA and MS-275 Deactivated Myc Signalling Pathway 
The gene set analysis identified 122 genes as components of Myc (HALLMARK MYC 
TARGETS V1) (NOM P<0.0001) pathway however, only 24 genes showed shared 
differential expression between the three conditions (Figure 50).  Comparing the 
expression showed that the majority of these genes were upregulated in the untreated cell 
whereas, treating with HDACis resulted in downregulating 113 genes in HDACis treated 
cells (Figure 51).  
 
Figure 50: Illustration of the DGE with high enrichment scores in Myc Signalling 
pathway  
The genes that showed high ES in the Myc pathway were compared in order to identify the 
shared genes between the HDACis treated and untreated cells. The table shows the fold 
change expression of the shared genes across the three conditions, upregulated expression 
in red and downregulated expression in green.  
Myc Signalling Pathways 
Genes D.Vehicle D.SAHA D.MS-275
CDC20 1.289 -0.500 -0.347
DUT 1.014 -0.660 -0.746
HNRNPA2B1 0.832 -0.571 -0.490
RANBP1 0.761 -0.501 -0.437
NPM1 0.740 -0.744 -0.368
PSMB2 0.734 -0.596 -0.513
EEF1B2 0.731 -0.731 -0.429
PCNA 0.709 -0.280 -0.270
DEK 0.682 -0.359 -0.296
SET 0.681 -0.581 -0.343
ERH 0.669 -0.352 -0.536
HDGF 0.668 -0.445 -0.454
NAP1L1 0.635 -0.555 -0.425
HNRNPA1 0.622 -0.359 -0.392
PABPC1 0.620 -0.324 -0.400
PSMA1 0.546 -0.263 -0.382
PSMB3 0.539 -0.519 -0.313
NHP2 0.526 -0.368 -0.359
PSMA4 0.470 -0.443 -0.270
SRSF3 0.442 -1.112 0.325
SSBP1 0.417 -0.261 -0.259
RPS6 0.407 -0.262 -0.287
NOP56 -0.264 -0.380 0.299
RPS10 -0.694 -0.849 0.834
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Figure 51: Fold change expression of the Myc signalling pathway  
The bar chart displays the fold change expression of 122 genes that showed high 
enrichment score in Myc signalling pathway.  The red bars are the D.Vehicle, the green 
are the D.SAHA, and the blue are the MS-275.   
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 Treating with SAHA and MS-275 Decreased the Expression of Cell Cycle 
Specific Genes 
The gene set enrichment analysis showed high enrichment of 148 genes in the cell cycle 
pathway (NOM P 0.005).  Several of these genes showed more than one-fold significant 
differential expression with 32 genes were shared across the three conditions (Figure 52).  
Treating with HDACis results in reducing the expression of large number of these genes.    
(Figure 53).     
 
Figure 52: Illustration of the DGE with high enrichment scores in cell cycle signalling 
pathway  
The genes that showed high ES in the cell cycle pathway were compared to identify the 
shared genes between the HDACis treated and untreated cells. The table shows the fold 
change expression of the shared genes across the three conditions, upregulated expression 
in red and downregulated expression in green.  
Cell Cycle Pathways 
D.Vehicle D.SAHA D.MS-275
CCNB1 1.866 -0.698 -0.715
UBE2C 1.464 -0.536 -0.568
CKS1B 1.374 -0.905 -0.758
BIRC5 1.330 -0.619 -0.653
HIST1H4C 1.295 -0.555 -0.361
CDC20 1.289 -0.500 -0.347
CCNB2 1.009 -0.319 -0.315
SPC25 0.843 -0.267 -0.302
PSMB5 0.762 -0.704 -0.478
PSMB6 0.749 -0.448 -0.470
DHFR 0.747 -0.322 -0.346
NPM1 0.740 -0.744 -0.368
PSMB2 0.734 -0.596 -0.513
PCNA 0.709 -0.280 -0.270
CENPN 0.658 -0.287 -0.306
RPA3 0.642 -0.289 -0.376
PSMD11 0.595 -0.284 -0.433
PSMB8 0.569 -0.382 -0.365
PSMC5 0.558 -0.455 -0.309
PSMA1 0.546 -0.263 -0.382
PSMB3 0.539 -0.519 -0.313
NHP2 0.526 -0.368 -0.359
PSME2 0.510 -0.429 -0.310
PSMB9 0.495 -0.433 -0.262
PSMA4 0.470 -0.443 -0.270
PSME1 0.435 -0.259 -0.304
TUBA1A -0.261 -0.720 0.284
HSPA2 -0.274 -0.270 0.307
HSP90AA1 -0.316 -1.126 0.338
TUBB4B -0.549 -0.864 0.617
TUBA4A -0.589 -0.312 0.458
CDKN1A -1.014 -0.519 0.763
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Figure 53: Fold change expression of the cell cycle regulating genes  
The bar chart displays the fold change expression of 148 genes that showed high 
enrichment score in cell cycle pathway of the GSEA analysis.  The red bars are the 
D.Vehicle, the green are the D.SAHA, and the blue are the MS-275.   
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 The expression of the Apoptosis Genes  
The GSEA analysis identified several subsets of genes that were identified as regulators 
for apoptosis in each condition.  With the untreated Daoy cells, two subsets of genes were 
associated with the positive and the negative phenotypes with 7 genes were shared between 
the two phenotypes (HMGB2, BID, TNFSF10, LMNA, PMAIP1, DFFA, and H1F0) 
(Figure 54 and Figure 55).  Across the three conditions, D.SAHA and D.MS-275 showed 
differential expression of 33 and 20 genes respectively, with 17 shared genes (Figure 56) 
 
Figure 54: Illustration of the DGE with high enrichment scores in cell apoptosis 
signalling pathway  
The genes that showed high ES in the apoptosis pathway were compared in order to 
identify the shared genes between the HDACis treated and untreated cells. 
 
  
Apoptosis Pathways 
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Figure 55: Fold change expression of the D.Vehicle positive and negative phenotype 
apoptotic genes  
The bar chart displays the fold change expression of 80 genes that showed high enrichment 
score in the positive and negative phenotype of the apoptosis regulation.  The blue bars 
present the shared genes between the positive and negative phenotypes, the green bars 
represent the negative phenotype and the red bars show the positive phenotype.   
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Figure 56: Fold change expression of the apoptotic genes  
The bar chart displays the fold change expression of 82 genes that showed high enrichment 
score in apoptosis regulation of the GSEA analysis.  The red bars are the D.Vehicle, the 
green are the D.SAHA, and  the blue are the MS-275.   
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 Normal Human Neurons scNGS Data Analysis 
As the cell-type is possibly the main element of the transcriptional heterogeneity between 
the neurons, the analysis was established by identifying the cells identity of each cluster 
using the Cell-type Specific Expression Analysis (CSEA) server 129.  The analysis was 
carried out using the maker genes that characterized each cluster and the identity of the 
cells was assigned based on the significance of the P-value (Appendix 11). 
The analysis predicted the identity of the neurons as cortex, striatum, and amygdala 
neurons (Figure 57).  The t-SNE plot displayed the cortex neurons as two distinct clusters 
(hereinafter referred to as Cortex.1 and Cortex.2) with more than 150 cells in each cluster.  
Similarly, the striatum neurons formed two distinct clusters, the first (hereinafter referred 
to as Striatum.1) has more cells and was captured in the three conditions were the neurons 
of the second Striatum cluster were not among the N.SAHA neurons.  Due to the 
predominance of Cortex.1, Cortex.2 and Striatum.1 across the three conditions, the 
subsequent analysis was performed using these cells (Figure 57).   
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N.Vehicle 
 
Cells Number 
Cortex.1 = 226  
Cortex.2 = 221         
Striatum.1 = 304 
Striatum.2 = 124 
Striatum.3 =71 
Amygdala =108  
 
N.SAHA 
 
Cortex.1 = 174         
Cortex.2 = 260           
Striatum.1 = 166         
Amygdala = 37 
 
N.MS-275 
 
Cortex.1 =153         
Cortex.2=328 
Striatum.1= 207         
Striatum.2 =133  
Amygdala = 92 
 
Figure 57: t-SNE plots of the untreated and treated neurons  
The t-SNE plots display the dimensional reduction of the untreated; N.Vehicle (A) and 
treated neurons N.SAHA (B), and N.MS-275 (C).  The dimensional scaling was performed 
using the quality improved data and the analysis was carried out using the Seurat R 
package.  The cells identity of each cluster was characterized based on the expressed genes 
of each cluster using the CSEA server analysis. 
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 Clustering the Neurons Based on their Type 
In order to study the effect of SAHA and MS-275 on the normal neurons,  the analysis was 
carried out by extracting the cluster data set of each cell type (i.e. Cortex.1, Cortex.2, and 
Striatum.1) and the clusters with the same identity (i.e. Cortex.1 of N.Vehicle, N.SAHA, 
and N.MS-275) were merged in a single Seurat object.  The data were then normalized, 
dimensionally reduced, and displayed on t-SNE plots (Figure 58).  In this analysis, the 
merge function was implemented as the Seurat (Combined) function, which combined the 
whole three conditions in one Seurat object, did not allowed comparing the expression 
across the clusters of the same identity and it only allowed comparing the differential 
expression across the three conditions as whole.  
The t-SNE space plots of the merged clusters revealed a significant transcriptional 
heterogeneity across the conditions.  For example, the clustering of SAHA was located in 
a close proximity to the N.Vehicle with some overlap between the cells.  Whereas, the MS-
275 clusters showed a considerable distance to the other two conditions in the three cell 
types (i.e. Cortex.1, Cortex.2, and Striatum.1) which may indicate the significant effect of 
MS-275 on the normal cell gene expression (Figure 58).    
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Cortex.1 
N.Vehicle=226 
N.SAHA=174 
N.MS275=214 
 
Cortex.2 
N.Vehicle=221 
N.SAHA=260 
MS275=370 
 
 
Striatum.1 
N.Vehicle=304 
N.SAHA=166 
N.MS275=228 
 
 
Figure 58: t-SNE plots of the merged Cortex.1, Cortex.2, and Striatum.1 data set 
The data sets of Cortex.1, Cortex.2 and Striatum.1 of each condition were extracted and 
the clusters with the same cell identity across the three conditions were merged in one 
object using the Seurat R package.  The numbers on the left are the cell count of each 
condition.   
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In order to show the transcriptional heterogeneity across the different cell types, the fold 
change expression of the above t-SNE clusters were presented on heatmap plot (Figure 59 
A).   The heatmap showed considerable differences between the three treatment conditions 
and across the different cell types.  For instance, the expression patterns showed extensive 
difference between the untreated and treated neurons also, there was slight difference 
between the SAHA and MS-275 treated cells.  Similarly, there was some differences 
between the different cell types in particular between the cortex and the striatum neurons 
(Figure 59 A).   
Additionally, the major differences in the expression patterns across the three treatment 
conditions on the heatmap were classified into five sections (A, B, C, D, and E) and the 
genes in each section were functionally annotated.  The annotation analysis showed the 
downregulation of several cellular regulations in the HDACis treated cells including the 
cell cycle, the translation, and the ATPase activity genes.  In addition, the analysis showed 
downregulation of a subset of genes annotated as negative regulators for cell death (Figure 
59 B).  
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Figure 59 : The expression differences between the three neurons samples and across 
the different cell types 
The expression of the highly variable genes (fold change ≥ 1) of each cell type and for each 
treatment condition was filtered out and the mean values were z-score to zero and scaled 
to 1 SD and presented on a heatmap plot (A).  The genes that formed distinct differential 
expression patterns (A, B, C, D and E) across the clusters were subjected to functional 
annotation using GenClip annotation tool and the pathways that characterized each group 
A 
B 
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was presented in table (B). The blue bars are represent the fold enrichment sore of each 
Go term.  
 Exploring the Effect of HDACis on the Normal Neurons  
In order to investigate the effect of HDACis on normal cells, the genes of each cell cluster 
(Figure 58) were subjected to GSEA.  The results of GSEA revealed several cellular 
regulations both in the untreated and treated neurons however, the majority of these 
pathways were statistically insignificant (Table 8).  Several of these regulations showed an 
inverse phenotype between the untreated and treated neurons including Myc and cell cycle 
pathways (Figure 60).  Noticeably, Myc pathway showed an inverse correlation between 
the cortex and the striatum neurons (the HDACis treated cortex neurons showed the 
positive phenotype whereas, the striatum neurons displayed the negative phenotype) 
(Figure 60).  Also, the MTORC1 pathway was one of the pathways that showed gene set 
enrichment however, it did not show any significant enrichment in the N.SAHA Cortex.1 
and Cortex.2, N.Vehicle Cortex.2, and N.MS-275 Striatum.1 (Table 8).  
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N.Vehicle N.SAHA N.MS-275 
   
   
   
 
Figure 60: GSEA enrichment plots of the highly enriched gene sets of the neurons 
The GSEA was carried out by ranking the upregulated and downregulated genes based on 
the decrease in their fold change, and the ES was calculated by walking down the ranked 
list.  In the above charts, the horizontal middle line in red and blue colours is the rank 
ordered list of the upregulated and downregulated genes, respectively, and the decrease 
in the intensity of the bar colour represents the decrease in the fold change.  The vertical 
black bars represent the gene hits, the vertical grey bars represent the ranking metric 
scores of the genes, the positive values indicate the correlation with the phenotype profile, 
the negative values indicate the inverse correlation, and the green fluctuating curve shows 
the enrichment score.  The red framed-charts show the gene set enrichment at the top of 
the ranked list (Positive ES) and the green framed-charts display gene set enrichment at 
the bottom of the list (Negative ES). 
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Table 8: GSEA results for some of the highly enriched gene sets of the neurons  
Name Size1 ES2 NES3 NOM p-val4 FDR q-val
5 
N.Vehicle Cortex.1 
REACTOME_DEVELOPMENTAL_BIOLO
GY 
30 0.381 1.745 0.015 
0.061 
HALLMARK_MTORC1_SIGNALING 30 0.216 0.978 0.485 1 
REACTOME_CELL_CYCLE_MITOTIC 33 0.083 0.390 0.997 0.998 
REACTOME_METABOLISM_OF_RNA 105 -0.663 -4.965 0.000 0 
REACTOME_METABOLISM_OF_PROTEI
NS 
114 -0.655 -4.957 0.000 
0 
HALLMARK_MYC_TARGETS_V1 51 -0.209 -1.292 0.124 0.145 
REACTOME_CELL_CYCLE 38 -0.108 -0.609 0.944 0.951 
N.SAHA Cortex.1 
REACTOME_TRANSLATION 71 0.486 3.083 0.000 0 
REACTOME_METABOLISM_OF_PROTEI
NS 
98 0.403 2.672 0.000 
0 
REACTOME_CELL_CYCLE 47 0.249 1.436 0.052 0.351 
HALLMARK_MYC_TARGETS_V1 56 0.211 1.243 0.171 0.724 
N.MS-275 Cortex.1 
REACTOME_TRANSLATION 54 0.556 3.521 0.000 0 
REACTOME_METABOLISM_OF_PROTEI
NS 
78 0.458 3.255 0.000 
0 
REACTOME_METABOLISM_OF_MRNA 60 0.447 2.888 0.000 0 
HALLMARK_MYC_TARGETS_V1 48 0.182 1.095 0.357 0.365 
HALLMARK_MTORC1_SIGNALING 35 -0.234 -1.244 0.199 1.000 
REACTOME_CELL_CYCLE 46 -0.156 -0.911 0.599 1.00 
HALLMARK_E2F_TARGETS 32 -0.107 -0.556 0.951 1.000 
N.Vehicle Cortex.2 
HALLMARK_MYC_TARGETS_V1 43 0.123 0.625 0.912 1.000 
REACTOME_METABOLISM_OF_RNA 94 -0.703 -5.127 0.000 0.000 
REACTOME_TRANSLATION 88 -0.728 -5.123 0.000 0.000 
N.SAHA Cortex.2 
REACTOME_METABOLISM_OF_RNA 59 0.097 0.599 0.960 0.947 
REACTOME_METABOLISM_OF_PROTEI
NS 
74 -0.177 -0.965 0.520 
0.890 
REACTOME_METABOLISM_OF_MRNA 54 -0.132 -0.669 0.875 1.000 
HALLMARK_MYC_TARGETS_V1 46 -0.126 -0.610 0.925 0.995 
REACTOME_CELL_CYCLE 44 -0.124 -0.605 0.939 0.928 
N.MS-275 Cortex.2 
REACTOME_TRANSLATION 77 0.585 3.753 0.000 0.000 
REACTOME_ACTIVATION_OF_THE_MR
NA 
31 0.590 2.846 0.000 0.000 
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HALLMARK_MTORC1_SIGNALING 36 -0.218 -1.187 0.250 0.872 
REACTOME_CELL_CYCLE 32 -0.219 -1.134 0.307 0.921 
HALLMARK_MYC_TARGETS_V1 44 -0.105 -0.602 0.942 1.000 
N.Vehicle Striatum.1 
REACTOME_CELL_CYCLE 55 0.282 1.477 0.070 0.150 
HALLMARK_MYC_TARGETS_V1 66 0.266 1.471 0.063 0.135 
HALLMARK_E2F_TARGETS 37 0.245 1.158 0.282 0.415 
HALLMARK_MTORC1_SIGNALING 36 -0.209 -1.249 0.158 0.299 
REACTOME_METABOLISM_OF_PROTEI
NS 
50 -0.144 -0.908 0.614 
0.602 
N.SAHA Striatum.1 
REACTOME_CELL_CYCLE 51 -0.331 -1.464 0.058 0.046 
HALLMARK_MYC_TARGETS_V1 81 -0.257 -1.228 0.185 0.508 
HALLMARK_MTORC1_SIGNALING 30 -0.165 -0.655 0.872 0.885 
N.MS-275 Striatum.1  
REACTOME_TRANSLATION 54 0.337 1.659 0.019 0.029 
REACTOME_METABOLISM_OF_PROTEI
NS 
64 0.311 1.589 0.024 
0.038 
HALLMARK_MYC_TARGETS_V1 31 -0.292 -1.510 0.066 0.044 
The light red shaded rows show the positive phenotype and the light green display the 
negative phenotype.  The statistically insignificant pathways are in dark red font colour. 
1 The number of the detected genes.  
2 Enrichment Scores. 
3 Normalized Enrichment Score (used to compare analysis results across gene sets). 
4 Nominal P-value (statistical significance of the enrichment score). 
5False discovery rate (the probability that the NES represents a false positive finding). 
 
4.2.7.2.1 The Effect of HDACis on Myc Signalling Pathways 
Further, the gene differential expression of Myc signalling pathway of each cell type was 
used in order to compare the variation in the response to HDACis between the cells.   The 
expression results showed the upregulation of most genes in the untreated striatum and the 
downregulation of the majority of genes in the treated cells (Figure 61).  In contrast, the 
expression of the Myc genes in the untreated cells showed a combination of upregulation 
and downregulation with more than 70% of the genes were downregulated in Cortex.1.  
Yet, the cortex neurons treating with HDACis showed upregulation of Myc pathway-genes 
(Figure 61).  It should be noted that the ES of Myc pathway was statistically insignificant.  
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Figure 61: Fold change expression of Myc Pathway across the different neuron cells  
The charts display the fold change expression of Myc pathway in Cortex.1, Cortex.2, and 
Striatum.1.  The red bars are the N.Vehicle, the green are the N.SAHA, and the blue are 
the N.MS-275.   
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4.2.7.2.2 The Effect of HDACis on Cell Cycle Pathway  
The GSEA results of the cell cycle pathway were insignificant both the untreated and 
treated neurons.  The N.Vehicle (Cortex.1) and N.MS-275 (Striatum.1) also did not show 
any gene set enrichment for cell cycle genes.  In order to explore the effect of the SAHA 
and MS-275 on the neurons, the expression of the genes that were identified as component 
of the cell cycle pathway was presented on charts.  The general theme across the different 
types of the neurons is the inverse expression in the HDACis treated to the untreated 
neurons (Figure 62).  The annotation analysis of these genes showed several GO terms that 
were associated with cell cycle, nuclear division, and regulation of transcription.  The 
genes that were annotated as a cell cycle arrest were further compared across the different 
conditions however, the expression of these genes was not detected in the majority of the 
cells (Table 9).  The expression of few genes was more informative such as NPM1 which 
showed upregulation in MS-275-treated neurons and the expression of CCND2 which 
showed downregulation in most HDACis treated neurons.  It should be noted that the ES 
of Myc pathway was statistically insignificant.  
Table 9: The DGE of the genes that were annotated as cell cycle arrest  
 
Genes N.Vehicle N.SAHA N.MS-275 N.Vehicle N.SAHA N.MS-275 N.Vehicle N.SAHA N.MS-275
CDKN1A 0 0 0 0 0 0.421 -0.731 0 1.087
CDKN2A 0 0 0 0 0 0 -0.404 0 0.524
NPM1 -0.607 -0.304 0.758 -0.464 -0.546 0.736 0 -0.885 0.477
RAD9A 0 0.467 0 0 0.629 0 0 0.915 0
CDKN1B 0 0 0 0 0 0 0.501 0 0
CDK4 0 0 -0.444 0 0 0 0.432 0 0
PSMC6 0 0 0 0.509 0 -0.486 0.406 0 0
RAD1 0 0 0 0 0.513 0 0 0 0
CDKN2D 0 0 -0.261 0 0.307 0 0 0 0
GMNN -0.495 0.583 0 0 0.289 0 0 0 0
RFC4 0 0.273 0 0 0 0 0 0 0
CCNH -0.267 0 0 0 0 0 0 0 0
HDAC1 -0.325 0 0 0 0 0 0 0 0
CCND3 0 0 -0.265 0 0 0 0 0 0
SKP1 0 0 0 0 0 -0.298 0 0 0
HSP90AA1 -0.346 0.601 -0.274 0 0.575 -0.400 0 0 0
BUB3 0 0.437 -0.257 0 0.415 -0.445 0 0 0
RPA2 0 0 0 0 0 0 0.359 -0.262 0
CEP57 0.483 0 -0.515 0.495 0 -0.457 0.478 -0.359 0
PTTG1 0 0.341 0 0 0 0 0.500 -0.361 0
RAD21 0 0 -0.313 0.536 0 0 0.569 -0.508 0
PPP2CA 0 0 0 0 0 0 0.460 -0.578 0
CCND2 0.740 -0.630 -0.337 0.844 -0.497 0 0.806 -0.850 0
MAX 0 0.315 -0.406 0 0 0 0.306 0 -0.342
MCM7 0 0 0 0 0 0 0.563 -0.336 -0.416
TERF1 0 0.391 -0.433 0 0.320 -0.586 0.374 0 -0.503
Cortex.1 Cortex.2 Striatum.1
Chapter 4                                                Results II 
185 
 
 
Figure 62: Fold change expression of the cell cycle component genes across the 
different neuron cells 
The charts display the fold change expression of the genes that were identified as 
components for cell cycle pathway in Cortex.1, Cortex.2, and Striatum.1.  The red bars are 
the N.Vehicle, the green are the N.SAHA, and the blue are the N.MS-275.   
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 The Expression of HDAC and HAT Genes  
In cancer, aberrant expression of acetylation and deacetylation regulating genes has been 
frequently observed in a broad range of tumours and they contribute to the overall concept 
of cancer epigenetic therapy 6.  However, it is not known whether the changes in the 
acetylation condition are due to the alterations in HDACs and HATs genes expression.   In 
this study, the expression of HDACs and HATs in the untreated and treated Daoy cells and 
neurons was extracted from the scNGS data in order to explore their expression in tumour 
and normal cells.    
The results revealed the elevated expression of HDAC1 and HDAC2 in D.Vehicle, 
D.SAHA, and D.MS275.  Also, SAHA-treated cells showed a statistically significant 
(P>0.0001) increase in HDAC3 by 0.3-fold change compared to the D.Vehicle and D.MS-
275.  The results also showed an increase in the SIRT7 in SAHA- and MS-265-treated 
cells (Figure 63).   
The neurons result of the HDACs and HATs expression showed an upregulation in 
HDAC2 in the untreated and treated neurons and it reached to 0.4-fold change (P>0.0001) 
higher in the MS-275-treated Cortex.1.  The results showed a significant (P>0.05) decrease 
in the ATAT1 expression level in the MS-275-treated Cortex.2 and Striatum.1 neurons by 
0.3- and 0.7-fold change, respectively (Figure 65 and Figure 66).  The results also showed 
a slight increase in HDAC and HAT enzymes in small subsets of cells however, the 
expression was statistically insignificant due to the small size of these populations when 
compared to the overall population of a sample ( 
 
, Figure 64, Figure 65, Figure 66).   
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Figure 63: t-SNE plots of the HDAC genes in the Daoy untreated and treated cells 
The t-SNE plots show the average fold change expression of HDAC genes in the Daoy 
untreated and treated cells.  Each dot represents a cell and the level of the expression is 
represented by a gradient increase in colour from yellow to red as it appears in the legend 
of each plot.  The plots were produced by the Seurat R package and each plot has a 
different expression scale (the package is less flexible).  The clusters identity is presented 
in the HDAC2 and SIRT7 plots. 
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Figure 64: t-SNE plots of HATs genes in the Daoy untreated and treated cells 
The t-SNE plots show the fold differential expression of HATs genes in the Daoy untreated 
and treated cells.  Each dot represents a cell and the level of the expression is represented 
by a gradient increase in colour from yellow to red as it appears in the legend of each plot.  
The plots were produced by the Seurat R package and each plot has a different expression 
scale (the package is less flexible).  The clusters identity is presented in the HAT1 plot.  
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Figure 65: t-SNE plots of HDAC genes in the untreated and treated human neurons 
The t-SNE plots show the fold differential expression of HDAC genes in the untreated and 
treated neurons.  Each dot represents a cell and the level of the expression is represented 
by a gradient increase in colour from yellow to red as it appears in the legend of each plot.  
The plots were produced by the Seurat R package and each plot has a different expression 
scale (the package is less flexible).  The clusters identity is presented in the HDCA2 plot.  
 
 
Chapter 4                                                Results II 
190 
 
 
 
 
Figure 66: t-SNE plots of HATs genes in the untreated and treated neurons   
The t-SNE plots show the fold differential expression of HATs genes in the untreated and 
treated neurons.  Each dot represents a cell and the level of the expression is represented 
by a gradient increase in colour from yellow to red as it appears in the legend of each plot.  
The plots were produced by the Seurat R package and each plot has a different expression 
scale (the package is less flexible).  The clusters identity is presented in the ATAT1 plot.  
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 Pathway Analysis of the Untreated and Treated Samples  
Further, the gene expression values of the differentially expressed genes of each sample 
were uploaded into the PathVisio pathway visualization software.  The pathway analysis 
identified several pathways with high representation including TNFα and apoptosis 
pathways.  The pathway analysis did not show high representation of the differentially 
expressed genes in all the examined pathways and limited number of the genes were 
represented in the pathways.  For example, D.SAHA showed downregulation of genes that 
regulate apoptosis such as BID, BRIC5, TNFSF10 and TB53.  With the D.MS-275 BIRCS 
and CYCS were only represented in the apoptosis pathway in additional to interferon IRF3 
and IRF7.  The N.SAHA showed two genes BNP3L and DFFA where the N.MS-25 
presented JUN only (Figure 67).   
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Figure 67: Pathway analysis of the differentially expressed genes  
The differentially expressed genes of each sample were visualised using the PathVisio 
software and the analysis was performed by including the genes ID and expression values 
of all the genes. (A) D.Vehicle, (B) D.SAHA, (C) D.MS-275, (D) N.Vehicle, (E) N.SAHA, 
(F) N.MS-275.  The expression level of a gene is represented by the change in the colour 
from green to red and the expression value is shown next to the box.  The gradient bar 
represent the expression values, green as downregulated and red as upregulated. 
(E)  N.SAHA 
(F)  N.MS-275 
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4.3 Discussion  
HDAC enzymes are a group of epigenetic molecular switches that regulate genes 
expression, cellular proliferation, survival and apoptosis. Thus, they have been attractive 
targets for cancer therapy.  The aim of targeting HDACs is to reverse the effect of the 
epigenetic abnormalities that support the cancer cell proliferation.  In contrast, the HDAC 
inhibitors are a group of molecular compounds that block the HDAC binding site and they 
have attracted a substantial in vitro and in vivo research interest.  The results of the in vitro 
analysis have revealed the potency of certain HDACis in inducing anticancer effect 
through several downstream mechanisms including cell-cycle arrest, blocking 
angiogenesis, inhibition of metastasis, inducing autophagy, and stimulate apoptosis 73, 220.  
Whereas, the findings of the in vivo analysis exhibited the high selectivity of HDACis to 
target tumour cells with minimal effect on normal cells 60.   
However, even though several studies have proposed some possible HDACis anticancer 
mechanisms, there have been several research questions remained unexplored.  
Accordingly, in this study, I set out to obtain a more in-depth knowledge of HDAC-
dependent cancer regulation in tumour and normal cells using large-scale droplet-based 
single-cell transcriptome profiling.  This approach was used to explore the transcriptome 
variability between cells and to avoid the effect of the transcriptome heterogeneity between 
the cells.  Unravelling tumour heterogeneity may help in; unveiling the molecular 
regulation that sustains cancer cell progression, the molecular action of anticancer drugs, 
and identifying the subclone resistance to therapy.  In this study, I tried to; identify the 
molecular regulation of HDACs in sustaining the medulloblastoma cell growth, investigate 
the molecular mechanisms of how HDACis initiate the cell death mechanism, and explore 
the effect of the HDACis on the molecular  regulations of normal cells.  
In order to address these questions, I profiled the gene expression of the Daoy 
medulloblastoma cells and non-cancerous human neurons pre- and post-treating them with 
SAHA (a pan-Inhibitor) and MS-275 selective inhibitor (HDAC1 and to lesser extent, 
HDAC2 and HDAC3).  As the scNGS gene expression data often contain technical and 
biological noises, I subjected the data to stringent quality improvement measures and I 
used the quality improved data in the analysis.  I studied the most dominating pathways 
Chapter 4Chapter 5             Results II 
             Discussion Section  
196 
 
using the gene set enrichment analyses, and I used the differential expression analysis to 
explore the differences in the molecular regulations between the cells.  
The evidence of this study may suggest the ability of HDACis to disturb the cancer 
regulation through disrupting the pathways that support the cell cycle such as Myc and 
TNFα via NFκB pathways.  The results showed the considerable effect of HDACis on gene 
transcription of the normal cells in particular on genes that drive the cellular differentiation.  
The following sections, will discuss the findings of the study, compare them to what it has 
been known and draw a conclusion based on the evidences.  
 Assessing the Quality of the scNGS  
Several studies have tried to decipher the therapeutic mechanisms of HDACis using the 
microarray and the NGS bulk analysis.  The findings of these studies have suggested 
several cellular factors that collectively result in stimulating cell death mechanisms 83, 153, 
221, 222, 223.  Yet, the HDACis anticancer regulations are often intricate and embedded in a 
network of molecular interactions that occur simultaneously which make the bulk analysis 
of heterogenous cells less likely to reveal the molecular regulations behind these networks.  
As any analytical approach, the scNGS analysis has several technical and biological factors 
that may limit the ability of the generated data in addressing some important regulations.  
The quality of the scNGS data depends significantly on the number of the targeted cells 
and the sequencing depth, and it also highly affected by the technical and biological noises. 
Thus, in order to generate meaningful results, the data were subjected to several levels of 
quality controls assessment to filter out poor data before investigating the gene expression. 
 Assessing the Quality Based on the Number of the Analysed Cells  
The number of the individual cells is an important factor for generating a statistically 
significant result.  In this study, I aimed to target at least 2000 cells for each condition.  
The data of the tumour cells showed the presence of more than 1800 cells in the D.Vehicle 
and D.SAHA samples and it reached to more than 2700 with the MS-275-treated cells.  
Whereas, the number of the analysed neurons was less than 1400 cells.  The main factor 
of not achieving the aimed number was due to the inaccurate count of the neurons.  As per 
the 10x Genomics recommendations, the number of the loaded cells should be accurately 
measured with considering the multiplets rate and the percentage of the dead cells.   
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In the subsequent data improvement analysis, the number of the cells was further reduced 
after filtering out the poor-quality cells.  The count of the Daoy samples was more than 
1700 cells where, the count of the neurons reduced to around 1000 cells in the untreated 
and MS-275-treated cells, and it was less than 700 cells in the SAHA-treated neurons.  
Calculating the gene differential expression between the different conditions of the same 
cell identity showed statistically significant results (P<0.0001) which may suggest the 
suitability of the data to identify the difference in gene expression across the samples.    
 Assessing the Quality Based on the Sequencing Saturation and Depth 
The sequencing saturation is the average number of reads (mRNA, cell-barcode, and UMI) 
that confidently mapped to known reference bases, and it is used to estimate the number 
of additional reads to detect a new transcript.  Whereas, the sequencing depth is the number 
of the transcripts that were detected for each cell 224.  The values of these measures are 
important to ensure; obtaining the most transcriptome of a single cell, accurate 
identification of gene expression, detecting genes with low abundance, and reducing the 
technical noise.  The recommended sequencing saturation for the scNGS is >85% and the 
recommended depth is >50.000 reads for the RNA-rich cells such as cell lines.   
In this study, the sequencing saturation of the Daoy samples was less than 33% and it 
resulted in reducing the sequencing depth to a suboptimal level.  The sequencing saturation 
of the neurons was between 52 to 63% where the sequencing depth was between the 35 
and 43 thousand read per cell.  Despite several attempts to improve the magnitude of the 
sequencing depth though, the number of reads did not show any significant improvement.  
This could be due to a technical problem and it may result from an inaccurate normalization 
of the cDNA libraries between the samples.  The low sequencing depth often affect the 
reliability of gene detection in particular genes with low transcriptome abundance. 
Accordingly, the low sequencing depth of the Daoy untreated- and SAHA-treated cells 
could have an impact on the interpretation of the findings 121.   
Despite the higher sequencing depth of the neurons in comparison to the Daoy cells 
however, the number of the detected genes in the Daoy samples was higher (between 3000 
to 5000 genes) than the neurons (1000 to 1300 genes).  This could be due to the nature of 
cancer cells which require more functional genes for the cell proliferation, metabolism, 
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DNA repair, chromosome stability, cell matrix interactions, cell communication, tumour 
invasion, angiogenesis, and inhibiting apoptosis 225.   
 Assessing the Quality Based on the Q30 and the Background Noise 
The Q30 score is another important factor as the scNGS data often contain technical and 
biological noise.  The average Q30 of the data (the Barcode, the RNA, the sample index, 
and UMI) in all the samples exceeded the 80% which considered an average score with 
Illumina sequencing and it may indicate the optimal quality of the reads.    
The data showed that the majority of the cells in each treatment condition have a relatively 
equivalent number of genes however, there were cells with a higher number of genes when 
compared to the whole population.  The analysis also exposed cells with low number of 
genes which could result from having a free-RNA.  Additionally, the analysis displayed a 
subset of the Daoy cells with a higher mitochondrial gene count compared to the majority 
of the cells which often results from have broken cells where the mRNA is lost and the 
RNAs enclosed in mitochondria is retained 226.  Therefore, the data were subjected to 
multiple levels of quality improvement analysis using the CellRanger and the Seurat 
analysis tools and the effect of the multiplets, free-RNA background, and the mitochondrial 
genes were removed.  The cell-specific bias such as the dropout (is a true zero value in 
gene expression matrix could result from absence of gene expression) and the batch effect 
were also removed by data normalization 227.   
 The Analytical Approach used to Process the Data 
As the phase of the cell cycle is the main driver of the transcriptome heterogeneity in the 
Daoy cells, each cell was scored according to the expression of a pre-set of the cell cycle 
genes 128.  This analysis was carried out to allow the comparison between the data set of 
the untreated and the treated cells based on the cell cycle phase (i.e. G1 phase of untreated 
compared to G1 of treated).  The result of the untreated Daoy cells showed that the 
clustering of the cells was mainly driven by the cell cycle phase.  This finding demonstrated 
the active proliferation of the tumour cells and it also displayed the transcriptional 
heterogeneity across cells of the same genetic identity.  
In contrast, the cell cycle scoring of the SAHA- and MS-275-treated cells showed an 
extensive overlap between the cells and the expression of the cell cycle genes was 
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considerably different when compared to the untreated cells.  These results clearly 
demonstrated the effect of HDACis on the cell cycle genes which makes the comparison 
of the gene expression based on the cell cycle phase is inapplicable.   
The alternative approach was to merge the three Daoy samples into one data set.  The data 
were then subjected for clustering analysis which resulted in clustering the cells according 
to the transcriptome similarity between the three samples.  The outcome of this approach 
showed that each sample maintained a clear distance from the other samples and the 
untreated cells maintained their original (unmerged) clustering (Figure 44).  Whereas, the 
treated cells showed a new clustering with a smaller number of clusters and very minimal 
overlap between the SAHA- and MS-275-treated cells.  Interestingly, the cluster of the 
MS-275-treated cells showed a considerable distance to the untreated cell whereas, the 
SAHA-treated cells were positioned near to the untreated cells.  This outcome is further 
demonstrated the considerable effect of HDACis on gene transcription, and it also suggests 
that the ability of MS-275 to induce more transcriptional variations compared to SAHA.   
The clusters were than subject to GO annotation analysis to identify the clusters that exhibit 
the HDACis effect.  The GO annotation analysis showed the enrichment of the main 
clusters, which have the majority of the cells, of SAHA- and MS-275-treated cells with 
GO terms of apoptosis and cell cycle regulations.  Hence, these clusters were used to study 
the anticancer regulation.  Further, the differential expression of the upregulated and 
downregulated genes of each cluster was used to run a preranked GSEA analysis in order 
to identify the gene set enriched-pathways of each cluster.  This analysis mainly depends 
on grouping the genes that share common biological function, chromosomal location, or 
regulation according to priori defined sets of genes.  The results of the GSEA was evaluated 
based on; the ES (reflects the overrepresentation of a genes set), the statistical significance 
of the ES (account for the size of the set and presented by the normalized ES), and 
proportion of false positives (FDR) 131.  Typically, this analysis is significantly affected by 
the number of the expressed and detected genes 228.  The results of the Daoy samples 
showed several gene set-enriched pathways with a statistically significant ES.  However, 
the GSEA results of the neuron clusters did not reach the statistical significance in the 
majority of the identified pathways despite the presences of more 30 genes in each 
pathway.  The main factor that affected the neurons GSEA results could be the low number 
of the genes that play a significant role in a particular pathway.  This could be due to; the 
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biological regulation that determine the response to the HDACis, or a technical matter as 
for example the suboptimal sequencing depth.   
 HDACis Affected the Expression of Several Cellular Pathways 
HDACis are known by their ability to induce extensive transcriptome changes in tumour 
and normal cells.  These changes were suggested to contribute, at least, in part in the 
HDACis anticancer effect and cell proliferation.  Using SAHA and MS-275, I showed that 
these inhibitors induced a transcriptional activation of several cellular pathways in the 
Daoy cells including TNFα-Signalling-via-NFκB, p53, and apoptosis pathways.  They also 
induced transcriptional repression of cell cycle and Myc pathways.  The most noticeable 
theme between the two inhibitors was their ability to induce a transcriptional pausing of 
the cell cycle regulating genes in both the transformed and normal cells.  The two drugs 
showed some slight differences in the number of the differentially expressed genes and 
also in the gene set enrichment analysis.  On the cell type level, the response to the two 
drugs showed also some differences between the different neurons.  Interestingly, the effect 
of the HDACis was not limited on upregulating the transcription of genes but it also 
contributed in transcription downregulation.  Likewise, previous HDACis transcriptome 
analysis showed considerable upregulation and downregulation of a large number of genes 
105, 153, 229, 230.   
The transcriptional repression function of HDACis is not completely understood.  The 
Genome-wide analysis that were applied to identify the localization of HDAC suggested 
that the function of HDACis is often associated with activating gene transcription 231.  The 
downregulation activity of HDACis could be a result of deacetylating non-histone proteins 
which function as transcription factors 232.  This assumption is further supported by a recent 
study which suggested the ability of HDACis to target the transcription elongation complex 
(bromodomain-containing protein 4 (BRD4)) and inhibit its activity 233.  
The patterns of changes in genes expression -apart from the apoptotic regulation- are 
relatively similar for different inhibitors yet, they are highly variable between transformed 
cells 105, 234, 235, 236, 237.  Some changes in gene transcription are possibly due to the direct 
effect of HDACis on gene promoter where other could be secondary and downstream 
effects.  Also, the changes that occur at the start of the acetylation may not reflect the 
anticancer effect in tumour cell, or the tolerance regulation in the normal cell 236.  In 
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addition, the anticancer mechanism may occur at any time from the exposure to prior the 
cell death.  Also, the cell apoptosis regulations in a response to an inhibitor are different 
between various cells and with different inhibitors 146.    
 HDACis Disrupted the Expression of Cell Cycle-Specific Genes  
The active progression in cell cycle is the main factor of tumour cell growth and it is one 
of the treatment targets.  Cancer cells sustain their growth through activating the cell cycle 
pathway whereas, the ability of the anticancer agents to disrupt the cell cycle regulation is 
a central factor in inhibiting tumour cell growth and it may leads to cell death 238.   
In this study, the GSEA results of the untreated Daoy cells a showed a positive phenotype 
of several pathways including the cell cycle, Myc, E2F and DNA replication pathways.  
These pathways are often amplified among many different human cancers and they have 
pivotal role in cell growth, proliferation, and tumorigenesis 84, 239, 240, 241.  The cell cycle 
pathway of the untreated Daoy cells showed a significant enrichment of 141 genes that 
were annotation as regulator for cell cycle, DNA replication, mitosis, nuclear division, and 
active transition in cell cycle.  Some of these genes have also a direct role in cell cycle 
transition including the cyclin-dependent kinase (CDK) genes such as CCNB1, CDC20, 
CDKN2D.  The CDKs are a family of proteins that regulate the transcription of cell 
cycle regulating genes and they play an essential function in regulating normal cell 
division 242.  Overexpression of cyclins is frequently observed in human malignancies and 
their expression has been associated with aggressive cancer and poor prognosis 80, 243.  The 
GSEA results also showed the downregulation of genes that have a direct effect on 
inhibiting the progression in cell cycle and the DNA repair mechanisms such as CDKN1A, 
BIRC5, PCNA, HSPA2, and HSP90AA1.   
In contrast, the GSEA results of the HDACis treated cells showed a negative phenotype of 
the cell cycle pathway.  The most significant differential expression was in CDK genes 
such as CCNB1, CDC20, CKS1B, and CCNB2. The finding also showed the 
downregulation of genes that are components in G1 and S phase checkpoint signalling such 
as CDK1 and CDK4.  The transcriptional inhibition of CDK1 and CDK4 has been 
suggested to arrest the cell cycle and allow DNA repair to occur, which may trigger 
apoptosis when cellular damage cannot be properly repaired in transformed cells 80.   
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The results also showed a robust increase in CDKN1A (also known as p21CIP1, hereinafter 
referred to as p21WAF1) expression, which was more noticeable in the MS-275-treated cells 
compared to the SAHA.  p21WAF1 is a CDK inhibitor with a high potential to arrest cell 
cycle progression at G1 phase by inhibiting the activity of the CDKs.  It is also involved 
in regulating transcription, apoptosis, DNA repair, and cell motility 238.  In several tumours, 
the downregulation of p21WAF1 was connected with tumour cell growth where its 
upregulated expression was associated with anticancer regulation 238.  It has been reported 
that p21WAF1 inhibits the DNA replication by binding to the proliferating cell nuclear 
antigen (PCNA) which inhibits the cell cycle and allow the DNA repair 244.  The increase 
in the p21WAF1 expression has been reported to inhibit caspase-induced apoptosis by 
binding to caspase-2 and caspase-3 in the cytoplasm and block their activity 220, 238.  
However, it has been suggested that p21WAF1-arrested cells may undergo apoptosis 
following the activation of proapoptotic genes in a p53-dependent or -independent manner 
244. 
The exact regulation of p21WAF1 induction is not well known however, it has been 
suggested to occur though the p53 depletion in wild-type expressing tumour cells 83.  
Despite the expression of a non-functional form of p53 protein in the Daoy cells, the 
treatment with HDACis in this study resulted in upregulated p21WAF1 expression which 
may indicate the existence of an alternative regulation and it warrant further investigation 
83, 113.   
Treating the normal human neurons with HDACis also caused a considerable effect on 
genes transcription resulted in up or downregulation of several subsets of genes however, 
many of the identified pathways were statistically insignificant.  The effect of SAHA and 
MS-275 on the neurons cell cycle genes was slightly different and the MS-275-exposed 
cells showed more gene downregulation compared to SAHA.   The GSEA results of the 
treated normal human neurons showed a negative phenotype of several cellular pathways 
compared to the untreated neurons.  For instance, the negative phenotype of the cell cycle 
and Myc pathways was common in all treated neurons whereas the mTORC1 positive 
phenotype was only observed in the untreated cortex.1 neurons.  The most noticeable 
difference in the cell cycle-regulating genes between the Daoy and the neurons was the 
absence of the CDK genes expression in the neurons.   Where the expression of p21WAF1 
was only detected in the Corext.2 neurons treated with MS-275.  The transcriptional 
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changes induced by the inhibitors suggest their effect in modulating gene transcription in 
normal cells which may impair the cells ability to maintain their biological function and 
consequently could lead several of downstream implications.  
Comparing the cell cycle genes between the Daoy and the neurons identified 19 shared 
genes however, the annotation analysis of these genes showed that these genes were 
involved in general biological functions including histone and tubulin regulation with 
eleven genes annotated as ribosomal genes.   
Collectively, the cell cycle gene expression results showed the ability of the HDACis to 
downregulate the CDK genes and upregulate the p21WAF1 gene expression which could 
support the stimulation of the apoptosis pathway.  In contrast, the expression of the CDK 
genes was not detected in the untreated and treated neurons.  This may suggest that the 
anticancer effect of HDACis could depend on CDK and p21WAF1 in tumour cells.   
Whereas, the regulation of the cell cycle in normal cells is less dynamic hence the effect 
of HDACis on the transcripts did not lead to the activation of death mechanisms.  
Collectively, these findings may demonstrate how tumour cells sustain their growth and 
suggest CDKs and p21WAF1 as therapeutic targets.   
 HDACis Disrupted the Expression of Myc Pathway  
Further the results of the untreated Daoy cells showed a statistically significant up or 
downregulation of a large number of genes that were associated with Myc pathway.  Myc 
expression has been reported in many cancers and in medulloblastoma.  However, the 
expression of Myc genes is significantly variable across the medulloblastoma subgroups 
239.   Treating with SAHA and MS-275 resulted in a significant disruption in the expression 
of a subset of genes that were identified as Myc components pathway.  Myc regulation has 
critical part in several aspects of cancer biology, including proliferation, migration and 
treatment response where, treating with HDACis has been suggested to suppress Myc-
oncogenic function.  Myc has been suggested to induce the proliferation activity through 
interacting with a number of HDACs including HDAC1, HDAC2 and HDAC3 83.  
Accordingly, the expression of HDACs in tumour cells has been reported to contribute in 
Myc-driven proliferation.  Tumours with elevated expression of Myc and HDAC2 have 
been reported to show higher sensitivity to class I HDACis 54.  Inhibition of HDAC2 in 
medulloblastoma Group3 has been reported to reduce the stabilization of Myc protein and 
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induce cell death 54.  Myc-induced apoptosis has been reported to occur through indirect 
downregulating the antiapoptotic proteins such as Bcl-2 and Bcl-xL, and through p53 -
dependent and independent manners 245.   
In this study, exposing the neurons to SAHA and MS-275 HDACis resulted in varying 
response across the different neuron types.  The GSEA results showed a negative 
phenotype of Myc in all the different types of the neurons apart from the MS-275-treated 
Cortex.1 which displayed a positive phenotype. However, the Myc pathway was 
statistically insignificant in all treatment conditions.   
The expression of Myc in normal cells has been suggested as the developmental signals as 
Myc works as a factor to integrate the growth signals to support cell growth 240.  Where, 
the expression of Myc in postmitotic neurons has been suggested to drive cell cycle re-
entry and emerged as a potential pathogenic factor which could lead to neuronal 
degeneration and death 246.  The results of this study may indicate the deactivation of Myc 
pathway however, the conclusion cannot build on the current results.     
 HDACi Disrupted the Expression of TNFα signalling via NFκB Pathway 
In this study, the GSEA results of the untreated Daoy cells showed a statistically significant 
negative phenotype of TNFα signalling via NFκB pathway.   Tumour necrosis factor (TNF) 
is a cytokine that binds to TNF cell surface receptors receptor (TNFR) 1 and TNFR2 and 
upon its ligation it activates either of three pathways; the Nuclear Factor kappa-light-chain-
Enhancer of Activated B Cells (NFκB) pathway, MAPK pathways, or cell death pathway 
247.  TNF has a complicated role in cancer as it stimulates proliferation, migration, and 
angiogenesis in cancers that are resistant to TNF-induced cytotoxicity 247.  TNF has also 
been suggested to induce cell death through the TNFR1 which is universally expressed on 
most cell types and has a direct role in NF-κB activation.  The ligation of TNF with 
TNFR1 results in recruitment of TNFR1-associated death domain protein (TRADD) which 
works on promoting apoptosis when binds to caspase-8 in presence of Fas Associated Via 
Death Domain (FADD) 247.  It could also promote survival through TNF Receptor 
Associated Factor 2 (TRAF2) via JNK-dependent kinase cascade 248.   
The expression results of the Daoy untreated cells showed the downregulation of CCL2, 
CEBPD (stimulates the cancer cell proliferation through E2F1), NFKB Inhibitor Alpha 
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(NFKBIA) which collectively promote; the cell growth, reduce the inflammatory 
processes, and inhibit apoptosis 249, 250, 251.  The results also showed the downregulation of 
INHBA, CDKN1A, and PHLDA2 which were suggested to work as tumour suppressor 
genes 252. 
The GSEA results of SAHA- and MS-275-treated Daoy cells showed the positive 
phenotype of TNFα signalling via NFκB pathway (SAHA FDR q-val=0.932, and MS-275 
FDR q-val=0.002).  The gene expression results showed the inverse expression of CCL2, 
CEBPD, NFKBIA, INHBA, CDKN1A, and PHLDA2 and several of other cytokine genes 
that are components of TNFα signalling via NFκB pathway such as TNFSF9, IER2 and 
MAP2K3.  It is unclear whether HDACis have a direct effect on cytokine gene regulation 
or the change is caused due to a secondary effect of HDACis.  Similarly, it is not known if 
the expression of NF-κB is directly regulated by acetylation 253. Additionally, it is not 
well known how TNF stimulates apoptosis especially and it activates NF-κB which has 
a significant contribution in supporting the cell proliferation, cell differentiation, and 
cell death as well.  However, it has been suggested that TNF may induce cell death 
through activating Caspase 3 247.  In several studies, combining HDACis treatment with 
NFκB with proteasome inhibitors enhanced the tumour cell death of Hodgkin lymphoma 
cells and glioblastomas and has been suggested to limit the toxicity associated with 
using either drugs 254.   
 The Expression of HDAC and HAT Genes 
It has been commonly assumed that the imbalance in the HDACs and HATs expression is 
the causative of increasing the deacetylation level in various cancers.  Whereas, treating 
with HDACis has been suggested to reverse the epigenetic states which supresses the cell 
growth and stimulates apoptosis 255.  In this study, the scNGS data were used to explore 
the expression of HDAC and HAT enzymes before and after the HDACis treatment.  The 
results of the Daoy cells showed an increase in the HDAC1 and HDAC2 level in the 
untreated and treated cells.  Where treating with SAHA resulted in a significant increase 
in HDAC3.   
The upregulated HDACs expression has been reported in various types of neuronal and 
non-neuronal cancers however, the expression is vary greatly between tumours 146.  The 
expression is also inversely correlated with the overall survival rate and significantly 
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associated with active tumour progression and poor prognosis  146, 256, 257.  In brain tumours, 
HDACs have been found to play a key role in sustaining cell growth.  For example, in 
glioblastoma the expression of HDAC1, HDAC3 and HDAC6 has been reported to be 
significantly higher than non-plastic brain tissue, where the expression of HDAC9 is 
frequently reported with prognostically poor glioblastoma multiforme patients 257.  
Elevated HDAC2 has been reported in medulloblastoma SHH, Group 3 and Group 4 
subgroups and it was also connected with poor prognosis 54.  The expression of HDAC5, 
HDAC9, and SIRT1 was also associated with the increasing in medulloblastoma tumour 
progression and was suggested as drug targets 45.  Blocking the expression of HDAC2 or 
HDAC3 has been found to inhibit the tumour growth and induce apoptosis which may 
suggest their oncogenic properties 147, 193.  Several studies have reported the decrease in 
HDAC3 expression when treating with HDACis however, in this study treating the Daoy 
cells with SAHA resulted in upregulating the expression of HDAC3 147, 193.  It is not known 
why SAHA increased HDAC3 expression however, it has been reported that treating with 
SAHA often results in reducing the expression of the HDAC enzymes at the protein level 
where the mRNA level remained unchanged 147.  Similarly, a previous clinical trial 
reported that the expression of HDACs remained unchanged in pre- and post-treatment 
with SAHA 258.  This may suggest the ability of HDACis to induce their effect on the 
protein level only where they do not affect the active transcription of the HDAC enzyme.  
The results also showed an upregulation in HDAC2 expression in a small subset of the 
untreated and treated neurons with a noticeable increase in the MS-275-treated cortex 
neurons.  The elevated expression of HDAC2 in neurons has been reported to have a 
critical role in regulating neuronal cell differentiation, and its expression has been reported 
in mature neurons 102.  The current evidence of this study cannot completely explain the 
effects of HDACis on neurons and if it will lead to a cytotoxic effect.  The role of HDACs 
in regulating neuronal survival or death is intricate and involved several regulations.  For 
example, the activity of HDAC1, HDAC4, HDAC5 or HDAC6 has been reported to 
contribute in inducing neurons death 259, 260.  Whereas, the expression of HDAC2, HDAC3, 
HDAC7 or SIRT1 has been suggested to promote neuronal survival 260, 261.   
The expression results of this study also showed an increase in SIRT7 expression in the 
SAHA- and MS-275-treated Daoy cells.  SIRT7 is a deacetylase enzyme that has a high 
involvement in various cellular processes in normal cells.  In cancer cells, SIRT7 has been 
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reported to have an oncogenic property 262.  Overexpression of SIRT7 has been found to 
protect tumour cell against DNA damage and support the tumour cell survival 262.  It is not 
clear why treating with HDACi resulted in upregulating SIRT7 expression.  However, it 
has been reported that treating with HDACis, in particular SAHA, does not significantly 
inhibit SIRT7 enzymatic activity even at high concentration of SAHA 263.  This is 
consistent with the ability of SAHA to inhibit Class I and II HDACs enzymatic activity 
and not class III HDACs.  
The results also showed a slight decrease in the α-tubulin acetyltransferase 1 (ATAT1) 
expression in the MS-275-treated Cortex.2 and Striatum neurons.  ATAT1 is microtubule 
acetyltransferase and play a major part in destabilizing the microtubules and accelerating 
their dynamic 264.  The relation between the HDACis treatment and ATAT1 expression has 
not been studied previously, and the decrease of ATAT1 in the MS-275-treated Cortex.2 
and Striatum could result in decreasing the microtubule dynamics and conformation 265.  
Several of previous studies have examined the roles of HAT members in controlling neuron 
fate and they concluded that the increase in HAT activity is often associated with apoptosis 
265, 266. For example, enhancing EP300 or CREBBP HAT activity has been reported to 
promote the apoptosis of dopaminergic neurons and cerebellar granule neurons, 
respectively 265, 266. 
Collectively, the results of HDACs and HATs expression showed the upregulated 
expression of HDAC1 and HDAC2 in the Daoy medulloblastoma cells which may suggest 
their direct role in increasing the deacetylation level and proposed them as a potential 
treatment target.  The results also showed an increase in HDAC3 mRNA expression in the 
SAHA-treated cells which may suggest the ability of HDACis to induce their effect on the 
HDAC protein but not the transcriptional levels.  Hence, the efficiency of HDACis 
treatment should be monitored on the HDAC protein level.  Incomplete HDACis treatment 
may result in restoring the deacetylation back to its upregulated level. However, the critical 
effect of HDACis on neuronal cell survival needs further exploration.   
 The limitation of the scNGS  
In this study, the scNGS analysis showed great advantages as it allowed me to; measure 
the transcriptome at single cell level, study cell-to-cell heterogeneity, assign cells into their 
cell cycle phases, and identify the highly variable genes that drive the variability across a 
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population of cells.  However, there were some technical and biological factors that may 
impacted the quality of the data and the finding interpretations.  In additional to the 
suboptimal sequencing saturation and sequencing depth that were addressed previously, 
the used 10x Chromium kit (V2) is another factor that could have an effect in reducing the 
sequencing depth.  The efficiency of this version in capturing and reverse-transcribing 
mRNA to cDNA is not significantly high and it displayed a high frequency of not detection 
transcripts with low abundance 121.  Recently, the 10x Genomics has released a new version 
(Chromium V3’) which showed a significant increase in the detection level and more 
transcripts per cell.   
In the biological side, the scNGS analysis showed several limitations.  For example, it does 
not measure the expression of non-coding RNA such as microRNA and Long non-coding 
RNA .  Thus, the number of the expressed genes are lower compared to RNA-seq bulk 
analysis.  The analysis is also subject to cell-size variation, cell cycle phase, transcriptional 
bursting and temporal fluctuations 121.  The transcriptional bursting is a state where the 
transcription from DNA to RNA occur in random fluctuating bursts or pulses followed by 
variable periods of inactivity.  The transcriptional burst often affects the total transcript 
number which it could impact the number of detected genes per cell 121, 267.   
The ability of scNGS to identify most of the potential therapeutic targets is also limited by 
abundance of transcripts.  The abundance of transcripts is controlled by the functional 
category to the gene and the quantity that is needed for producing certain proteins.   For 
example, the expression of genes with high abundance such as collagens and matrix 
metalloproteinases are more redundant in scNGS, where not all low-abundance genes such 
as cytokines are detectable.  Also, some proteins work in small intracellular compartment 
therefore, their transcriptome often less than the genes that are involved in major cellular 
regulations.  This often leads to increase the frequency of dropout events (i.e. none of gene-
transcripts are captured) 227.  At the statistical level, the heterogeneity of the analysed cells 
is often result in a negative binomial or multimodal distribution (data are not normally 
distributed) and this may affect the statistical tests that assume the normal distribution of 
the data 268.   Hence, the findings of the scNGS should be interpreted with caution.   
Finally, pathway or network analyses were performed to gain biological insight into the 
underlying molecular regulation as it could reduce the complexity and help in explain the 
findings however, the results of this analysis did not show high representation of the genes 
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in the identified pathways.  The main limitation in this analysis was due to the suboptimal 
sequencing depth of the current transcriptomic data which impacted the detection of genes 
and affected the subsequent bioinformatic analysis.  The findings representation could be 
improved by using commercial systems such as Ingenuity Pathway Analysis and 
iPathwayGuide software.
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5 General Discussion  
5.1 Summary of the Research Aims and Methodology  
In this thesis, I have investigated the contribution of REST, HDACs, and HDACis in 
medulloblastoma tumorigenesis and treatment response.  To study the contribution of 
REST, I used CRISPR/Cas9 system to knockout REST expression in the Daoy 
medulloblastoma cells, one of the most frequently used cell lines in medulloblastoma 
studies 43.  In addition, and as CRISPR/Cas9 has not been used previously to modulate 
REST expression, I used the shRNA knockdown system to confirm the knockout findings.  
I examined the effect of blocking REST expression on the cell growth, cell-cycle, and cell 
migration ability, and I explored if the HDACis induce their action through the HDACs 
recruited in REST repression complexes.   
Further, I investigated the anticancer molecular regulation of SAHA and MS-275 using the 
Daoy medulloblastoma cells, and I explored their effect on normal human neurons.  I 
carried out the analysis at the transcriptome level using the single cell next generation 
sequencing analysis and I applied the PCA to compare the gene expression of the 
untreated- and treated-Daoy and neurons cells in order to explore the molecular regulation 
of HDACis. 
5.2 Knockout REST did not Induce Medulloblastoma Cell Death   
This study has found that the expression of REST is elevated in the medulloblastoma 
subgroups compared to normal cerebellum and its expression has important role in 
regulating the transcription of some RE1-containing genes.  Blocking REST expression 
resulted in increasing the cell accumulation in G1 phase and decreasing the cells migration 
ability however, it did not reduce the Daoy cells proliferation or stimulate apoptosis.  The 
results also displayed the high sensitivity of the Daoy cells to the used HDACis yet, the 
HDAC enzymes in REST repression complexes were not the primary elements for the 
inhibitors to induce their action.   
Collectively, these data suggest that REST is not a main regulator of the Daoy cell growth, 
and the tumour may depend on other factors to sustain its self-renewal potential.  Also, the 
induction of the Daoy medulloblastoma cell death by HDAC inhibitors is not dependent 
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on, or affected by, REST expression status rather, they may work through other HDAC 
complexes.   
This conclusion does not support what it has been proposed previously to use REST 
expression as a clinical marker for HDACis treatment efficiency in medulloblastoma 14.  
These findings could suggest the lack of the tumour cell the primary components required 
for employing the differentiation factors.  In addition, it demonstrated the ability of the 
tumour regulation to avoid progression in the maturation stages despite the expression of 
the neuronal genes.   
These conclusions are in congruent with some of the latest research findings.  For example, 
Das et al., (2013) used shRNA to knockdown REST expression in the Daoy cells and they 
found that loss of REST resulted in increasing the accumulation in G1 phase with a 
concomitant decrease in the S phase however, it did not lead to cellular apoptosis.  Also, 
they reported that loss of REST expression led to; a decrease in the expression of MYCN 
(a proliferative marker), and an increase in the expression of certain antiproliferation 
markers such as p27 and UPS37 52.  Similarly, Zhang et al., (2016) modulated REST 
expression in glioblastoma U-87 and U-251 cell lines using the shRNA knockdown system 
and they found that knocking down REST expression resulted in inhibiting the 
glioblastoma cells migration yet, it did not stimulate cell death or reduce tumour size 12.  
In addition, several of gene expression analysis studies were performed using primary 
human medulloblastoma however, the elevated REST expression was not proposed as a 
factor in sustaining the cell growth 38, 39, 41, 44.   
One important part of my work was using both of the knockout and knockdown approaches 
in order to examine the contribution of REST and to validate the findings.  The knockout 
approach resulted in completely blockage of REST expression hence, it limited the effect 
of the partial expression of REST in the shRNA knockdown approach which can induce a 
repression on different subsets of genes and affect with results interpretation.  This aspect 
could clearly indicate the importance of using a correct experimental tool to reach more 
evident conclusion.   
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5.3 HDACis Effected the Cell Cycle Regulation in Tumour and Normal 
Cells 
The findings of this study showed that treating the tumour cells with HDACis resulted in 
a considerable decrease in the number of the expressed genes compared to the untreated 
cells.  The treatment also resulted in activating the TNFα signalling via NFκB pathway and 
deactivating the cell cycle and Myc pathways.   
The expression of several genes that are known by their significant function in cells faith 
such as CDKN1A, CCNB1, CDC20, CCNB2, CCL2, CXCL1, NPM1, CCND1, AREG, 
TOP2A and BIRC3 was also affected by the treatment (Table 10).  The dynamic changes 
in gene expression pattern in a response to HDACis may provide important insight into the 
cellular response. 
The significant effect of SAHA and MS-275 on the cell cycle genes was clearly 
demonstrated on reducing the expression of most cell cycle regulations which resulted in 
delaying the progression in the cell cycle and increasing the accumulation in cell cycle 
phases, as it was demonstrated in the cell cycle analysis.  These data therefore strongly 
suggest the ability of HDACis to exert an inhibitory effect on the cell cycle in cancer cells 
which could be one of the anticancer regulations.  
Exposing the normal cell to HDACis also caused considerable changes on the 
transcriptome level.  These changes were diverse between the untreated and treated 
neurons and across the different neuron types.  For example, HDACis resulted in 
downregulating the expression of the genes that were annotated as regulator for; cell cycle, 
translation, ATPase activity, and the nonsense-mediated decay of mRNAs.  The data also 
show a considerable cell-to-cell variation in total transcript level.  The difference in the 
cell response to SAHA and MS-275 was observed in ability of each inhibitor to regulate 
different sets of genes that are components in the metabolic activity, cellular process, and 
cell-cell communication mechanisms.  These changes are potentially harmful on normal 
cell and may lead to impair their normal biological function. 
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Table 10: Gene information 
Gene Abbreviation Function 
Cyclin-Dependent 
Kinase Inhibitor 1A 
CDKN1A 
Inhibits cellular proliferation in response to DNA 
damage 269 
Cyclin B1 CCNB1 
Essential for controlling the cell cycle at the G2/M 
(mitosis) transition 270 
Cell division cycle 
20 
CDC20 
Interacts with several proteins at multiple points in the 
cell cycle 271 
Cyclin B2 CCNB2 
Essential for controlling the cell cycle at the G2/M 
(mitosis) transition 272 
C-C motif 
chemokine ligand 2 
CCL2 
A chemokine and it stimulates host anti-tumour 
activities 272 
C-X-C motif 
chemokine ligand 1 
CXCL1 
Aberrant expression of this protein is associated with 
the growth and progression of certain tumours 273 
Cyclin D1 CCND1 
Regulator of progression through G1 phase during the 
cell cycle 274 
Amphiregulin AREG Inhibits the growth of various types of cancers 275 
Topoisomerase 
(DNA) II Alpha 
TOP2A 
Encodes a DNA topoisomerase which controls the 
topologic states of DNA during transcription 276 
Baculoviral IAP 
Repeat Containing 
BIRC3 
Inhibits apoptosis by binding to tumour necrosis factor 
receptor-associated factors TRAF1 and TRAF2 277 
Nucleophosmin NPM1 
In complex with MYC, NPM1 enhances the 
transcription of MYC target genes and tumour 
suppressors p53/TP53 278 
Four studies in the literature (Chiba et al., 2004, bolden et al., 2013, Halsall et al., 2015, 
Markozashvili et al., 2016) have compared the effect of HDACis on normal and tumour 
cells in order to understand why tumour cells are more sensitive and how normal cells 
tolerate the hyperacetylation effect 279, 105, 280, 281.  The studies profiled the gene expression 
using microarray analysis after treating the normal and their tumour counterpart cells with 
HDACis.  The drug concentrations, exposure time and the cell lines were different between 
the studies (Table 11).  The rationale behind choosing the used concentrations and time 
was not built on an experimental approach, apart from Bolden et al., study which used the 
CDKN1A (cell cycle progression) gene expression to select for the treatment duration 
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length 105.  The findings of the microarray gene expression profiling were different between 
the studies and revealed different cellular mechanisms (Table 11).   
Only Halsall et al., study has claimed that the molecular regulations which protect normal 
cells from the hyperacetylation effect is through down-regulation of the expression of HAT 
enzymes which in minimized protein hyperacetylation, slowed the growth and re-balanced 
the gene expression 280.  However, in this study there were several sources of uncertainty.  
For example, the immunoblotting analysis of global histone showed an increase in the 
acetylation level in the treated cells during the first 120 minutes and this contradicts what 
they claimed about the HAT downregulation.   
Typically, HDACis induce an increase in the acetylation level until the drug loses its 
pharmacokinetic activity or is washed out.  The study by Bolden et al., showed a sustained 
increase throughout the treatment with SAHA (25µM) for 32 hours .  Similarly, the 
increase in the acetylation was reported in several of other studies that used non-disease 
cell lines 106, 107, 108.  The study by Halsall et al. did not take into account comparing the 
decrease of HAT genes in the normal cells to the transformed cells as the expression of 
HAT components could decrease in transformed cells, as well 280.   
Another limitation in the Halsall et al., study is that the fold-change of the HAT genes was 
small and only measured by microarray methodology.  Inspecting the HAT expression 
results at GEO (GSE65297) showed that the changes in the HAT gene expression also 
varies between the biological replicates and some values could be considered as outliers 
when compared to the other replicates.  It is well known that the sensitivity of microarrays 
is affected by several factors including the amount of the mRNA and the hybridization.  
Yet, these limitations are irrelevant if the microarray was used for screening first and then 
the expression results should be verified independently.  Real-time PCR is the method of 
choice for most researchers especially when the fold change in gene expression is low.  
However, the study did not verify the expression of the KAT component genes despite it 
was the main question of the study.  The Halsall et al., study also included clustering of the 
genes according to their expression changes over time.  However, the criteria of selection 
was very limiting as they used an algorithm that allowed selection of very few groups with 
a very small number of genes 280.  This approach may have an advantage of showing very 
limited subgroup of genes however, it eliminates large groups of genes that may have 
similar cellular mechanisms. 
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Table 11: Summary of the four studies 
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Collectively, the four studies were designed to understand the molecular regulation of 
HDACis in tumour and normal cells yet, each study came to different conclusions which 
may reflect the variation between the cell models used and the experimental approaches.  
The findings of these studies have been inadequate to demonstrate the cellular mechanism 
that reduce the hyperacetylation effect of HDACis.  There are several factors that possibly 
contributed in limiting the research outcomes of these studies.  For example, the cultured 
cells are often in different phases of the cell cycle and each phase has different gene 
expression.  Hence, the bulk analysis results often present the average of the variations in 
gene expression of all the phases which could hide many cellular mechanisms and show 
some variations between biological replicates.  
One of the objectives of this study was addressing the controversy about which HDACis 
treatment regime is better: treating with a selective HDACis (e.g. MS-275 (Entinostat)) or 
a pan-HDACis (e.g. SAHA (Vorinostat)).  The data of this study did not allow to further 
explore this debate due to the low sequencing depth of the Daoy cells which may 
underrepresent some important regulations.  No convincing experimental or clinical 
evidence is currently available to support using either type of HDACis.  However, evidence 
from some clinical trials suggests that monotherapy of selective blocking of a HDAC or 
several HDACs might not be sufficient in achieving complete cell death 254, 282, 283.   
Despite the promising results in some of the pre-clinical studies, most HDACis used in 
clinical trials failed to achieve the treatment goals as single agents 254.  Monotherapy 
treatment using HDACis have shown varying antitumor activity however, with some solid 
tumours they did not show a favourable outcome.  In recent years, it has become 
abundantly obvious that HDACis are unlikely to make a substantial effect when used alone 
hence, a rational combination of therapy is largely important to induce more effective 
treatment.  In clinical trials, many of the combination therapies that were performed using 
cytotoxic chemotherapy and hypomethylating drugs have not met the regulatory approval 
yet or been adopted in clinical use 80.   
Combination treatment with DNA damaging agents or ionizing radiation has been reported 
to increase the DNA double-strand breaks and delay the tumour growth 79, 100.   SAHA 
combination with DNA damaging agent has been reported to enhance the treatment 
through upregulating the expression of Bax (a proapoptotic gene) and downregulating 
RD51, RD55, Ku70, and ku86 expression which results in suppression of the DNA repair 
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mediated by homologous recombination 79, 284.  Also, in a number of in vitro studies SAHA 
combination treatment with ionizing radiation and chemotherapy have been found to 
enhance the radio-sensitivity and promote apoptosis 79.  Combination therapy with agent 
that interfere with cell cycle checkpoints, mitosis, antiapoptotic proteins, or proteasome 
activity has also shown an encouraging preclinical effectiveness 79, 100.  Hopefully, the 
theoretical bases of HDACis in combination treatment will successfully be translated into 
more effective therapies to treat cancers in the near future.  This will offer an advantage 
over the current conventional treatment which exhibit adverse side effect on normal cells.   
The findings of this study have contributed in improving our understanding about the 
REST involvement in cancer regulation and suggested new conclusions about the 
contribution of REST expression in brain tumours.  Also, it showed that the cancer cell 
growth does not mainly depend on REST expression otherwise, the treatment of cancer 
would become more approachable with modulating a single factor.  Investigating the 
HDACis anticancer regulation in this study has provided a deeper understanding about the 
ability of HDACis to induce their effects across multiple pathways including the cell cycle, 
TNFα signalling via NFκB pathway, Myc pathways, and inhibiting cell migration.  Despite 
the relatively high tolerance of normal cell to HDACis however, this study demonstrated 
the ability of HDACis to cause considerable changes on the transcriptome level in normal 
cells.  This study provides additional evidence with respect to the effect of HDACis on 
gene regulation in health and disease. 
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5.4 Future Work 
The work presented in this thesis has potential to lead to deeper investigations of several 
molecular regulations however, they have been left for the future due to lack of time.  There 
are number of research ideas that should be considered for future works: 
The off-target effect of CRISPR/Cas9 in the KO cell clone was not examined in this study 
due to the high cost of the NGS analysis.  It is highly recommended to sequence the KO 
cell clone genome.  
The KO and KD cell clones showed a significant increase in the expression of the measured 
RE1 genes however, it has not been confirmed if the increase is caused as a results of direct 
REST modulation or due to a downstream effect.  In future work, it is highly recommended 
to re-induce the expression of REST in order to approve the direct REST effect.  
The Daoy cell line contains a subpopulation of CD133+ and CD133- cells.  In this study, 
the KO and KD cell clones were established from a single cell growth yet, it is not known 
if the cells expressing the CD133 marker.  It is highly recommended to screen the cell 
marker of the KO and KD cells using the FACS analysis.   
The findings of this study suggested that the expression of REST in the Daoy 
medulloblastoma cell line does not have a significant effect on cell growth and the cell 
continued to grow even in the absence of REST expression.  However, this conclusion was 
built on one experimental cell model which represents the SHH medulloblastoma subtype.  
It is not completely known if the other cell models would show the same cell response to 
REST modulation.  Also, it is not known if other cell lines are sensitivity to HDACis. 
The findings of this study also showed that the HDACis induced Daoy cell death 
independent of DNA fragmentation.  However, it is not known if this event was due to the 
dysregulation of the DNA fragmentation machinery in the Daoy cell or it was due to the 
ability of HDACis to induce a caspase-independent cell death.   
Due to the low sequencing depth of the scNGS data, the results did not help in exploring 
the molecular regulation of the HDACis in tumour and normal cells.  Future analysis 
should consider using high depth scNGS data in order to avoid the underrepresentation of 
genes.  In additional to the gene expression analysis, the proteomic analysis using mass 
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spectrometry analysis can be used to characterize the affinity and selectivity of HDACis 
toward HDACs multiprotein complexes. Incorporating the proteomic and the genomic 
analysis can help in systematically and confidently determine the HDACis to HDACs 
interaction specificity.  
 As the effect of HDACis on gene expression could be a direct effect of increasing the 
promoter acetylation, or it could be due to a downstream effect, the chromatin 
immunoprecipitation followed by high-throughput DNA sequencing can be used in future 
analysis to determine the entire subset of genes targeted by HDACis which could help in 
clarifying their mechanism of action and assess in predicting inhibitor efficacy.  
The results of treating the tumour cells with HDACis suggested the activation of TNFα 
signalling via NFκB pathway.  Whereas this signalling pathway is well investigated 
however, its contribution in HDACis anticancer effect remain a topic of investigation. 
In literature, the regulation and function of HDACis in nonhistone protein compared with 
HDACs are still understudied, and the involvement of nonhistone in the HDACis 
anticancer regulation has not been well investigated.  In order to gain more comprehensive 
understanding about the HDACis anticancer effect, the involvement of nonhistone proteins 
should be consider in future work.     
The question of which treatment regime is better: the selective HDACis or the pan-
HDACis remained unaddressed.  Profiling the effect of HDACis at the transcriptome and 
proteome level may help in addressing this question.    
Although the acetylation of histone tails has an effect on the stability of an individual 
nucleosome and the chromatin fibre however, it is not known if the cell death is due to the 
ability of HDACis to impair the DNA packaging regulation during mitosis.
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5.5 Final Conclusion  
In this thesis, I explored the contribution of REST, HDAC, and HDACis in 
medulloblastoma using CRISPR/Cas9 system and scNGS analysis.  The experimental 
evidence of this thesis suggests the low importance of REST expression in regulating 
tumour cell growth or inducing cell death.  It revealed also the ability of HDACis to induce 
their anticancer effect independent of HDACs recruited in REST repression.  The data 
presented in this research demonstrated the ability of HDACis to alter gene expression and 
induce a considerable effect on the cell cycle, Myc and TNFα via NFκB pathways.  The 
central theme underlying the synergism between these pathways is their ability to inhibit 
the cell cycle regulation in tumour cells.  Whatever the mechanisms involved, the data of 
my research suggest that the use of HDACis should carefully be revised even with their 
minimal side-effect in clinical trials.  
Identifying the regulatory network is not the final outcome of a study rather, it is an 
intermediate stage connecting the genotype and the epigenotype to the global cell 
behaviours.  Better understanding of the molecular networks of HDACs and the underlying 
anticancer mechanisms of HDACis and their off-target effects will certainly help in 
developing more rational HDACis treatment strategies.  The research of HDACis has 
revealed several of significant findings that collectively have improved our understanding 
in cancer tumorigenesis and will have major contribution in clinical treatment.    
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7 Appendices  
Appendix 1: Partial list of non-histone protein substrates of HDACs 
This table was adapted from60. 
Effect of 
acetylation 
Protein 
Intracellular 
function 
HDAC 
implicated 
Increased 
DNA-binding 
affinity 
p53 
Tumour 
suppressor 
 
SRY  
sex-determining region Y 
Transcription 
factor 
HDAC3 
STAT3 
signal transducer and activator of 
transcription 
Signalling 
mediator 
HDAC1, 2, 3 
GATA1 
Transcription 
factor 
HDAC3, 4, 5 
GATA2 
Transcription 
factor 
HDAC3, 5 
E2F1 
Transcription 
factor 
HDAC1 
MyoD 
Transcription 
factor 
HDAC1 
Decreased 
DNA-binding 
affinity 
YY1 
 transcriptional repressor protein 
Transcription 
factor 
HDAC1, 2, 3 
HMG-A1  
High Mobility Group 
Nuclear factor  
HMG-N2 Nuclear factor  
p65 
Transcription 
factor 
 
Increased 
transcriptional 
activation 
p53 
Tumour 
suppressor 
 
HMG-A1 Nuclear factor  
STAT3 
Signalling 
mediator 
HDAC1, 2, 3 
AR Nuclear receptor HDAC1 
ERα (basal) 
Steroid hormone 
receptors 
HDAC1 
GATA1  
GATA-binding factor 
Transcription 
factor 
HDAC3, 4, 5 
GATA2 
Transcription 
factor 
HDAC3, 5 
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GATA3 
Transcription 
factor 
 
EKLF 
Transcription 
factor 
HDAC1 
MyoD 
 myogenic differentiation 
Transcription 
factor 
HDAC1 
E2F1 
Transcription 
factor 
HDAC1 
RUNX3  
Runt-related transcription factor 
Tumour 
suppressor 
HDAC1, 5 
Decreased 
transcriptional 
activation 
ERα (ligand-dependent) 
Steroid hormone 
receptors 
HDAC1 
HIF1α  
Hypoxia-inducible factor 
Transcription 
factor 
 
Increased 
protein 
stability 
p53 
Tumour 
suppressor 
HDAC1 
c-MYC Oncoprotein  
AR Nuclear receptor HDAC1 
ERα  
Estrogen receptor 
Steroid hormone 
receptors 
HDAC1 
E2F1  
E2F transcription factor 
Transcription 
factor 
HDAC1 
Smad7 
Signalling 
mediator 
HDAC1, 3 
RUNX3 
Tumour 
suppressor 
HDAC1, 5 
Decreased 
protein 
stability 
HIF1α 
Transcription 
factor 
 
Promotes 
protein–
protein 
interaction 
STAT3 
Signalling 
mediator 
HDAC1, 2, 3 
AR 
 androgen receptor 
Nuclear receptor HDAC1 
EKLF 
 Erythroid Kruppel-like factor 
Transcription 
factor 
HDAC1 
Importin α 
Nuclear import 
factors 
 
Disrupts 
protein–
protein 
interaction 
NF-κB 
 nuclear factor kappa-B 
Transcription 
factor 
 
Ku70  
ATP-dependent DNA helicase 
DNA-repair 
protein 
 
                       Hsp90 
              heat-shock protein  
Chaperone HDAC6 
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Appendix 2: The chemical information about the used HDACis  
SAHA 
Formal Name N1-hydroxy-N8-phenyl-octanediamide 
Synonyms Suberoylanilide Hydroxamic Acid (Vorinostat) 
Molecular Formula C14H20N2O3 
Formula Weight 264.3 
MS-275 
Formal Name 
N-[[4-[[(2-aminophenyl) amino]carbonyl]phenyl] 
methyl]-3-pyridinylmethyl ester, carbamic acid 
Synonyms Entinostat, SNDX 275 
Molecular Formula C21H20N4O3 
Formula Weight 376.4 
MI-192 
Formal Name 
N-(2-aminophenyl)-4-[(3,4-dihydro-4-methylene-1-
oxo-2(1H)-isoquinolinyl) methyl]-benzamide 
Synonyms Has no other names  
Molecular Formula C24H21N3O2 
Formula Weight 383.4 
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122 Apicidin 
Formal Name 
cyclo[(2S)-2-amino-8-oxodecanoyl-1-methoxy-L-
tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl] 
Synonyms OSI 2040 
Molecular Formula C34H49N5O6 
Formula Weight 623.8 
Valproic Acid (sodium salt) 
Formal Name 2-propyl-pentanoic acid, monosodium salt 
Synonyms 
2-Propylvaleric Acid                                        
Sodium Valproate 
Molecular Formula C8H15O2 • Na 
Formula Weight 166.2 
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RNA-seq approach four time-points were suggested to generate snapshots of the 
treatment response (1st Untreated, 2nd At the start of expression of cell apoptosis, 3rd 
A middle point: the start of the apoptosis & apoptosis, 4th When cell death >40%).  
With the second time point, I suggested to use an apoptotic marker that could indicate 
the initiation of the apoptosis mechanism.  After a thorough search for an appropriate 
maker for apoptosis initiation I found that BIM gene expression could be the most 
potential marker.  Bim is essential protein for initiating intrinsic apoptosis pathway 
due its ability in activating most anti-apoptotic proteins and involvement in 
recognising a large number of apoptosis stimuli under many normal and disease 
conditions.  Bim expression has been detected in a wide variety of tissues including 
brain, liver, heart, lung, kidney in additional to hematopoietic cells and several of 
other tissues 287.  Normally, Bim expression level is low and increases with the 
stimulation of cell death.  Increase Bim expression has been reported to deactivate 
most anti-apoptotic proteins of BCL2 superfamily and activate Bax and Bak pro-
apoptotic factors leading to increase the permeability of mitochondrial outer 
membranes 288.  Where, knocking-out Bim expression results in decrease apoptosis 
though, it does not induce a major effect on cell survival 289.  In addition, it has been 
reported that blocking Bim expression resulted in stopping Bax activation 226. 
Uncontrolled expression of Bim is typically associated with increase in cell damage 
and it has been connected with neurodegenerative diseases, diabetes, and liver 
damage.  Bim expression is tightly regulated at transcriptional, translational and post-
translational levels, which may ensure a sensible activation of Bim when required 
287. 
It should be noticed that using the increase in the acetylation level to identify a time-
point is also not indicative as it causes wide variations in gene expression that are not 
necessarily represent the cell response or the anticancer mechanism of the inhibitors. 
 
Appendix 3: The proposed plan for gene expression analysis using bulk NGS 
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Appendix 4: NGS Experimental Considerations  
In optimal condition of cell culture, there are several biological variations that present on 
many levels and could limit the ability of the bulk cell analysis to uncover the molecular 
regulations.  One of the factors is the cell cycle effect which results in heterogeneity within 
an identical cell population.  The cell cycle has a strong and timely association with gene 
expression and showed a considerable variation in total transcript number between the 
phases 243.  For example, G1 subpopulation of cells is often characterized by low total 
transcript level with a downregulation in most of the proliferation associated genes 243.  The 
variation in transcript numbers often results in altering the response to the internal and 
external singles and could lead to change the path of cell proliferation or differentiation 
243.  RNA-seq analysis of pooled cells typically generate average gene expression of 
different subpopulations especially and the tumour cells are in a continuous transition 
throughout the cell cycle phases.  Cell synchronization (bringing the cell to the same phase 
of cell cycle) could be suggested as a possible solution to overcome the cell cycle effect 
though, the cells are often lose the synchrony when progressing through the G1 phase and 
thereby they become less synchronous in other phases 285.   
Another possible biological factor with tumour cell lines is that with each cell division 
there could be additional mutations that were not present in the precursor cell.  With 
continuous growth of a cell line there inevitably an accumulation of additional mutations 
within a single cell that could advantage the growth of a particular cell, promote 
heterogeneity, and ultimately could change the treatment response.   
Up to date, most of our knowledge in understanding the anticancer effect of HDACis came 
from studies that averaged data from mixed populations of cells.  Such data are largely 
affected by the proportion of the cells at different stages of cell growth which may affect 
detecting some important molecular regulation.  
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Appendix 5: The Suggested Time-points for the Bulk NGS analysis and how they 
could be used to address the molecular mechanisms 
With such approach a time-course treatment should be done in order to give snapshots for 
the molecular changes that happen during the treatment.  Though, the selection for these 
time-points should be grounded on specific cellular response or markers as the arbitrary 
selection may not show the initiation or downregulation of certain cellular mechanisms. 
Several of previous works were performed using random time-points of treatment yet, the 
findings did not help in addressing the mechanism of action of HDACis. 
• Fist time point Untreated (2 samples, DAOY, Control)  
This will represent the default genes expression for each cell line.   
➢ Including these samples will help in  
❖ Comparing the results of treated cell to untreated cell of the same cell line will be 
used to study: 
▪ the variation in genes expression before and after treatment.  
▪ the acetylation difference between different inhibitors 
▪ understand why some inhibitors are more efficient in blocking tumorigenesis than 
other  
▪ identifying the cellular mechanisms that prompt the cell death for these inhibitors 
❖ The cross- analysis between the DAOY and the control will help: 
▪ validate and support the results of DAOY cell data analysis 
▪ understand the mechanism that trigger apoptosis in DAOY  
▪ understand how cancer cells sustain their proliferation  
▪ how cancer cell and normal cell responses to HDACis 
▪ understand if deacetylation is one of the cancer growth mechanism and how cancer 
cell induces deacetylation mechanism 
❖ Control cancer vs. control normal  
▪ illustrates the effect of HDACis on normal cell 
▪ describes how can normal cell resist the effect of hyperacetylation 
(Hyperacetylation Rescue Mechanism)  
▪ suggests the possible side effect of HDACis treatment    
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• Second time point: At the start of expression of cell apoptosis genes (8 samples: 
3 DAOY+ 3Control + untreated DAOY and Con) 
There will be large changes in genes expression though, I need to focus on how the 
HDACis stimulate the apoptosis.  So, I need to focus on the genes that have high DGE 
though they are more related to apoptosis regulation.  This time point could show initial 
signal that stimulate the apoptosis. Though it is very difficult to know what is it. 
Comparing the expression between the control and the tumour will help in identifying this 
time point.  
❖ DAOY: shows the apoptotic pathway that is involved in cell death, also it will help in 
identifying the difference in hyperacetylation effect between the inhibitors  
❖ Control: shows the effect of HDACis on genes expression in normal cells  
❖ Untreated cells: as all the cells are actively dividing cell, the genes expression levels 
will be different during their proliferation.  Therefore, this control may help in 
understand the expression profile of the treated cells 
• Third time point: A middle point between the start of the apoptosis and 
apoptosis (8 Samples:  3 DAOY+ 3 Control + untreated DAOY and Con) 
❖ DAOY: the regulation that initiates the apoptosis  
❖ Control: the regulation that rescue the against the hyperacetylation, if there is any, or 
there is not regulation and differentiation of the cell protect it from cell death.  Check 
the expression of DNA repair and other genes families.  
• Fourth time point: At the initiation of caspases (point of no return) (8 Samples:  
3 DAOY+ 3 Control + untreated DAOY and Con) 
❖ DAOY: the regulation of apoptosis mechanism  
❖ Control: understand the rescue mechanism or the faith of normal cell  
Stage 5: NGS Results validation  
Western blot and qPCR will be used in order to validate the finding of NGS analysis.   
The limitation of Bulk NGS analysis  
➢ HDACis may induce their action through non-histone proteins  
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➢ In culture plate each cell has a different stage of cell cycle, therefore, they will show 
different genes expression between replicates. 
It could be reduced by synchronize them. For example, using colcemid to as arrest them 
in metaphase stage and then release them however, the cells may lose their synchronisation 
after a few hours.   
➢ The differential gene expression of HDACis may represent the acetylation effect and 
not the cell response to maintain the balance between the acetylation and deacetylation, 
or to stimulate apoptosis.  
➢ Identifying the treatment time is very critical though, it is difficult to identify exactly 
when the cells start to response to the effect of HDACis (Hyper-acetylation). 
➢ As cancer cells are polyploidy and they have large number of mutations, it not easy to 
map all the results of the NGS to the Ref-seq. 
➢ During the data analysis: there will be a large number of genes that show high 
differential gene expression though, they are not related to the cell response to HDACis 
which may make identifying the regulation that control normal cell response very 
difficult. 
➢ Points to consider: 
➢ Acetylated gene expression response: very changeable, the high or the low gene 
expression variation represent the acetylation effect and not the cell response to 
maintain the balance between the acetylation and deacetylation.  
➢ When the cell started to response to correct the hyper-acetylation effect: could be 
early or late, and to identify the time I may measure the expression of the genes that 
regulate the HDAC and HAT genes expression. 
➢ Identify the hyper-acetylation rescue mechanism: is time dependent, and can be 
identified by genes expression. 
➢ As measuring acetylation alone will show the effect of the inhibitors and histone 
modification, and does not represent if the cells started to correct the hyper-acetylation. 
Genes expression could be the alternative to identify the cell correction response. However, 
not all expression variation is indicator for the rescue mechanism.  Some genes are very 
sensitive to acetylation and their expression is increased or decrease by more than 8 folds 
though, I cannot use them as the change in their expression is not a correction mechanism.  
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Appendix 6: Western blot of REST protein (Complete image)  
  
The blot shows the complete image of the anti-REST antibody western blot analysis.  
According the manufacturer’s information, the anti-REST antibody (OriGene, TA330562) 
is a synthetic peptide towards the middle region of human REST.   Previously, I have tried 
to identify the immunoreactive bands with the help of one of my co-supervisors however, 
we could not identify which isoform an immunoreactive band is related to.  Similarly, Chen 
et al., 2018 162 have concluded the following:  
“Unfortunately, despite the mRNA evidence, not all REST protein isoforms have been 
experimentally verified and they are usually observed as unexpected sizes due to post-
translational modifications, making it challenging to determine whether an unknown 
immunoreactive band is non-specific or a REST isoform. For example, REST4 and RESTC 
(a new REST isoform that is not much known about it) are predicted as 37 and 86 kDa yet, 
they were observed as 53 and 130 kDa, respectively, while the full-length REST has been 
reported as variable sizes ranging from 120 to 200 kDa. So, even if detectable by WB, 
specific REST isoforms might be simply considered as non-specific and excluded from 
being presented in publication, such may explain why RESTC was not reported until 
recently” 162.   
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Appendix 7: REST mRNA expression in the KO cell clone 
 
Interestingly, the KO mRNA was included in this reaction and it did not show any 
significant reduction in the transcriptional level ( 
 
Figure 23).  The expression of REST mRNA in the KO reaction could be due to the 
presence of a truncated form of REST mRNA which it possibly generated by splicing out 
or deletion of the edited exon 2 during the transcription.  This truncated mRNA can be 
degraded by nonsense-mediated decay or by blocking the access of the ribosomes during 
the translation 286.  However, the   Thus, the qPCR analysis may not accurately represent 
the functional effect of CRISPR/Cas9 modulation in the KO cell.   
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Appendix 8: Cell migration assay analysis images  
 0h 24h Closure (%)  
Daoy 
  
 
 70% 57% 13% 
KO 
  
 
  72 % 64 % 7% 
Scra
mble 
  
 
 56 % 37 % 19 % 
KD 
  
 
 49 % 42 % 7 % 
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Emp
Vec 
  
  
 
 63 % 44 % 19 % 
 
 
 
 
Appendix 9: shRNA and TUNEL Assay Images of Kamal et al, 2012 Study  
The above images were taken from Kamal et al, 2012 study to demonstrate the level of 
shRNA knockdown and the apoptosis identified.  These images were used here as a 
reference for the reader only.  
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Appendix 10: scNGS Cell Sorting (BD FACSDiva) 
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Appendix 11: The neurons gene list that were used to identify the cells identity 
N.Vehicle 
0 Striatum.Late.Infancy 2.70E-31 
Striatum.Late.Infancy : BLOC1S1, RPS29, NDUFA4, UQCRB, RPL7, FAU, RPS12, RPS20, RPL35A, 
C12ORF57, RPL37, RPS18, RPL32, RPS27A, RPS5, RPL34, RPL30, RPL38, RPS10, RPL23, RPL28, 
RPL27A, RPL18, PFDN5, RPL31, RPL12, RPL23A, RPL9, RPS7, RPL24, RPS14, RPS28, SSR4, RPS24, 
RPLP1, RPL39, RPL27, RPS23, RPL11, RPS15A, RPL26, RPS27, RPS9, RPL36, RPS8 
1 Cortex.Early.Mid.Fetal 3.55E-34 
Cortex.Early.Mid.Fetal : CTTNBP2, BCL7A, HMGCR, SIAH1, NELL2, FAM110B, DAB1, SATB2, 
CDK5R1, CD24, YTHDF2, DOK5, GNAI1, DAAM1, WASF1, MARCKSL1, KLF6, WDR47, FRMD4B, 
TNPO1, PTP4A1, CHL1, SLA, RNF219, MEF2C, SCN3A, SLC38A1, TNIK, CXADR, KIDINS220, 
CRMP1, FAM13A, REEP1, BRD3, NEUROD6, ITSN1, STMN2, CSRP2, KLF7, RUNX1T1, NEUROD2, 
ZNF195, RNF182, SLC37A3, BHLHE22, NCAM1, NHSL1, SRGAP1, PDIK1L, PAK2, EPM2AIP1, 
GNG2, MAPK8, BCL11A, MAPT, BZW2, MLLT3, FNBP1L, FSD1L, VCAN, CCDC112, MAP1B, 
KBTBD6, SOX11, ZNF300 
2 Cortex.Early.Mid.Fetal 1.03E-09 Cortex.Early.Mid.Fetal : TCF4, CTTNBP2, SLA, CXADR, KIDINS220, MLLT3, NFIB, LBH, MEIS2, DCX, SEMA3C, MAPT, FAM13A, NEUROD2, SOX4, AUTS2, SOX11 
3 Striatum.Early.Fetal 
2.45E-
166 
Striatum.Early.Fetal : SMC1A, H2AFX, BUB3, LMNB2, G3BP1, TOX3, CEP57, TMX1, ANP32E, 
NCAPG, IPO5, ECT2, NRM, CKAP2, RNASEH2B, PLK1, DBF4, UHRF1, TCF12, HAUS8, ERI2, 
UBE2C, PAICS, DTYMK, RNF138, KIFC1, OIP5, BUB1B, HAT1, HNRNPK, CTNNAL1, SNRPB, 
CBX5, FAM83D, RAD21, KIF14, AURKA, CENPN, NKAIN3, PRR11, CDK2, MCM3, UBE2T, CDH2, 
ASF1B, ARRDC3, FSTL1, MPHOSPH9, DLGAP5, CDK5RAP2, ARHGAP11A, TK1, HMGN2, 
RAD51AP1, PSMC3IP, TMEM97, ZFP36L2, PHF19, TMEM123, ACTL6A, FAM111A, BRCA2, CKS1B, 
CCDC18, PMAIP1, CEP135, PPP1CC, MPPED2, RFC3, TUBB6, ZNF273, MCM5, CYR61, LBR, 
BRCA1, ASPM, KIF2C, CDK4, TROAP, H2AFV, SYNE2, HJURP, POLD3, BTG3, CNTLN, RAD18, 
CENPE, SMC3, SASS6, BLM, PSRC1, RFC5, CENPV, DNAJC9, SSRP1, BARD1, NAP1L1, RRM1, 
MCM7, UBA2, SMCHD1, PRKDC, BRIP1, HNRNPF, KIF22, HMGN1, E2F1, ELAVL1, NASP, 
DEPDC1, FANCI, ATAD2, ERI1, FBXO5, PHIP, C4ORF46, GTSE1, MELK, CHD1, KIF23, NUSAP1, 
CLIC1, CHAF1A, PPAT, RCC1, PCNA, PBK, PPM1D, QSER1, HELLS, HNRNPU, TRAIP, CDC20, 
MTHFD2, CKS2, DONSON, INSM1, HMMR, GINS2, ARL13B, RRM2, MAD2L1, HNRNPR, HMGB2, 
PRC1, SMC2, TOPBP1, VRK1, GMNN, POLA2, TACC3, ERLIN1, CDCA5, G2E3, SCML1, CDCA3, 
PTTG1, H2AFZ, SUPT16H, EXO1, CCNE2, ITGB3BP, SMARCA5, MASTL, HNRNPA3, ASCL1, 
HIST1H4C, CBX3, NCAPH, DTL, HES6, CENPA, SERTAD4, TOP2A, FANCD2, DEPDC1B, NFATC3, 
RBBP4, RBBP8, FAM111B, ATAD5, USP1, DHX15, CENPK, RBMX, N4BP2, ZFP36L1, CDCA7L, 
CCDC15, CHEK1, CHAF1B, NUDT1, RDX, HMGB1, CDC6, ZNF43, CDCA2, TMPO, UBE2S, NVL, 
H2AFY2, IGFBP2, CDC25C, ESCO2, DEK, ZWILCH, TIMELESS, NDC80, CENPH, CEP152, CHEK2, 
HAUS1, CENPM, SPC25, DSN1, RTKN2, SOAT1, MCM10, KPNA2, GAS2L3, KIF15, PTBP1, MCM2, 
TMSB15A, FOXM1, GEN1, SMC5, CLSPN, TCF19, WDHD1, PBRM1, NCAPG2, KIF4A, HMGXB4, 
RFC4, SOX2, CDC25B, CCDC14, WDR34, TPX2, NUF2, HMGB3, CDCA4, CKAP2L, CCNA2, MCM4, 
BAZ1A, ARL6IP6, CASP8AP2, HDAC2, HAUS6, CCNB2, TYMS, LMNB1, KIF11, CCNB1, CENPF, 
WDR76, KIF20B, SHCBP1, ODC1, NEK2, NEDD1, C21ORF58, SPAG5, CDKN3, MEST, CDC7, 
CORO1C, EZH2, CDT1, CDCA8, DIAPH3, AURKB, MKI67, BIRC5, ZWINT, PTAR1, SMC4, ID4, 
MXD3, BUB1 
4 Amygdala.Late.Fetal 2.15E-26 
Amygdala.Late.Fetal : ARX, NRG1, SFRP1, NKAIN3, TNC, CA12, ASCL1, PLAGL1, SDCBP, MSI1, 
SOX9, CHRDL1, PSAT1, SOX2, DDIT4, SLC35F5, LHX2, RPS18, MOXD1, SORD, SLC16A1, FABP7, 
EEPD1, TMTC4, HSPA6, GNG5, SOX6, GPX3, TRAM1, GATM, RPS2, TSPAN6, PTPRZ1, TFAP2C, 
CPNE3, ABHD3, LOX, SLC1A3, COL11A1, GPC4, LIFR, SLC16A9, LITAF, HMOX1, CDO1, PRSS23, 
HSPA1B, GNG12, GPR137B, MSN, HOPX, CD164, CDCA7L, ZFP36L2, LRRC3B, FABP5, CXCR4, 
PEA15, MFGE8, PHLDA1, DMRTA2, FSTL1, TMEM123, MDK, CNN3, CMTM6, ITGB8, TMEM98, 
PON2, PDPN, PALLD, LEPROT, TSPO, SDC2, CARHSP1, TAGLN2, TGIF1, VIM, PYGL, NCAN, 
ZFP36L1 
5 Striatum.Late.Infancy 4.57E-38 
Striatum.Late.Infancy : RPS29, RPL7, FAU, RPS12, RPS20, RPL35A, RPL35, RPL37, RPS18, COX7C, 
RPL32, SERF2, RPS27A, MYL6, RPS5, RPL34, PHPT1, DBI, CD63, RPL28, RPL27A, RPL18, RPL31, 
S100A11, S100A6, RPL12, RPL23A, CLIC1, RPL9, RPS7, RPL24, RPS14, RPS28, RPS24, RPLP1, 
RPL39, RPL11, FTL, RPS23, B2M, LGALS1, RPS15A, RPL30, MT3, RPL26, RPS27, RPS9, RPL36, RPS8 
N.SAHA 
0 Cortex.Early.Mid.Feta 0.049 Cortex.Early.Mid.Fetal : TCF4, KLF6, SOX4, SOX11 
1 Cortex.Late.Infancy 0.054 Cortex.Late.Infancy : RPL31, SCG3, SNRPG, RPL27, RPL41, GTF3A, C1ORF61, RPL9, HSPB11, RPS27, ARC, RPL39, UBL5, UQCRQ, COX7B, NDUFB6 
2 Striatum.Late.Infancy 0.066 Striatum.Late.Infancy : FTL, MT1E 
3 Amygdala.Late.Infancy 
2.105e-
13 
Amygdala.Late.Infancy : RPS27L, RPL7, RPS20, RPL35, MT1X, S100B, DBI, SERF2, MT1E, RPL34, 
SAT1, MT3, PFDN5, RPL31, S100A11, S100A6, RHOC, RPL9, RPS28, RPL39, FTL, RPL27, LGALS1, 
MT2A, RPS27, LGALS3, RPL36 
N.MS-275 
0 Cortex2.Early.Mid.Fetal 5.52E-08 Cortex.Early.Mid.Fetal : TCF4, ID2, SLA, MLLT3, RND3, FRMD4B, SOX4, FAM126A, ARL4D, SOX11 
1 Striatum1.Late.Infancy 6.54E-07 
Striatum.Late.Infancy : FTL, S100A11, S100A6, IGFBP7, CLDN10, LGALS1, CD63, CST3, TIMP1, 
MT2A, DBI, SERF2, B2M 
2 Cortex1.Early.Mid.Fetal 1.42E-08 
Cortex.Late.Fetal : SLA, NELL2, MLLT11, CD24, CCNI, STMN1, PTPN2, MARCKSL1, TUBA1A, 
MEF2C, TRAF4, PAFAH1B3, CXADR, SRM, CRMP1, NEUROD6, CSRP2, GPM6A, RTN1, RPRM, 
RAC3, TUBB, RASL11B, PTP4A1, NEUROD2, BZW2, STMN4, STMN2, MAPK8 
3 Striatum2.Late.Infancy 1.77E-54 
Striatum.Late.Infancy : RPS15A, RPS29, NDUFA4, UQCRB, GSTK1, RPL7, FAU, RPS12, RPS20, 
RPL35A, RPS27L, RPL35, MT1X, IFITM3, UQCRQ, COX7C, RPL32, SERF2, RPS27A, MYL6, MT1E, 
RPS5, RPL34, PHPT1, RPS27, DBI, RPS10, RPL37, RPL23, COX5B, TIMM8B, RPL27A, RPL38, SAT1, 
RPL18, GUK1, PFDN5, RPL31, S100A11, S100A6, RPL12, RPL23A, RHOC, CLIC1, RPL9, RPS7, 
RPL24, SNRPD2, RPS14, RPS28, IFI27L2, RPS24, RPLP1, HSPE1, RPS18, RPL28, FTL, RPL27, RPL11, 
LGALS1, MT2A, ANAPC11, RPL30, MT3, RPL26, RPS21, MYL12A, RPS9, UBL5, RPL36, RPS8, 
COX7B 
4 Amygdala.Late.Fetal 1.37E-16 
Amygdala.Late.Fetal : SFRP1, TNC, CA12, SDCBP, CXCR4, DDIT4, RHOBTB3, LHX2, GPX3, 
SLC16A1, PSAT1, SOX9, CTBP2, SLC40A1, TRAM1, GATM, F2R, TSPAN6, MEIS2, PTPRZ1, CPNE3, 
MMP2, ABHD3, LOX, SLC1A3, GPC4, COL11A1, SRP9, LIFR, LITAF, HSPA6, PRSS23, GNG12, 
GPR137B, CNN3, CD164, CDCA7L, CCND2, ZFP36L1, ARL6IP6, ADD3, PEA15, MFGE8, PHLDA1, 
PTTG1IP, FSTL1, TMEM123, MDK, CMTM6, ITGB8, TMEM98, PON2, PALLD, LEPROT, SDC2, 
SOX2, TGIF1, VIM, NCAN, MOXD1 
 
